

INHIBITING HIV-1 USING RNA INTERFERENCE (RNAi) TO TARGET NOVEL HIV DEPENDENCY FACTORS (HDFs)

Mishka D Blondeel



**Dissertation submitted to the Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg, in fulfillment of the requirements for the degree of
Master of Science in Medicine.**

Johannesburg, 2010.

DECLARATION

I, Mishka Blondeel, declare that this dissertation is my own work. It is being submitted for the degree of Master of Science in Medicine in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

.....

..... day of May, 2010

DEDICATION

To my long-suffering family and Martin

Publications and presentations

Blondeel M, Arbuthnot P, Weinberg M. Verifying two novel host factors' role in HIV-1 replication. Proceedings of the 22nd Congress of the SASBMB; 2010 Jan 17-21; Bloemfontein.

ABSTRACT

Three separate recent publications used genome-wide RNA interference (RNAi) to screen for novel host factors that are required for HIV-1 infection and replication. This was achieved using small interfering RNAs (siRNAs) to silence the expression of ~21 000 human genes and determining the effect of each gene's loss of function on HIV-1 replication. Collectively, several hundred genes have now been implicated as novel HIV-1 host factors (termed HIV-1 Dependency Factors, HDFs). However, differences in study design resulted in little overlap and limited interpretive value from the three published datasets. To identify novel HDFs that are potential targets for anti-HIV therapy, five putative HDFs (*SPTBN1*, *TMED2*, *KIAA1012*, *PRDM14* and *SP110*) were chosen for validation. RNAi effectors (both siRNAs and expressed short hairpin RNAs) were used to silence the selected genes. Gene suppression was measured by quantitative RT-PCR assay and two candidate genes were studied further (*SPTBN1* and *SP110*) based on efficient mRNA inhibition (over 90%). As efforts to deliver the RNAi effectors to a T-cell line were unsuccessful, the effect of this knockdown on HIV-1 replication (both early- and late-stage) was assessed in cultured TZM-bl cells, a HeLa-derived cell line that expresses HIV-1 entry receptors and an integrated luciferase reporter for HIV-1 transcriptional activity (also used in the first genome-wide RNAi screen). An initial viral challenge assay with Subtype C-enveloped pseudovirus showed a 60% decrease in TZM-bl luciferase reporter activity in cells with suppressed *SPTBN1* function, while knockdown of *SP110* showed no effect on reporter activity. The final experiment, using fully-replicating Subtype B virus, showed a 75% decrease in late-stage viral replication when *SPTBN1* expression was suppressed. In addition, *SP110* suppression was confirmed to have no effect on TZM-bl reporter activity during any stage of HIV-1 replication. In conclusion, *SPTBN1*, but not *SP110*, is required for late-stage HIV-1 replication, though these results need to be confirmed in CD4+ T-cells. The absence of several important viral accessory factors from

the virus used in the genome-wide screen may explain these findings and emphasises the need for using physiologically representative viral and cellular models to study the viral/cellular interactome.

ACKNOWLEDGEMENTS

I would like to thank my supervisors, Dr M S Weinberg and Prof P Arbuthnot, for their academic support and guidance.

I would like to acknowledge Dr Papathanasopoulos for providing access to the HIV-1 Pathogenesis Research Laboratory and for generously providing the pseudovirus used in this study and thank Mark Killick for his guidance and assistance in that laboratory.

My personal thanks go to all the members of the Antiviral Gene Therapy Research Unit (AGTRU), especially Victoria Green and Abdullah Ely for their advice and support.

Finally, I am grateful for the financial assistance I received from the German Academic Exchange Service, DAAD (Bonn), the South African Medical Research Council (MRC) and the Poliomyelitis Research Foundation, as well as the Postgraduate Merit Award granted by the University of the Witwatersrand.

TABLE OF CONTENTS

DECLARATION.....	II
DEDICATION	III
PUBLICATIONS AND PRESENTATIONS	IV
ABSTRACT	V
ACKNOWLEDGEMENTS.....	VII
TABLE OF CONTENTS	VIII
LIST OF FIGURES	XIII
LIST OF TABLES.....	XV
ABBREVIATIONS	XVI
CHAPTER 1 : INTRODUCTION	1
1.0 Chapter summary	1
1.1 HIV-1/AIDS.....	2
1.1.1 Global and local burden of the AIDS pandemic.....	2
1.1.2 AIDS pathogenesis.....	3
1.1.3 The HIV-1 replication cycle	4
1.2 Host factors required for HIV-1 replication.....	5
1.2.1 Entry.....	6
1.2.2 Uncoating and Reverse Transcription.....	7
1.2.3 Inward trafficking and nuclear import	7
1.2.4 Integration	8

1.2.5	Transcription.....	9
1.2.6	RNA processing and export.....	10
1.2.7	Translation, processing and trafficking.....	11
1.2.8	RNA encapsulation and assembly	12
1.2.9	Virion budding.....	12
1.2.10	Virus transfer	13
1.3	Current approaches to managing HIV-1/AIDS	14
1.4	RNA interference (RNAi)	16
1.4.1	The endogenous RNAi pathway	16
1.4.2	RNAi as a reverse genetics tool.....	19
1.4.3	RNAi as an exciting and powerful new gene therapy	20
1.5	RNAi approaches targeting HIV-1	21
1.5.1	Viral versus cellular targets.....	22
1.6	Genome-wide siRNA screens for novel HIV-1 host factors	23
1.6.1	Selection of novel host factors for validation in this study.....	24
1.7	Aims and Objectives	28
CHAPTER 2 : METHODS AND MATERIALS		29
2.1	RNAi effecters.....	29
2.1.1	shRNA-encoding sequences	29
2.1.2	Specificity and structure of shRNA sequences.....	30
2.1.3	siRNA SMARTpools	31
2.2	Previously constructed plasmids used in this study	32

2.3	Molecular cloning	34
2.3.1	Cloning of shRNA expression cassettes	34
2.3.2	Cloning of target reporter plasmids	36
2.3.3	Transformation and verification of clones	38
2.4	Mammalian cell culture	40
2.5	Transfection of DNA and RNA into cultured cells	41
2.5.1	Lipofectamine™ 2000 transfections	41
2.5.2	ESCORT™ V transfections.....	41
2.5.3	DharmaFECT®-4 transfections.....	42
2.6	Dual-Luciferase reporter assays	42
2.7	qRT-PCR assays	43
2.8	Electroporation	45
2.9	Delivery of DNA and RNA to SupT1 cells by cationic lipid-based transfection reagents	46
2.10	Cytotoxicity assays	47
2.11	Virus production	48
2.12	Viral titration	49
2.13	Viral challenge assays	50
2.13.1	Env-pseudotyped viral challenge	51
2.13.2	Replication-competent viral challenge	52
2.14	Statistical analyzes	53

CHAPTER 3 : RESULTS.....	54
3.1 Criteria-based selection of five genes.....	54
3.2 Gene-specific knockdown by Pol III-expressed shRNAs.....	57
3.2.1 Design of shRNA expression cassettes	57
3.2.2 Cloning of shRNA expression cassettes and reporter targets	58
3.2.3 Knockdown of luciferase reporter targets.....	59
3.3 Accurate detection of mRNA by quantitative RT-PCR	62
3.3.1 Testing of non-targeting controls.....	62
3.3.2 Testing of positive controls	64
3.3.3 Other controls used in optimising qRT-PCR assays.....	66
3.4 shRNA-mediated knockdown of endogenous mRNA targets.....	67
3.5 Knockdown of endogenous mRNA by siRNA SMARTpools.....	70
3.6 Knockdown efficacy of shRNAs derived from pooled siRNAs.....	72
3.7 Delivery to SupT1 cells by electroporation.....	74
3.8 Delivery to SupT1 cells by transfection reagents.....	75
3.9 Cytotoxicity assay	78
3.10 The effect of <i>SPTBN1</i> and <i>SP110</i> knockdown on HIV-1 replication.....	80
3.10.1 Single-round challenge of transfected cells with pseudovirus	80
3.10.2 Two-part challenge of transfected cells with replication-competent virus	82
CHAPTER 4 : DISCUSSION	84
4.1 The possible roles of <i>SPTBN1</i> in HIV-1 replication	84
4.2 <i>SP110</i> and HIV-1 replication	85

4.3	Comparison of viruses used in this study and by Brass <i>et al.</i> (2008)	86
4.4	Gene selection	88
4.5	Broader perspectives	88
4.5.1	Large-scale lentiviral shRNA transduction of T-cells	88
4.5.2	Alternative techniques for characterizing the viral/cellular interactome	90
4.6	Factors of RNAi experiments highlighted by this study	91
4.6.1	Primer design in PCR-based cloning of shRNAs	91
4.6.2	Target mRNA accessibility to the RNAi machinery	92
4.6.3	The importance of reliable reference genes and controls in qRT-PCR assays	93
4.6.4	Off-target effects and the benefits of Dharmacon's ON-TARGET ^{plus} SMARTpool technology	94
4.6.5	siRNA-related cytotoxicity	95
4.6.6	Delivery of RNAi effectors to a T-cell line by electroporation and lipid-based reagents	98
4.6.7	Alternative delivery methods.....	98
 CHAPTER 5 : CONCLUSIONS		102
 APPENDIX A: SEQUENCE INFORMATION		104
 APPENDIX B: EXPERIMENTAL PROCEDURES		112
 APPENDIX C: SELECTION OF GENES		119
 REFERENCES		127

LIST OF FIGURES

Figure 1-1: The number of people living with HIV/AIDS in each country worldwide	3
Figure 1-2: HIV-1 genome structure.....	5
Figure 1-3: The mammalian RNAi pathway.....	17
Figure 1-4: Model of putative HDF roles in the HIV lifecycle.....	27
Figure 2-1: Example of shRNA design approach.	30
Figure 2-2: Schematic of two-step PCR approach used in construction of shRNA cassettes.	35
Figure 2-3: Reporter target cloning strategy.....	38
Figure 2-4: Schematic of two-part viral challenge assay	51
Figure 3-1: Example of restriction digest and sequence data used to verify correct clones.	60
Figure 3-2: Knockdown efficiency of shRNAs against luciferase reporter targets.	61
Figure 3-3: Testing knockdown of SPTBN1, TMED2, KIAA1012 and SP110 by non-specific shRNA controls.	63
Figure 3-4: Knockdown of positive control <i>HTATSF1</i>	64
Figure 3-5: Knockdown of LTR-driven luciferase by positive controls shLTR and shTat...66	
Figure 3-6: Standard curve of plasmid standards for each primer set	67
Figure 3-7: Knockdown of endogenous <i>SPTBN1</i> mRNA by shRNAs.	68
Figure 3-8: Knockdown of endogenous <i>TMED2</i> mRNA by shRNAs.....	69
Figure 3-9: Knockdown of endogenous <i>KIAA1012</i> mRNA by shRNAs.	69
Figure 3-10: Knockdown of endogenous <i>SP110</i> mRNA by shRNAs.	70
Figure 3-11: Knockdown of endogenous <i>SPTBN1</i> mRNA by siRNA SMARTpools.	71
Figure 3-12: Knockdown of SPTBN1 and SP110 by shRNAs derived from SMARTpool siRNAs	73

Figure 3-13: Delivery of plasmid DNA and siRNA to SupT1 cells.....	76
Figure 3-14: Knockdown by siRNA SMARTpools in SupT1 cells.....	77
Figure 3-15: Knockdown of <i>SPTBN1</i> and <i>SP110</i> by siRNA-derived shRNAs in SupT1 cells.	78
Figure 3-16: MTT assay for RNAi-related cytotoxicity	79
Figure 3-17: Changes in pseudovirus activity in cells transfected with shRNA	81
Figure 3-18: Changes in pseudovirus activity in cells transfected with siRNAs.....	82
Figure 3-19: Changes in HIV-1 ^{p81A-4} activity in cells transfected with siRNAs	83

LIST OF TABLES

Table 3-1: The final five putative HDFs selected for validation in this study	56
Table 3-2: Results of electroporation experiments (average of data in triplicate).....	75
Table A-1: Genomic location of shRNA target sequences.....	104
Table A-2: Genomic location of siRNA-derived shRNA target sequences.....	105
Table A-3: Primer sequences used in two-step PCR-amplification of shRNA expression cassettes for <i>SPTBN1</i> , <i>TMED2</i> and <i>KIAA1012</i>	106
Table A-4: Primer sequences used in two-step PCR-amplification of shRNA expression cassettes for <i>PRDM14</i> and <i>SP110</i>	107
Table A-5: Primer sequences used in single-round PCR-amplification of siRNA-derived shRNA expression cassettes	108
Table A-6: shRNA Target Oligonucleotide Sequences.....	109
Table A-7: qRT-PCR primers.....	110
Table A-8: Control siRNA/shRNAs and target primers	111
Table B-1: Preset electroporation protocols	117
Table B-2: Electroporation protocols from the literature	118
Table C-1: Genes that decreased HIV-1 activity by 75% or more.....	120
Table C-2: Genes that scored with two or more siRNAs in Part 1 (left) and Part 2 (right)	121
Table C-3: Part 1 genes excluded due to important cellular functions	122
Table C-4: Final Part 1 gene selection	123
Table C-5: Part 2 genes excluded due to important cellular functions	124
Table C-6: Part 2 genes with five or fewer homologs	125
Table C-7: Final Part 2 gene selection	126

ABBREVIATIONS

(Only those used more than once are listed)

°C: degrees Celsius

A/T/C/G-residue: Adenosine, Thymine, Cytosine, Guanine-residue (DNA bases)

ABCE1: ATP-binding cassette, sub-family E (OABP), member 1

AdV/AAV: Adenovirus/Adeno-associated virus

AIDS: Acquired immune-deficiency syndrome

ANOVA: Analysis of variance

APOBEC: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like

ARV: Antiretroviral

BAF: Barrier to auto-integration factor

BDH: Burani Design Holding

BLAST: Basic local alignment search tool

bp: base-pair

BSA: Bovine serum albumin

CA: Capsid

CCR5: C-C chemokine receptor type 5

CD4: Cluster of differentiation 4

CMV: Cytomegalovirus

CXCR4: C-X-C chemokine receptor 4

DEAE: Diethylaminoethyl

DMEM: Dulbecco's modified Eagle's medium

DMSO: Dimethylsulfoxide

DNA / cDNA: deoxyribonucleic acid / complementary DNA

EBV: Epstein-Barr virus

EDTA: Ethylenediaminetetraacetic acid

Env: Envelope

ER: endoplasmic reticulum

ESCRT: Endosomal sorting complex required for transport

FBS: Fetal bovine serum

g (500 × g): Unit of gravitational force

g: gram

Gag: Group-specific antigen

GAPDH: Glyceraldehyde-3-phosphate dehydrogenase

GFP/eGFP: Green fluorescent protein/enhanced GFP

HAART: Highly active antiretroviral therapy

HBV: Hepatitis B virus

HDAC: Histone deacetylase

HDF: HIV-1 dependency factor

HEK293: Human embryonic kidney cell line 293

HEPES:4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HIV-1: Human immunodeficiency virus type 1

hnRNP: Heterogeneous nuclear ribonucleoprotein

HTATSF1: HIV-1 Tat-specific factor 1

IN: Integrase

KIAA1012: NCBI gene name, encodes TRS85 homologue

LB: Luria-Bertani

LEDGF: Lens epithelium-derived growth factor

LTR: Long terminal repeat

Luc/FF Luc: Luciferase / Firefly Luc

m/ μ /n/p/f (e.g. mg/ μ g/ng/pg): milli-/micro-/nano-/pico/femto- (e.g. femtograms)

M: Molar

miRNA: microRNA

MTT: (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NARRRP: NIH AIDS research and reference reagent program

NC: Nucleocapsid

NCBI: National Centre for Biotechnology Information

NEB: New England Biolabs

Nef: Negative regulatory factor

NIH: National Institute of Health

ns: not significant

nt: nucleotide (DNA base)

NTP/dNTP: Nucleoside triphosphate / deoxy-NTP

ORF: Open reading frame

PBS: Phosphate-buffered saline

PCR/qRT-PCR: Polymerase chain reaction / quantitative RT-PCR

PIC: Pre-integration complex

Pol: Polymerase

PR: Protease

PRDM14: PR domain-containing 14

PTGS/TGS: Post-transcriptional gene silencing / transcriptional gene silencing

RISC: RNA-induced silencing complex

RNA/mRNA: Ribonucleic acid / messenger RNA

RNAi: RNA interference

RNase: Ribonuclease

RT: Reverse Transcriptase

RTC: Reverse-transcription complex

shRNA/siRNA: Short hairpin RNA / short interfering RNA

SP110: NCBI gene name, encodes nuclear body protein

SPTBN1: Spectrin, beta, non-erythrocytic 1

TAP: Transcytosis-associated protein

Taq: *Thermus aquaticus*

TAR: Trans-activation response

Tat: transcriptional activator protein

TBE: Tris/borate-EDTA

TCID50: 50% tissue culture infectious dose

TMED2: Trans-membrane emp24 domain-containing protein 2

TRBP: TAR RNA binding protein

TRC: The RNAi Consortium

TRC: The RNAi Consortium

TRIM: Tripartite motif

TSA: Trichostatin A

U: Enzyme unit (amount required to digest 1 μg of DNA in an hour)

UNAIDS: The joint United Nations programme on HIV/AIDS

URL: Universal resource locator (website address)

UTR: Untranslated region

VC/NV: Virus control / no virus

Vif: Viral infectivity factor

Vpr: Viral protein R

Vpu: Viral protein U

CHAPTER 1 : INTRODUCTION

1.0 Chapter summary

Acquired Immune-Deficiency Syndrome (AIDS) is an infectious disease caused by the Human Immunodeficiency Virus (HIV) that is now a pandemic affecting 33.4 million people worldwide, with 5.7 million of these living in South Africa. HIV-1 is a retrovirus that makes extensive use of its host cell's pathways during its replication cycle in cells of the immune system. Antiretroviral (ARV) therapies targeting various steps in the HIV-1 replication cycle can suppress viral activity in infected patients and prevent the onset of AIDS (Palella *et al.*, 1998). However, these therapies are not without adverse side effects and cannot eradicate latent viral reservoirs. Alternative antiviral strategies include gene therapy approaches, the most promising of which uses RNA (ribonucleic acid) interference (RNAi) to specifically and potently silence gene expression and thereby suppress critical viral and/or cellular gene functions that are required for efficient HIV-1 replication (Barichievy *et al.*, 2009). RNAi-based silencing of viral genes has suppressed HIV-1 infection in several cellular and animal models. However, the error-prone Reverse Transcriptase enzyme of HIV-1 leads to the rapid evolution of mutant strains, resulting in resistance developing to both ARVs and RNAi-based therapies in the long term. By targeting HIV-1 host factors the risk of viral mutational escape can be alleviated. However, several concerns exist regarding the possible side-effects of inhibiting a cellular gene function, as well as the existence of functional redundancy in the pathways used by the virus.

Apart from gene therapy applications, RNAi is widely used as a tool to explore gene function [reviewed by (Castanotto and Rossi 2009)]. RNAi has been widely used to reveal the complex interplay that occurs between cellular and viral gene products during

HIV-1 infection and replication. The advent of high-throughput technology has allowed RNAi to be used at a genome-wide scale and has resulted in the identification of hundreds of novel HIV-1 host factors. However, as the cellular and viral models used in these studies do not represent a natural infection validation of these candidate host factors is required.

1.1 HIV-1/AIDS

1.1.1 Global and local burden of the AIDS pandemic

The HIV/AIDS pandemic is placing an increasingly heavy burden on global health, with 33.4 million people living with the disease worldwide (see Figure 1-1). Over two thirds of these people (22.4 million) are living in Sub-Saharan Africa. This region also accounts for 32% of all new HIV infections and 72% of global AIDS-related deaths (1.9 million and 1.4 million people, respectively) (UNAIDS 2009). South Africa's population has the largest number of infections in the world (5.7 million people) (UNAIDS 2008).




Figure 1-1: The number of people living with HIV/AIDS in each country worldwide

Just over thirty-three million people are living with HIV/AIDS world-wide. Sub-Saharan Africa's infected population stands at 22.4 million people (UNAIDS 2009).

1.1.2 AIDS pathogenesis

AIDS is a complex and variable syndrome whose pathogenesis is not yet completely understood. However, it is generally characterized by progressive immune deficiency that results in susceptibility to viral, bacterial and fungal opportunistic infections [reviewed by (El-Atrouni *et al.*, 2006; Martinez and Temesgen 2006; Tsigrelis *et al.*, 2006)]. AIDS patients also have increased risk of developing tumours of the gastrointestinal tract, lungs or skin that are mostly caused by co-infections with oncogenic (cancer-causing) viruses like Epstein-Barr Virus, EBV [reviewed by (Angeletti *et al.*, 2008)]. Finally, neurological symptoms (including encephalopathies, meningitis and AIDS dementia complex) often develop in late-stage AIDS patients [reviewed by (Levy *et al.*, 1985; Navia *et al.*, 1986)], as well as non-specific symptoms like weight-loss, diarrhea and fevers.

The course of the disease begins with an acute stage following HIV-1 infection, progresses to a chronic asymptomatic stage that can last for 10 years or more and culminates in the clinical symptoms of AIDS and subsequent death. During the acute stage, high levels of virus target the T-helper lymphocytes that express the CD4 (cluster of differentiation 4) surface marker and cause them to undergo apoptosis (programmed cell death) (Laurent-Crawford *et al.*, 1991; Lu *et al.*, 1994). The immune system is in a chronically activated state throughout the course of the infection, contributing to the virus-mediated depletion of CD4+ T-cell numbers (Hazenbergh *et al.*, 2003), especially those bearing the CCR5 (C-C chemokine receptor type 5) marker that are concentrated in the gut mucosal lining, but also newly generated in the thymus and circulating in peripheral blood (Brenchley *et al.*, 2004). As the T-helper cells are critical for an effective immune

response, their loss is directly involved in the progression of the disease. When the CD4+ T-cell count becomes lower than 200 cells per microlitre of blood, signs and symptoms of AIDS generally ensue (Hogg *et al.*, 2001).

1.1.3 The HIV-1 replication cycle

HIV-1 is a retrovirus (i.e. a virus with an RNA genome that is converted to DNA (deoxyribonucleic acid) by its Reverse Transcriptase (RT) enzyme during replication) that was discovered over 25 years ago (Barre-Sinoussi *et al.*, 1983) and associated with causing AIDS not long after (Gallo *et al.*, 1984). A brief summary of the HIV-1 replication cycle follows: Firstly, the enveloped virus recognizes and binds to entry receptors on its target cells, which include T-helper lymphocytes, macrophages, dendritic cells and microglial cells of the neural system (Klatzmann *et al.*, 1984; Macatonia *et al.*, 1990; Watkins *et al.*, 1990; Kalter *et al.*, 1991). This leads to fusion of the viral envelope with the cell membrane and subsequent entry (Stein *et al.*, 1987). Once inside the cell, the virus sheds its coat (made of capsid, CA, proteins) and forms a reverse transcription complex (RTC) to convert the two copies of its single-stranded RNA genome into double-stranded DNA by viral RT (Bukrinsky *et al.*, 1993). The resulting pre-integration complex (PIC) is then trafficked towards the nucleus where import of the PIC occurs for subsequent integration (mediated by viral Integrase, IN) of the viral DNA into the host genome (Farnet and Haseltine 1991; Bukrinsky *et al.*, 1992; Bukrinskaya *et al.*, 1996).

Viral gene expression requires the initial transcription and translation of the Tat regulatory protein, which then causes transactivation (via the transactivation response, TAR, loop) for high-level long terminal repeat (LTR)-driven transcription of the viral genes encoding the accessory factors Vif (viral infectivity factor), Vpu (viral protein U), Vpr (viral protein R) and Nef (negative regulatory factor), the Env (envelope) and Gag (group-specific antigen) structural proteins and the Pol-encoded RT / ribonuclease (RNase) H

integrase (IN) and protease (PR) enzymes (see Figure 1-2) (Sodroski *et al.*, 1985; Fisher *et al.*, 1986). The Rev regulatory protein plays an important role in allowing partially spliced and unspliced viral transcripts to exit the nucleus for subsequent translation and processing of viral proteins (Malim *et al.*, 1989; Kjems *et al.*, 1991). The Gag and Env proteins are transported to the membrane where the RNA genome and other viral factors are encapsulated. As the assembled viral components bud outward from the host membrane (which has viral Env proteins embedded in it) a new virion is formed (Bugelski *et al.*, 1995). During budding, virion maturation occurs when the PR enzyme cleaves the Pol and Gag precursor proteins into their subunits, readying the virus for infection of a new cell (Peng *et al.*, 1989).




Figure 1-2: HIV-1 genome structure.

Depiction of HIV-1's nine open reading frames (ORFs) — Gag, Env, Pol, Tat, Rev, Vpu, Vif, Vpr and Nef — flanked by long terminal repeats (LTRs) in the HIV-1 genome. Group-specific antigen (Gag) polyprotein is cleaved to form MA (p17 matrix protein), CA (p24 capsid protein), NC (p7 nucleocapsid protein) and p6. Pol encodes the viral enzymes protease (PR), reverse transcriptase (RT)/RNase H and integrase (IN). The envelope protein (Env) has surface (SU, gp120) and transmembrane (TM, gp41) subunits); Vif, Vpr, Vpu and Nef are viral accessory proteins while Tat and Rev are viral regulatory proteins (Robinson 2002).

1.2 Host factors required for HIV-1 replication

Apart from the viral gene functions described above, several host factors have been shown to be involved in each stage of HIV-1 infection and replication (Goff 2007). An overview of these factors is given below as a background to the novel host factors that were validated in this study. While small RNA species (microRNAs, miRNAs) of viral and

cellular origin, as well as dozens of cellular and humoral immune system factors, have been shown to be involved in regulating viral replication (Kaur and Mehra 2009; Mothe *et al.*, 2009; Ouellet *et al.*, 2009), these factors are not included in this overview, as they are not the focus of this study.

1.2.1 Entry

During cellular entry of HIV-1, the viral Env glycoprotein, gp120, binds to host receptor CD4 and a chemokine co-receptor, mostly CCR5 or CXCR4 (C-X-C chemokine receptor 4) (Doranz *et al.*, 1997), which are brought into close proximity by F-actin (Iyengar *et al.*, 1998), whose movement is regulated by moesin of the extrin-radixin-moesin protein family (Barrero-Villar *et al.*, 2009), within cholesterol-rich lipid microdomains (Manes *et al.*, 2000; Liao *et al.*, 2001). Actin and myosin drives the movement of CD4-bound virus particles along filopodia from the cell periphery to the cell body where fusion occurs between the lipid bilayers of the viral envelope and the plasma membrane (Lehmann *et al.*, 2005). The viral fusion protein (gp41) recruits a guanine nucleotide exchange factor (GEF) for the Rho GTPase, which together with CXCR4-activated cofilin (actin depolymerizing factor), acts to remodel the cortical actin barrier beneath the plasma membrane at the fusion site (Zhang *et al.*, 1999; Yoder *et al.*, 2008). The viral accessory protein, Nef, also appears to enable the entering viral capsid to cross this actin barrier (Campbell *et al.*, 2004). In addition, histone deacetylase (HDAC) 6 is activated that stabilizes microtubules, possibly for anchoring the fusion pore (Westermann and Weber 2003; Valenzuela-Fernandez *et al.*, 2005).

1.2.2 Uncoating and Reverse Transcription

Uncoating of the viral capsid after entry is mediated by cyclophilin A (CypA) and Tripartite motif-containing (TRIM) 5 α . These host factors recognize and bind viral CA protein and promotes its premature disassembly ((Luban *et al.*, 1993; Braaten *et al.*, 1996; Sokolskaja *et al.*, 2004; Chatterji *et al.*, 2006; Stremlau *et al.*, 2006). While human TRIM5 α weakly affects HIV-1, other species' orthologues have more potent effects (Stremlau *et al.*, 2005). It appears that activation of the actin polymerization nucleator, Arp2/3 (Komano *et al.*, 2004) is required for subsequent short-range actin-driven transport of the viral capsid to microtubule tracks where the RTC is formed (Bukrinskaya *et al.*, 1998). Subsequently, viral nucleocapsid (NC) protein (which coats the RNA) recruits the cellular tRNA^{Lys} primer to the viral primer binding site for initiation of cDNA synthesis (Chan and Musier-Forsyth 1997).

Reverse transcription is downregulated by APOBEC3G/F (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G and F). This cytidine deaminase converts cytosines to uracils during reverse transcription, resulting in DNA that is either degraded by cellular uracil-DNA glycosidases and repair enzymes (Mangeat *et al.*, 2003) or has G-A hypermutations (Lecossier *et al.*, 2003). In addition, APOBEC3G is incorporated into virions where it hinders subsequent rounds of infection. However Vif (viral infectivity factor) counteracts this action by binding it, inducing its degradation and preventing incorporation into virions (Sheehy *et al.*, 2002; Stopak *et al.*, 2003).

1.2.3 Inward trafficking and nuclear import

Trafficking of the PIC to the nuclear pore appears to occur by retrograde microtubule transport, probably using dynein motors (McDonald *et al.*, 2002). Subsequently, the PIC is actively transported across the nuclear envelope, an aspect that

enables HIV-1 (and other lentiviruses) to infect non-dividing cells where the nuclear envelope is not fragmented during mitosis. Several host factors have been suggested as being required for nuclear import, including importin 7, a nuclear import receptor for ribosomal RNA and histones (Fassati *et al.*, 2003), Nup98, a component of the nuclear pore complex (Ebina *et al.*, 2004), as well as transfer RNAs (tRNAs) and their precursors (Zaitseva *et al.*, 2006), which may act as transport carriers.

1.2.4 Integration

Integration comprises processing of the 3' ends of the viral DNA just after reverse transcription, followed by strand transfer in the nucleus and subsequent repair of the recombination intermediate. Integration is mainly controlled by viral IN via its interaction with host LEDGF (lens epithelium-derived growth factor)/p75 and BAF (barrier to auto-integration factor). Other IN-interacting host factors include INI1 (integrase interactor 1) (Kalpana *et al.*, 1994) and hRAD18 (Mulder *et al.*, 2002).

LEDGF is a nuclear transcriptional co-activator that acts as a chromatin-associated receptor for the PIC (Emiliani *et al.*, 2005; Llano *et al.*, 2006b). It interacts with IN (thereby preventing its degradation by the proteasome – (Llano *et al.*, 2004) and directs proviral integration to active transcription units (Cherepanov *et al.*, 2003; Ciuffi *et al.*, 2005). RNAi-mediated knockdown studies, as well as knockout mutant and overexpression studies, show an essential role for LEDGF in HIV-1 infection (Llano *et al.*, 2006a; Vandekerckhove *et al.*, 2006; Shun *et al.*, 2007).

BAF prevents intramolecular integration of the viral DNA by compacting the cDNA and forming DNA-protein structures on the HIV-1 long terminal repeat (LTR) ends for insertion of the provirus into the host chromosome (Lee and Craigie 1994; Chen and Engelman 1998). LAP2 α , a laminin-associated component of nuclear membrane, binds to BAF. Both are components of the PIC and are required for productive integration

(Shumaker *et al.*, 2001; Lin and Engelman 2003). In addition, emerin (a component of the inner nuclear membrane that interacts with BAF) seems to mediate association of the PIC with chromatin thus promoting integration (Lee *et al.*, 2001; Bengtsson and Wilson 2006).

1.2.5 Transcription

A vast network of 183 nuclear proteins that interact with the HIV-1 Tat transcriptional activator protein *in vitro* (i.e. in cultured cells) has recently been described (Gautier *et al.*, 2009). This Tat interactome could be subdivided into functional modules including transcriptional activators, transcriptional repressors, replication and chromosome organization factors and nuclear structure components. Several transcription factor binding sites occur in the integrated viral DNA that modify the surrounding chromatin to control transcriptional activity by recruiting HATs (histone acetyltransferases) and HDACs. Some of the most well-known factors are members of the Sp1 (Harrich *et al.*, 1989) and NF- κ B signaling pathways (Kawakami *et al.*, 1988).

PCAF (p300/CBP-associated factor) (Deng *et al.*, 2000) and TRBP (TAR RNA binding protein) (Gatignol *et al.*, 1991) recruit Tat and bind the HIV-1 TAR loop, respectively. Cyclin T1 and cyclin-dependant kinase 9, CDK9 (subunits of the positive transcriptional elongation factor b complex, P-TEFb) (Bieniasz *et al.*, 1998) are recruited by Tat to relieve RNA Polymerase II stalling for the production of full-length viral transcripts (Yankulov and Bentley 1998). Recently, integrase interactor 1 (INI1), the key subunit of the SWI/SNF (switch/sucrose non-fermentable) chromatin remodeling complex, was found to downregulate basal LTR promoter activity and may induce one of two states post-integration: either latency or high-level, Tat-dependant gene expression (Boese *et al.*, 2009).

1.2.6 RNA processing and export

The transcribed 9 kb viral RNA encoding the Gag and Gag-Pol precursor protein can be spliced to a 4 kb RNA encoding Vif, Vpr, Vpu and Env or further spliced to a 2 kb RNA encoding Tat, Rev and Nef (Schwartz *et al.*, 1990; Purcell and Martin 1993). HIV-1 RNA splicing is controlled by viral exonic splicing silencers (ESS) and an intronic splicing silencer (ISS) that are bound by the cellular hnRNP (heterogeneous nuclear ribonucleoprotein) A/B family (Bilodeau *et al.*, 2001) or by hnRNP H. In addition, viral exonic splicing enhancers (ESE) are bound by the host SR (serine-arginine) proteins (Stoltzfus and Madsen 2006). HIV-1 Tat-specific factor 1 (HTATSF1), previously defined as a Tat regulatory factor (Zhou and Sharp 1996) has recently been shown not to function in stimulation of transcription but rather in regulating the relative levels of spliced and unspliced viral transcripts ((Miller *et al.*, 2009).

The fully-spliced 2 kb RNA encoding Rev is exported to the cytoplasm for translation, after which Rev shuttles back to the nucleus and binds the Rev-responsive element (RRE) in the introns of the 9 kb and 4 kb RNAs. The nuclear export signal of Rev then allows the bound RNA to be exported via the Ran-CRM1 (exportin 1) pathway (Fridell *et al.*, 1996), involving host factors Rev-interacting protein, hRIP (Bogerd *et al.*, 1995), Ran binding protein 1, RanBP1 (Zolotukhin and Felber 1997) and Sam68 (Reddy *et al.*, 1999). A Rev-independent RNA export pathway using the constitutive transport element (CTE) can also be used (Bray *et al.*, 1994) that relies on host factors Sam68, transcytosis-associated protein (TAP) and RNA helicase A (Tang *et al.*, 1997; Li *et al.*, 1999; Reddy *et al.*, 2000).

1.2.7 Translation, processing and trafficking

HIV-1 can use cap-independent translation by means of an internal ribosomal entry site (IRES) in its 5' untranslated region (UTR) (Brasey *et al.*, 2003) and in the Gag ORF (Buck *et al.*, 2001). This appears to be the favoured mode of translation as the viral PR inhibits a crucial host factor for cap-dependant translation, eukaryotic translation initiation factor 4G1, eIF4G1 (Ventoso *et al.*, 2001). Finally, for Gag-Pol translation to occur, an RNA pseudoknot forms that allows for read-through of the Gag stop codon by inducing a translational frameshift (Kang 1998).

The viral structural protein precursors, Gag and GagPol are translated in the cytoplasm on soluble polysomes and then directly transported to the membrane where multimerization (promoted by host ATP-binding cassette, sub-family E (OABP), member 1 - HP68/ABCE1 (Zimmerman *et al.*, 2002)) causes a conformational change that increases its affinity for the membrane (Lindwasser and Resh 2001; Lingappa *et al.*, 2006). Membrane trafficking of Gag is inhibited by TRIM22 that is induced by the Type I Interferon response (Barr *et al.*, 2008). In addition, Gag appears to bud into intracellular vesicles for release from the cell by budding exosomes (Gould *et al.*, 2003; Perlman and Resh 2006). This pathway is especially important in macrophages (Nguyen *et al.*, 2003, Pelchen-Matthews *et al.*, 2003) and requires the adaptor protein AP-3 for sorting into endosomes (Dong *et al.*, 2005). Recently, the role of dynein motor complexes and late endosomes in trafficking the viral RNA genome and Gag for virion production has been shown (Lehmann *et al.*, 2009).

Although Env and Gag trafficking to the membrane can occur independently, when co-expressed they affect each other's localization (Lodge *et al.*, 1997; Bhattacharya *et al.*, 2006). The Env protein is trafficked via the Golgi body after translation by ribosomes bound to the endoplasmic reticulum (ER). During transit, it forms a trimer, is processed

into its subunits (gp120 and gp41) by cellular endoproteases and is modified by glycosylation (Earl *et al.*, 1991).

1.2.8 RNA encapsulation and assembly

Virion assembly and release is driven by the viral NC protein that stabilizes and encapsulates the RNA genome during virion formation. Incorporation of the Env proteins and assembly at the membrane occurs on cholesterol-enriched microdomains or lipid rafts (Ono and Freed 2001) and requires the 47-kDa tail interacting protein, TIP47 (Blot *et al.*, 2003). As the entry receptor CD4 inhibits Env incorporation, it is down-modulated by viral Nef, Vpu and Env soon after entry (Chen *et al.*, 1996). Several host proteins are also incorporated into the virion: These include cyclophilin A, CypA (Franke *et al.*, 1994), APOBEC3G (Mariani *et al.*, 2003), tumour susceptibility gene 101, TSG101 (Garrus *et al.*, 2001) and vacuolar protein sorting 28, Vps28 (Hammarstedt and Garoff 2004), immune molecules HLA-DR (human leukocyte antigen DR), β 2-microglobulin and MHC (major histocompatibility complex) class I proteins (Orentas and Hildreth 1993; Tremblay *et al.*, 1998), as well as heat shock protein 70, Hsp70 (Gurer *et al.*, 2002), INI1/SNF5 (Yung *et al.*, 2001) and lysyl-tRNA synthetase (Kleiman *et al.*, 2004). These factors are either passively incorporated (by being embedded in the part of the plasma membrane that buds off) or included due to functional interactions with various viral products.

1.2.9 Virion budding

Budding is mediated by the endosomal sorting complex required for transport (ESCRT) components I, II and III (Usami *et al.*, 2009). Briefly, this machinery is recruited to the plasma membrane by Gag, which is ubiquitylated at low frequency (Gottwein and Krausslich 2005), via its associations with AIP1 (atrophin-interacting protein 1) (Strack *et*

al., 2003) and TSG101, a component of the Class E vacuolar protein sorting (VPS) machinery (Garrus *et al.*, 2001; VerPlank *et al.*, 2001). Several other VPS proteins, as well as the charged multivesicular body (MVB) proteins, CHMPs, that form the ESCRT III complex are involved in mediating efficient viral budding (Zamborlini *et al.*, 2006).

Other host factors involved in the process include Gag-interacting annexin II (Ryzhova *et al.*, 2006) and endophilins that interact with the ESCRT machinery and induce membrane curvature for virion budding (Farsad *et al.*, 2001). Tetherin (BST-2) has recently been shown to inhibit the spreading and release of budding viral particles. One of the membrane-spanning domains of this protein is embedded in the viral envelope while the other is anchored in the host cell membrane, effectively “tethering” the virions to the host cell. This action is countered by viral Vpu that causes proteasomal degradation of tetherin, as well as CD4 (Bour *et al.*, 1999; Levesque *et al.*, 2003), via the β -TrCP2-dependent pathway (Neil *et al.*, 2008; Douglas *et al.*, 2009; Mangeat *et al.*, 2009).

1.2.10 Virus transfer

Mature virus passes between cells mainly by the formation of virological synapses (Jolly and Sattentau 2004) that are induced by Env-CD4-coreceptor interactions and Env-induced activation of lymphocyte function-associated antigen 1, LFA1 (Arthos *et al.*, 2008). Other requirements include actin and tubulin cytoskeletal rearrangements, polarization of the microtubule organizing centre (MTOC) and junction stabilization by cellular adhesion molecules (Chen *et al.*, 2007; Jolly *et al.*, 2007). These can form between T-cells (Jolly *et al.*, 2004) and T-cells and dendritic cells (Stoll *et al.*, 2002; McDonald *et al.*, 2003).

Viral transfer between HIV-1 CD4+ T-cells is promoted by trafficking of Env and Gag to tetraspanin-enriched membrane domains for assembly and budding (Jolly and Sattentau 2007). Dendritic cells can take up virus particles by the C-type lectin, DC-SIGN

(dendritic cell-specific ICAM3 (intercellular adhesion molecule 3)-grabbing non-integrin) (Geijtenbeek *et al.*, 2000) that internalizes the virus into endocytic vesicles without becoming infected. When contact is made with a CD4+ T-cell, the virus is passed to the T-cell across a virological synapse mimicking the process of antigen presentation across an immunological synapse (McDonald *et al.*, 2003). Polysynapses have also been described whereby virus is passed from one infected T-cell to multiple target cells (Rudnicka *et al.*, 2009). Other modes of virus transport across cell-to-cell contacts use tunneling nanotubes (Sherer and Mothes 2008; Sowinski *et al.*, 2008) and filopodial bridges (Sherer *et al.*, 2007) as physical cellular extensions for virus transfer.

1.3 Current approaches to managing HIV-1/AIDS

The last 25 years have seen the development of several classes of ARV therapies that target various steps of the HIV-1 lifecycle. These include eight nucleoside/nucleotide analogues that inhibit viral RT activity [reviewed by (Cihlar and Ray 2010)], four non-nucleoside RT inhibitors [reviewed by (de Bethune 2010)] and nine approved PR inhibitors [reviewed by (Wensing *et al.*, 2010)]. In addition, inhibitors of viral entry and fusion (by maraviroc and enfuvirtide, respectively) [reviewed by (Tilton and Doms 2010)] and one targeting integration (raltegravir) have recently been approved, while another IN strand-transfer inhibitor (called elvitegravir) [reviewed by (McColl and Chen 2010)] is currently undergoing clinical trials. ARVs are the only available treatment options at present. These drugs effectively suppress HIV-1 replication when their regimen is adhered to consistently. However, adverse reactions in some patients, as well as poor access to the drugs in developing countries, often results in non-compliance to treatment (Deeks 2006).

HIV-1's relatively short lifecycle (1.5 days) and low-fidelity RT enzyme contribute to an uncommonly high viral mutation rate of $\sim 2 \times 10^{-5}$ mutations per base per replication

cycle (Huang and Wooley 2005). This leads to rapid evolution of viral escape mutations during single-drug therapy resistance to all known ARVs. In response, a highly active antiretroviral therapy (HAART) treatment programme was developed, in which two or more drugs (usually from different classes) are combined. HAART has been very successful, particularly in developed countries, at reducing the morbidity and mortality of HIV/AIDS (Palella *et al.*, 1998). The extensive development of ARVs has provided both first-line therapies (for previously untreated, ARV-naïve, patients) and second-line options for those that develop resistance or do not respond to initial therapy, while new drugs continue to be tested for efficacy from each ARV class (McCull and Chen 2010). However, as HAART cannot prevent viral resistance developing (particularly in non-compliant patients) nor eradicate latent reservoirs of transcriptionally silent integrated provirus (Pierson *et al.*, 2000) novel approaches are constantly being sought.

While the United States Food and Drug Administration (US FDA) have yet to approve a single vaccine for clinical use (AIDSinfo 2008), there are currently around 30 vaccine candidates being tested for clinical efficacy (IAVI 2010). In November 2007, the field was dealt a major blow when advanced clinical trials (Human Phase 2b) of the Merck vaccine (based on Ad5 – Adenovirus Type 5) were halted. The vaccine could neither prevent infection nor lower viral load in infected patients, while potentially increasing the risk of infection (Watkins *et al.*, 2008). As a result, the focus has shifted to basic research of alternative strategies, including gene therapy. While catalytic ribozymes, antisense molecules, aptamers and RNA decoys have all been used to good effect to target HIV-1 [reviewed by (Sherer *et al.*, 2007; Reyes-Darias *et al.*, 2008)], the most exciting advances have been in using the molecular tool RNA interference (RNAi) for the specific silencing (termed knockdown) of any gene of choice.

1.4 RNA interference (RNAi)

1.4.1 The endogenous RNAi pathway

The Nobel prize-winning discovery of gene silencing in nematode worms mediated by double-stranded RNA, termed RNAi (Fire *et al.*, 1998), was followed by the finding that 21-base pair (bp) small RNA duplexes (termed small interfering RNAs, siRNAs) could direct sequence-specific inhibition of mammalian genes with complementary sequences (Elbashir *et al.*, 2001). Subsequently, this inhibition was found to occur via the same pathway that generates 21-23 nt microRNAs (miRNAs), of which more than 700 have now been cloned, according to miRBase (Griffiths-Jones *et al.*, 2008). These sequences have diverse functions in development and cellular physiology [reviewed by (Bala *et al.*, 2009; Coolen and Bally-Cuif 2009; Iorio and Croce 2009; Liang and Qin 2009; Yang *et al.*, 2009)].

Both siRNAs and miRNAs are processed by RNase III-like endonucleolytic complexes in the multi-step RNAi pathway (Figure 1-3). Genome-encoded long RNA Pol II-derived primary miRNA (pri-miRNA) transcripts fold into an imperfect hairpin structure that is cleaved by the Micro-processor complex comprising of the Drosha nuclease and its cofactor, DGCR8 (DiGeorge critical region-8) (Lee *et al.*, 2003; Gregory *et al.*, 2004; Han *et al.*, 2004; Lee *et al.*, 2004). The mechanism by which Drosha “measures” the duplex before cleavage is still under debate (Han *et al.*, 2006; Zeng and Cullen 2006), but this process has recently been shown to occur during transcription in association with 5'-3' and 3'-5' exonucleases that degrade intronic sequences before splicing occurs (Morlando *et al.*, 2008). In addition, mirtrons (a subclass of miRNAs within intronic sequences) are not processed by Drosha at all but are rather generated during the splicing reaction (Okamura *et al.*, 2007; Ruby *et al.*, 2007).




Figure 1-3: The mammalian RNAi pathway.

Long primary microRNA (pri-miRNA) transcripts form hairpin structures that are recognised and cleaved by the nuclease Drosha and its cofactor DGCR8. The resulting pre-miRNAs are exported from the nucleus and subsequently processed by Dicer/TRBP (HIV TAR RNA binding protein) into ~22-nt mature miRNAs with 5' phosphates and 2 nucleotide overhangs on the 3' end. The strand with the thermodynamically most unstable 5' end is incorporated into an RNA-induced silencing complex (RISC) as a guide strand, leading the complex to target mRNAs of complementary sequence for cleavage by Ago2 (in the case of perfect complementarity) or translational suppression (imperfect binding).

The ~70 nucleotide (nt) pre-miRNAs generated by Drosha processing are exported from the nucleus by G protein-coupled Exportin 5 (Yi *et al.*, 2003; Lund *et al.*, 2004). In the cytoplasm, these pre-miRNAs are further processed by Dicer and its cofactors TRBP, a factor that provides an interesting link between HIV-1 and RNAi, which may be used by the virus to subvert the RNAi machinery and prevent downregulation of viral gene expression (Bennasser *et al.*, 2006), and the protein, PACT (Kok *et al.*, 2007). Dicer “measures” 21-22-nt from the Drosha cleavage site to create mature miRNAs with 5’ phosphates and 3’ 2-nt overhanging ends (Bernstein *et al.*, 2001; Hutvagner *et al.*, 2001). Double-stranded RNA is similarly processed into 21-25 nt siRNAs. Subsequently, the duplex is unwound (by an unknown helicase) and one strand (the mature miRNA or guide strand) is incorporated into the RNA-induced silencing complex, RISC (Gregory *et al.*, 2005), selected based on the relative thermodynamic stability of the duplex ends (Khvorova *et al.*, 2003; Schwarz *et al.*, 2003).

Perfect complementarity with the guide sequence results in target mRNA cleavage by the Argonaute (Ago) 2 component of the RISC (Chendrimada *et al.*, 2005), while imperfect binding mediates translational suppression and mRNA destabilization [reviewed by (Ma *et al.*, 2009)]. The most important sequence in the latter mechanism is the “seed” or “nucleus”, a seven base-pair region at the 5’ end of the guide strand extending from nucleotides 2 to 8 (Doench and Sharp 2004). miRNA seed region matching allows a single miRNA to potentially target hundreds of genes, usually in their 3’ untranslated regions (Grimson *et al.*, 2007). When these genes are regulators of transcription or alternative splicing themselves, the compound effect of the miRNA on gene regulation can become complex [reviewed by (Makeyev and Maniatis 2008)]. The exact mechanism of miRNA translational suppression is incompletely understood but seems to include deadenylation of poly-A tails and decapping (or inhibiting 5’ cap recognition) of mRNA that leads to destabilisation and exonuclease degradation, respectively, as well as inhibition of the translation initiation machinery [reviewed by (Ma *et al.*, 2009)].

The mechanisms described above mediate post-transcriptional gene silencing by the RNAi pathway. Recently, a novel transcriptional gene silencing process in the nucleus has been described, whereby promoter-targeted siRNAs induce chromatin modifications associated with transcriptional silencing, including histone 3 lysine 9 (H3K9) dimethylation and H3K27 trimethylation (Mette *et al.*, 2000; Morris *et al.*, 2004; Strunnikova *et al.*, 2005; Weinberg *et al.*, 2006). Although the exact mechanisms are still unclear, Ago1, DNA methyltransferase 3a (DNMT3a) and HDAC1 appear to initiate siRNA-mediated transcriptional gene silencing, TGS, while DNMT1 is necessary for maintaining the silencing effect (Hawkins *et al.*, 2009). In addition, Ago1 and the Polycomb group component, EZH2, were associated with miRNA-mediated TGS of the polymerase (RNA) III (DNA directed (POLR3D) cell cycle gene promoter [reviewed by (Kim *et al.*, 2008)]. There is some controversy as to whether TGS targets the DNA or associated RNA of the promoter (Verdel *et al.*, 2004; Han *et al.*, 2007). Finally, as the silencing mediated by TGS is stabler than PTGS and also heritable, the prospect of its application in gene therapies is great. Recently, prolonged TGS of a sequence within the HIV-1 LTR promoter has been reported in a T-cell line model using a retrovirally delivered shRNA (Turner *et al.*, 2009).

1.4.2 RNAi as a reverse genetics tool

The RNAi pathway can be harnessed for use as a molecular tool by exogenously introducing synthetic siRNAs or vectors that express short hairpin RNAs (shRNAs) that enter the miRNA pathway post- and pre-Dicer processing, respectively. These shRNAs/siRNAs can be engineered for targeting specific genes for knockdown, which has rapidly become the most popular reverse genetic approach to studying gene function. Some of the organisms in which this approach has recently been used include: mammals (in vitro) (Chen *et al.*, 2010; Shahbazian *et al.*, 2010; Zalckvar *et al.*, 2010), invertebrates (Posnien *et al.*, 2009; Rehm *et al.*, 2009; Yang *et al.*, 2010), yeast (Hoffmann *et al.*, 2009;

Bolz *et al.*, 2010), plants (Petsch *et al.*, 2009; Zhang *et al.*, 2009), protoplasts (Zhai *et al.*, 2009), parasites (Stephens *et al.*, 2007; de la Fuente *et al.*, 2010; Verner *et al.*, 2010) and viruses (Heikkila *et al.*, 2010; Hirsch 2010; Karlas *et al.*, 2010). The advantage of RNAi over previous approaches like mutagenesis screens and mouse knock-out models is that it is far simpler, quicker and less costly to implement (even at a genome-wide scale) while providing potent gene inhibition to study loss-of-function effects.

1.4.3 RNAi as an exciting and powerful new gene therapy

Apart from functional studies, novel gene therapy strategies based on RNAi have been developed and even patented for a wide range of diseases [reviewed by (Grinberg 2008)]. These include neurodegenerative diseases [reviewed by (Farah 2007)], cancers [reviewed by (Ashihara *et al.*, 2009)], respiratory disorders like asthma [reviewed by (Huang and Chiang 2009)], cardiovascular disease (Hu *et al.*, 2009; Qiu *et al.*, 2009) and infectious diseases (Yokota *et al.*, 2007; Gao *et al.*, 2008; Lambeth *et al.*, 2009). Because of the ease with which RNAi effectors can be designed (using bioinformatic approaches) to target any gene, it is now possible to develop therapeutics for targets that have before now been declared “undruggable”, as well as for diseases that are rare or newly emerging. Moreover, diseases that manifest early or are heritable can be addressed by the advent of delivery of RNAi to human embryonic stem cells (HESCs) [reviewed by (Rassouli and Matin 2009)]. These cells are not only pluripotent (i.e. differentiate into every cell type during development) but also self-renewable (Thomson *et al.*, 1998), making RNAi-modified HESCs an attractive prospect for treating degenerative disorders.

1.5 RNAi approaches targeting HIV-1

There have been numerous studies using RNAi to silence HIV-1 gene expression, including the *gag*, *pol*, *vif*, *tat*, *rev*, *env* and *nef* genes and the LTR promoter region (Coburn and Cullen 2002; Hu *et al.*, 2002; Jacque *et al.*, 2002; Park *et al.*, 2003; Boden *et al.*, 2004; Das *et al.*, 2004). However, the high viral mutation rate makes it difficult to develop antiviral RNAi therapies with long-lasting efficacy. As with antiretroviral drug resistance, escape mutants arise rapidly to evade RNAi-mediated targeting, via single base changes within the target region or by evolving secondary structures that render the target region inaccessible (Boden *et al.*, 2003; Das *et al.*, 2004; Westerhout *et al.*, 2005). In response, researchers have combined shRNAs targeting several highly conserved viral regions simultaneously (ter Brake *et al.*, 2006), while multiple siRNAs targeting *gag*, *pol*, *int* and *vpu* conserved sequences have been shown to effectively inhibit various strains of HIV-1, as well as viral replication in a chronically infected cell line and in primary human peripheral blood lymphocytes (Chang *et al.*, 2005). Finally, a combination of three potent shRNA sequences that target highly conserved HIV-1 sequences was recently shown to inhibit replication of a HIV-1 molecular clone in shRNA vector-transduced T-cells without viral escape for more than three months (von Eije *et al.*, 2009).

The relative advantages and disadvantages of using siRNAs versus shRNA expression vectors in this setting are well reviewed (Subramanya *et al.*, 2010). The main issues raised are that siRNAs mediate transient knockdown (a few days), are not effectively delivered to T-cell or macrophage primary cells and cannot be incorporated into combinatorial therapies, while shRNAs are more time-, cost- and labour-intensive to produce and when stably expressed from lentiviral (HIV-derived) vectors pose safety concerns.

1.5.1 Viral versus cellular targets

An alternative strategy to prevent viral escape from RNAi is to target cellular genes that HIV-1 requires for efficient replication. While HIV-1 can evade RNAi effectors targeting its own genome with relative ease, targeting essential HIV-1 host factors would require the virus to evolve a novel or alternate method of exploiting the host cellular pathways. Another advantage to this approach is that the problem of eradicating latent integrated provirus may be overcome by targeting host factors involved in pre-integration stages of the replication cycle. Disadvantages of targeting host factors include HIV-1's ability to exploit multiple cellular pathways in parallel. This redundancy that has evolved between host and pathogen creates networks of interactions that are difficult to define and interrupt via therapeutic means. Targeting host genes may also have detrimental side-effects on normal cellular function: while knockdown of both CD4 and CXCR4 have been shown to inhibit HIV-1 replication (Martinez *et al.*, 2002; Novina *et al.*, 2002; Park *et al.*, 2002), CD4 is essential to immune function while CXCR4 is important for hematopoietic stem cell function and differentiation, thus limiting these factors' value as good therapeutic targets (Moore 1997; Lapidot and Kollet 2002). In contrast, the CCR5 entry co-receptor poses an attractive target for several reasons: 1) it is not essential for immune function, 2) individuals with a 32 base-pair genetic deletion (CCR5 Δ 32) are healthy and 3) these individuals either resist HIV-1 infection (if homozygous for the deletion) or progress much slower to AIDS (heterozygous carriers) (Samson *et al.*, 1996; Eugen-Olsen *et al.*, 1997; Garred *et al.*, 1997). Indeed, a recent report shows that transplantation of CCR5 Δ 32 stem cells to an HIV-1 infected patient inhibited the virus to undetectable levels for 20 months after the transplant, without HAART (Hutter *et al.*, 2009). The only apparent drawback of targeting this factor is that HIV-1 switches tropism during infection from using CCR5 as coreceptor to CXCR4 (Arien *et al.*, 2006). In addition, a recent study in South Africa has shown a concerning increase in primary HIV-1 strains that use CXCR4 as entry co-receptor (Connell *et al.*, 2008). However, by targeting conserved viral sequences in

addition to such cellular factors a more potent and durable therapy is made possible. As more host factors are identified and characterised, a greater diversity of such therapies can be developed.

1.6 Genome-wide siRNA screens for novel HIV-1 host factors

Before the development of genome-wide libraries of RNAi effectors approximately 50 host factors were known to be involved in regulating HIV-1 replication [reviewed by (Goff 2007)]. Since then, high-throughput technology and robotic systems have developed that have been used in several genome-wide siRNA screens in the last two years. These screens have collectively implicated several hundred novel host factors that appear to be involved in HIV-1 replication, effectively leap-frogging our understanding of this process. The first published study (Brass *et al.*, 2008) used a genomic siRNA screen to determine which of ~21,000 human genes HIV-1 needs to replicate. The authors discovered 273 host genes that could be classified by their criteria as HIV-1 dependency factors (HDFs), of which 237 were novel (see Figure 1-4, pg 27). Two independent research teams (Konig *et al.*, 2008; Zhou *et al.*, 2008) closely followed with reported discoveries of 213 and 267 novel HDFs respectively.

A meta-analysis comparing these three datasets, as well as several other studies' datasets (Chertova *et al.*, 2006; Hao *et al.*, 2008; Krishnan *et al.*, 2008; Studamire and Goff 2008) showed limited overlaps from individual pairwise comparisons (Bushman *et al.*, 2009). However, network analysis of the novel genes recovered formed several densely connected cellular-viral gene clusters representing cellular subsystems involved in HIV-1 replication. These include the proteasome, various subunits and factors of RNA Polymerase II, the Mediator complex, various transcription factors required for Tat activation and elongation of transcription, RNA binding and splicing proteins, protein

chaperones involved in protein folding and sorting, Tat activation and budding and finally factors involved in tRNA synthase functioning and transport (Bushman *et al.*, 2009).

The small overlap between these datasets mostly reflects fundamental differences in study design. All three groups used cell lines engineered to allow artificial infection by HIV-1. The pattern of gene expression in these cells differs greatly from CD4+ T-cells and macrophages (HIV-1 natural host cell types). This implies that gene expression products in these cell lines may allow interactions with viral proteins that do not represent true host-virus interactions occurring during a natural infection. In addition, viruses used were either lab-adapted strains or molecular clones missing several important viral accessory proteins (including Nef, Vpu and Vpr) or pseudotyped with the envelope protein of Vesicular Stomatitis Virus (VSV-G) that uses a different mode of entry to HIV-1. Screening for host factors using such virus models could thus mask many important viral/host interactions.

1.6.1 Selection of novel host factors for validation in this study

To address the need to validate these candidate factors, five of the novel HDFs implicated by Brass *et al.* (2008) as being required for HIV-1 infection were selected: SPTBN1 (spectrin beta non-erythrocytic 1), TMED2 (transmembrane emp24 domain trafficking protein 2), KIAA1012 (a gene of relatively unknown function), PRDM14 (PR domain containing 14) and SP110 (SP110 nuclear body protein), using unbiased criteria as described in Section 3.1. According to Brass *et al.*, SPTBN1, TMED2 and KIAA1012 are involved in the early phase (pre-Gag translation) of the HIV-1 lifecycle, while PRDM14 and SP110 are required for later stages involving assembly and budding of virions (see Figure 1-4, pg 27).

1.6.1.1 SPTBN1

SPTBN1 is one member of a family of beta-spectrin genes. Spectrin is an actin-crosslinking and molecular scaffold protein and functions in determining cell shape, arranging transmembrane proteins and organelle organization (Taylor-Harris *et al.*, 2005). In addition, it appears to play a role in regulating T-lymphocyte function via ankyrin, which binds directly to CD45, sequestering it from being recruited to the cell surface and abrogating Jurkat T-cell activation (Pradhan and Morrow 2002). Finally, this spectrin is directly cleaved by HIV-1 protease, along with other focal adhesion plaque proteins. Brass *et al.* hypothesize that SPTBN1 may be involved in inward trafficking of the virus via its interaction with the actin network.

1.6.1.2 TMED2

TMED2 (p24A) is part of the p24 cargo receptor family. This family has been shown to form complexes with GRASP55 and -65, peripheral membrane components of the Golgi matrix, which sequesters the p24 cargo receptors in the Golgi apparatus. In addition, p24A interacts with both ARF1 and ARFGAP (Majoul *et al.*, 2001), with studies implicating it as an integral receptor for the coatamer protein 1 (COP1) vesicle coat, cycling continuously between the intermediate compartments of the Golgi and the cis-Golgi network (Blum *et al.*, 1999). Recently, p24A has had a novel function described as a regulator of signal-dependent trafficking during the life cycle of PAR-2 (Protease-activated receptor 2) (Luo *et al.*, 2007). Thus this gene may play a role in retrograde Golgi-to-ER trafficking of virus.

1.6.1.3 *KIAA1012*

KIAA1012 is highly expressed in immune cells, both B- and T-lymphocytes, as well as NK (natural killer) cells. With three transcripts expressing five proteins, its function is still uncharacterised. Its homologue, TRS85, is a component of the transport protein particle complex (TRAPP) (Sacher *et al.*, 2000) and is involved in selective autophagy via the Cvt (cytoplasm to vacuole targeting) pathway, for the biogenesis of double membrane-layered Cvt vesicles (Meiling-Wesse *et al.*, 2005). A putative involvement in viral transport via these vesicles has still to be explored.

1.6.1.4 *PRDM14*

PRDM14, apart from containing a PR-domain, a subtype of the SET domain that catalyzes histone methylation, also has several zinc finger conserved domains. Recently, upregulation of this gene was found in two-thirds of all breast cancers, while an effect of reducing cancer cell sensitivity to chemotherapeutics was also described (Nishikawa *et al.*, 2007). Interestingly, PRDM14 is specifically expressed in undifferentiated human ES (embryonic stem) cells (Tsuneyoshi *et al.*, 2008). Taken together, these findings indicate a potential role in transcriptional regulation of viral gene expression.

1.6.1.5 *SP110*

SP110 acts as a nuclear hormone receptor transcriptional co-activator and is associated with the nuclear body complex. This gene is induced by the Interferon response (Regad and Chelbi-Alix 2001), offering immunoprotection against pathogens (Everett and Chelbi-Alix 2007). In contrast, it has also been found to be recruited by several pathogens, specifically Epstein Barr Virus (Nicewonger *et al.*, 2004) and *Anaplasma phagocytophilum* (de la Fuente *et al.*, 2007) where it modulates retinoid signalling and stabilises pathogenic gene expression. Thus a potential role in regulation of viral gene expression and/or the Interferon response is intriguing.

The functions and molecular interactions of these genes, as well as the findings published by Brass *et al.* (2008), support their putative role as novel HDFs. However, a robust, individual approach is required for careful validation of these genes' role in HIV-1 infection and replication. Validating each of the several hundred candidate HDFs that have been implicated recently will vastly accelerate our understanding of the way in which complex retroviruses like HIV-1 adapt to use their cellular environment for efficient replication. In addition, such HDFs will potentially provide a large array of novel targets for conventional drug-targeting and newer gene therapy approaches, thereby making an effective anti-HIV treatment a more feasible goal.




Figure 1-4: Model of putative HDF roles in the HIV lifecycle.

The function and sub-cellular location of HDFs was determined using multiple databases (Table S4 of Brass *et al.*, 2008). Proteins in multiple locations represent more than one possible role in the HIV lifecycle. The HDFs selected for this study are circled in red. Newly identified HDFs (red or blue, the latter late-acting); previously implicated HDFs detected (green), or not detected but with a relevant interaction (grey); HIV protein (black): matrix, MA, reverse transcriptase, RT, integrase, IN, envelope (gp41, gp120), ENV. Unfolded protein response, UPR. (Brass *et al.*, 2008)

1.7 Aims and Objectives

The overall aim of this project was to validate the role that *SPTBN1*, *TMED2*, *KIAA1012*, *PRDM14* and *SP110* play in HIV-1 infection and replication. The specific objectives were to:

- 1) Use expressed shRNAs and siRNAs to silence the expression of these genes by the RNA interference (RNAi) pathway.
- 2) Quantify the ability of these RNAi effectors to suppress their target sequences in (i) a minimal target/reporter system and (ii) at the endogenous mRNA level using a dual luciferase reporter assay and quantitative RT-polymerase chain reaction (qRT-PCR) assays, respectively. The latter would require optimisation and validation to ensure that the results are accurate and reproducible.
- 3) Determine if gene loss-of-function, as well as the RNAi process or cellular delivery method, had any detrimental effects on cell viability using a colorimetric assay for metabolic enzyme activity.
- 4) Optimise delivery of DNA- and RNA-based fluorescent reporters to a T-cell line using electroporation and lipid-based transfection reagents.
- 5) Determine the effect of each gene's knockdown on HIV-1 replication kinetics in (i) a single infection cycle pseudoviral challenge and (ii) a two-part challenge with fully-replicating virus.

CHAPTER 2 : METHODS AND MATERIALS

2.1 RNAi effecters

2.1.1 shRNA-encoding sequences

The original set of shRNAs was designed based on the sequences available in the Broad Institute/The RNAi Consortium (TRC) MISSION™ shRNA library (Moffat *et al.*, 2006; TRC 2008). This library consists of shRNA sequences designed to specifically target the transcripts of a large number of NCBI (National Centre for Biotechnology Information) human and mouse genes and can be accessed online at the following URL: <http://www.broadinstitute.org/rnai/trc/lib>. The 21-mer candidate shRNA sequences (typically five per gene) span the length of the coding region (25 bp after the initiation of transcription until 150 bp before the end of the transcript) and usually include one targeting the 3' untranslated region. They are sorted according to a score that is based on siRNA sequence criteria (Elbashir *et al.*, 2001; Reynolds *et al.*, 2004). These include strong base-pairing at the 5' end, weak base-pairing at the 3' end, no internal loop formations, a preferred GC-content of 60-70%, no single nucleotide polymorphisms (SNPs) or ambiguous bases, relatively AT-rich sequences from positions 6-11 and avoidance of seven consecutive GC bases or four of the same bases in a row. After sorting the candidates are further selected to avoid overlaps with each other and matches with other human gene sequences.

The TRC 21-nucleotide sense and antisense sequences were joined with a nine-nucleotide loop sequence (5'-CCT GAC CCA-3') (see Figure 2-1 for an example). A guanine residue (G) at the 5' end (the same first nucleotide as in the native U6 small nuclear RNA) and six T-residues at the 3' end ensured efficient initiation and termination

of transcription respectively. Where three or more T-residues occurred in the sense (anti-guide) strand, mismatches were introduced to avoid premature termination of transcription. If three or more T-residues occurred in the antisense (guide) sequence that is important for target sequence recognition, a different shRNA sequence was designed using the HPCDispatcher siRNA site selector application (Heale *et al.*, 2005). This is an online application available at the following universal resource locator (URL): <http://www1.infosci.coh.org/hpcdispatcher/siRNA.aspx> (HPCDispatcher) that calculates the difference in thermodynamic stability between the ends of a siRNA duplex. Duplexes with the greatest thermodynamic difference were chosen while incorporating the same design rules and modifications described above.




Figure 2-1: Example of shRNA design approach.

The top panel shows the duplex sequence from the online TRC MISSION shRNA library. The bottom panel shows 21 base-pairs of the duplex connected by a 9-nucleotide loop, including single-stranded end modifications and mismatches induced (bold) to remove triple uridine residues in the sense strand (anti-guide).

2.1.2 Specificity and structure of shRNA sequences

The specificity of all shRNA sequences was assessed using NCBI's online BLAST (basic local alignment and search tool) (Altschul *et al.*, 1990; BLASTn 1990) to detect off-

target matches with other gene sequences. This search tool can be found online at the following URL: <http://blast.ncbi.nlm.nih.gov/Blast>. The shRNA sequence was compared with the human genomic and transcript database using the megablast program of BLASTn (for nucleotide sequences) that optimises the search for highly similar sequences. In addition, the secondary structure of the shRNA sequence was assessed using the RNA mfold v 3.2 server (Zuker 1995-2010; Mathews *et al.*, 1999; Zuker 2003) using the default parameter settings. This program is available at the following URL: <http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi>.

2.1.3 siRNA SMARTpools

siRNA ON-TARGET^{plus}™ SMARTpools were ordered from Dharmacon® (Thermo Fisher Scientific, Lafayette, CO, USA) targeting *SP110* (target transcript NM_004510, catalogue number L-011875-00-0005) and *SPTBN1* (target transcript NM_178313, catalogue number L-018149-01-0005). As a non-targeting control, a siRNA targeting the HBx sequence of Hepatitis B Virus, HBV (designed by Prof Piet Herdewijn of the Rega Institute for Medical Research Laboratory of Medicinal Chemistry / Katholieke Universiteit Leuven in Leuven, Belgium and Prof Joachim Engels of Wolfgang Goethe University in Frankfurt, Germany) was used that comprised a Cy3 fluorescent dye-labelled antisense strand and a sense strand that were annealed together before use (see Table A-8 of Appendix A). All siRNAs were resuspended in buffer (60 mM KCl (Burani Design Holding, BDH, Chemicals, Poole, England), 6 mM HEPES (pH7.5), 0.2 mM MgCl₂ (Saarchem Merck Chemicals, Gauteng, South Africa)) and stored as 20 µM aliquots at -70°C.

Subsequently, new shRNAs were designed based on the individual siRNA target sequences of each SMARTpool. The same nine-nucleotide loop sequence was used to join the 19 bp sense/antisense (antiguide/guide) duplex, with six terminating T-residues at

the 3' end and a G-residue as the first nucleotide to be transcribed. Three or more T-residues were again avoided by introducing mismatches (if occurring in the sense strand). Where these occurred within the antisense (guide) strand the sequence was synthesized so that ~50% of the oligonucleotides would have a T-residue at that point and ~50% would have a C-residue (as both these nucleotides have pyrimidine bases, they have similar ability to bind the sense strand). Thus a single clone produced from these oligonucleotides would have either a T- or a C-residue. The genomic locations targeted by the shRNAs and siRNAs described above are listed in Tables A-1 and A-2, respectively, of Appendix A.

2.2 Previously constructed plasmids used in this study

Several plasmids were used routinely in cloning or in transfections that were not created during this study: pTZ57R (provided with the PureExtreme® InsTAclone™ PCR cloning kit from MBI Fermentas, MD, USA) was used in T/A cloning - this method exploits the fact that *Taq* polymerase adds an A-residue to the 3' end of amplicons (Clark 1988; Hu 1993). PCR products can easily be inserted into the linearised vector, pTZ57R/T, by ligating to the flanking T-residue of the T/A cloning site (Holton and Graham 1991; Marchuk *et al.*, 1991; Mead *et al.*, 1991).

psiCHECK-2.2 was created by Dr M S Weinberg of our laboratory: an oligonucleotide encoding several restriction sites was inserted into psiCHECK-2™ (Promega, WI, USA), thereby creating a new multiple cloning site. This vector encodes both *Renilla luciferase* and *Firefly luciferase* and is useful for rapidly assessing RNAi knockdown efficacy.

pCI-EGFP is a useful reporter plasmid expressing enhanced Green Fluorescent Protein (eGFP) from the Cytomegalovirus (CMV) immediate early enhancer/promoter. It

was constructed by cloning the EGFP ORF into the mammalian expression vector pCI Neo (Promega, WI, USA) (Passman *et al.*, 2000).

phRL-CMV (Promega, WI, USA) is a reporter plasmid that expresses *Renilla* luciferase from a CMV promoter. This plasmid was used to control for transfection efficiency and variation in cell density during experiments in TZM-bl cells that stably express integrated Firefly *luciferase* (Section 2.4).

All shRNAs used and created in this study are expressed from the pTZU6+1 vector (kindly provided by Dr David Engelke of the University of Michigan). To control for background activity from the U6 promoter, experiments always included this empty vector as a Mock control. To control for non-specific knockdown effects, several plasmids expressing shRNAs targeted to other sequences were tested for use in knockdown experiments. Two shRNAs targeted to HBV, U6 shRNA 5 and U6 shRNA 10 (Carmona *et al.*, 2006), renamed shHBx-5 and shHBx-10 here, as well as shLacZ (constructed in our laboratory to target the *lacZ* gene of *E. coli*) were tested for their ability to knockdown each of the genes targeted in this study.

Two shRNAs that have been shown previously to knock down HIV-1 were included as positive controls in virus knockdown experiments: shLTR was constructed in our laboratory by S Barichievy and targets the HIV-1 long terminal repeat (LTR) promoter. U6+1 *tat/rev* shRNA (Scherer *et al.*, 2004) was renamed shTat in this study and targets the viral *tat/rev* ORF. Two shRNAs targeting confirmed HIV-1 host factors were used: shPL3 (renamed shLEDGF in this study) was created by V Green of our laboratory to target *LEDGF* (lens epithelium-derived growth factor) (Section 1.2.4); shHTATSF-2 (also created by V Green) targets *HTATSF1* (Section 1.2.6). The sequences of these shRNA controls are given in Table A-8 of Appendix A.

2.3 Molecular cloning

2.3.1 Cloning of shRNA expression cassettes

Sequences encoding the first set of shRNAs were designed as two overlapping oligonucleotides. They were synthesized in reverse primer orientation to allow for two-step PCR-amplification of the U6 promoter template, similar to the approach used by Castanotto *et al.* (2002). Figure 2-2 shows a schematic of the PCR/cloning approach and Tables A-3 and A-4 (Appendix A) list the primer sequences used.




Figure 2-2: Schematic of two-step PCR approach used in construction of shRNA cassettes.

Two-step PCR amplification of the U6 promoter using a universal U6 forward primer and two reverse primers successively resulted in a final product comprising the U6 Pol III promoter, beginning with *Bam*HI and *Eco*RI restriction sites and ending in a Guanine residue (important for initiation of transcription), followed by the sense, loop and antisense sequences of the shRNA and ending with a poly-T termination signal of 6 Thymine residues. This PCR product (with 3' adenine residues added by *Taq* polymerase) could be cloned into T/A vector pTZ57R/T.

First-round PCR amplification of 10 pmol of U6 promoter template was performed using 10 pmol each of forward and reverse primer (R1) and 1 × PCR Master Mix (Promega, WI, USA) (25 U/ml *Taq* polymerase in a proprietary buffer at pH 8.5; 200 μM of each dNTP and 1.5 mM MgCl₂) in a 20 μl reaction volume. Thermal cycling parameters were as follows: initial denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation (95°C for 30 seconds), primer annealing (58°C for 45 seconds) and elongation (72°C for 30 seconds) and a 15 minute extension step (at 72°C). Approximately 10 ng of the product was used as template for the second round of PCR, using the same conditions as above with R2 reverse primer and the final step extended to 20 minutes at 72°C.

The PCR-amplified shRNA cassettes were then ligated with pTZ57R/T using the InstAclone PCR cloning kit. After PCR, 5 μl of the reaction volume was analyzed by gel electrophoresis (2% agarose, stained with ethidium bromide (Sigma-Aldrich Corp., MO, USA) (see Appendix B for safety precautions) and run at 5 V/cm in 1 × Tris-borate-EDTA (TBE) buffer (45 mM Tris-borate, 1mM EDTA (ethylenediaminetetraacetic acid), pH 8.3) (Saarchem Merck). When a single clear band was visible under UV light, 540 ng of the ~300 bp PCR product was used directly in the ligation reaction with 150 ng of pTZ57R/T (corresponding to a 3:1 ratio of insert:vector), 5 U T4 DNA Ligase and 1 × ligation buffer (40 mM Tris-HCl, 10 mM MgCl₂, 10 mM dithiothreitol (DTT), 0.5 mM ATP, pH 7.8) made up to a 20 μl reaction volume. When non-specific bands were visible, gel extraction of the correct-sized band was done (using the KOMA EzWay Gel Extraction Kit (KOMA Biotech,

Seoul, Korea) according to the instructions of the supplier) before ligation. Quantification of the DNA used in the ligation was done using the NanoDrop™ 1000 spectrophotometer (Thermo Scientific) at 260 nm relative to 280 nm.

Cloning of the second set of shRNAs, shSPTBN-A, shSPTBN-B, shSPTBN-C, shSPTBN-D, shSP110-A, shSP110-B, shSP110-C and shSP110-D, was done using the pooled siRNA sequences (see Section 2.1.3) and used a slightly different approach (also described by Castanotto *et al.*, 2002): a single round of PCR was performed using one long reverse primer (encoding a portion complementary to the 3' end of the U6 promoter, followed by the entire shRNA sequence) and a U6 forward primer with four upstream restriction sites: *Bam*HI, *Xho*I, *Not*I and *Nhe*I. The sequences of these primers are given in Table A-5 (Appendix A).

2.3.2 Cloning of target reporter plasmids

Target reporter plasmids (corresponding to the first set of shRNAs) were constructed so that the three shRNA target sites for each gene were cloned in tandem downstream of the *Renilla* luciferase ORF (see Figure 2-3, pg 38), expressed from the dual luciferase reporter plasmid, psiCHECK-2.2. A set of four oligonucleotides was designed to encode the various target sequences (Table A-6 of Appendix A and Figure 2-3). The F1 and R1 oligonucleotides were designed to anneal as double stranded DNA sequences encoding the first half of the three target sites and an overhang containing *Xho*I and *Eco*RV restriction sites at the 5' end. Similarly, the F2 and R2 oligonucleotides were designed to anneal as double stranded DNA sequences encoding the second half of the three target sites and a *Not*I overhang at the 3' end. The annealed F1/R1 and F2/R2 sequences would also have overhangs at their 3' and 5' ends respectively, that would allow them to be ligated together. psiCHECK-2.2 backbone was prepared for directional cloning by digesting 2 µg of plasmid with 2 U *Xho*I and 1 U *Not*I restriction enzymes using

Buffer O (MBI Fermentas, Ontario, Canada) (50 mM Tris-HCl, 10 mM MgCl₂, 100 mM NaCl, 0.1 mg/ml bovine serum albumin (BSA), pH 7.5) in a 30 µl reaction volume. This was followed by agarose gel electrophoresis (0.8% agarose, stained with ethidium bromide and run at 5 V/cm in 1 × TBE buffer) and extraction of the digested product with the KOMA EzWay Gel Extraction Kit (KOMA Biotech, Seoul, Korea). The four oligonucleotides for each target sequence were joined to form one double-stranded oligonucleotide by the following steps: First, the 5' ends of the F2 and R1 oligonucleotides were phosphorylated - 200 pmol of oligonucleotide was incubated with 2 µl of 10 mM ATP (Sigma-Aldrich) and 5 U of T4 Polynucleotide Kinase (PNK) (New England Biolabs, NEB) in 1 × T4 Polynucleotide Kinase Reaction Buffer (NEB) (70 mM Tris-HCl, 10 mM MgCl₂, 5 mM DTT, pH 7.6) in a 20 µl reaction volume at 37°C for 1 hour. Next, the F1/R1 and F2/R2 pairs were annealed to form two double-stranded oligonucleotides: 100 pmol each of the oligonucleotides were incubated at 80°C for 5 minutes, followed by slow cooling to ~25°C. Finally, these were three-way ligated into the prepared backbone: 60 fmol of vector backbone was added to 180 fmol each of insert and incubated with 5 U of T4 DNA Ligase and 1 × ligation buffer (composition described above) in a 20 µl reaction volume for 1 hour at 16°C.




Figure 2-3: Reporter target cloning strategy.

The oligonucleotides encoding the shRNA target sequences for TMED2. After ligating the oligonucleotide pairs, they were positionally cloned into psiCHECK2.2 digested with *XhoI* and *NotI*.

2.3.3 Transformation and verification of clones

Chemically competent DH5α *Escherichia coli* (*E. coli*) cells (see Appendix B) were transformed with the ligation mixes by incubating 100 µl cells with 10 µl of the ligation reaction for 30 minutes on ice, heat-shocking at 42°C for 90 seconds, followed by further incubation on ice for 5 minutes. Transformed cells were plated onto sterile Agar (see Appendix B) containing ampicillin (100 µg/ml) and spread with 40 µl X-Gal (20 mg/ml,

5-bromo-4-chloro-3-indolyl b-D-galactopyranoside) and 8 μ l IPTG (100 mg/ml, Isopropyl β -D-1-thiogalactopyranoside) and grown overnight at 37°C. In recombinant clones, the *lacZ* gene is interrupted by the ligation reaction and thus white colonies are formed (Sambrook and Russell 2001). White colonies were selected and used to inoculate 4 ml Luria-Bertani broth supplemented with ampicillin for overnight culture (see Appendix B). Subsequent plasmid preparation was done using the High Pure Plasmid Isolation kit (Roche Applied Science, Mannheim, Germany) as described in Appendix B. Target clones were screened by *EcoRV* (MBI Fermentas) digestion (10 U in Buffer R (MBI Fermentas) (10 mM Tris-HCl, 10 mM MgCl₂, 100 mM KCl, 0.1 mg/ml BSA, pH 8.5) for 1 hour at 37°C) and shRNA clones with *XbaI/HindIII* double digestion (2 U of *HindIII*, 1 U of *XbaI* and 1 \times Tango buffer (MBI Fermentas) (33 mM Tris-acetate, 10 mM Mg-acetate, 66 mM K-acetate, 0.1 mg/ml BSA, pH 7.5) in a 30 μ l reaction volume for 1 hour at 37°C), followed by agarose (stained with ethidium bromide) gel electrophoresis and visualization under UV light.

Positive clones were verified using automated sequencing with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). The cycle sequencing reaction was set up with 100 ng of template plasmid, 2 μ l Ready Reaction Mix (Applied Biosystems), 1 \times BigDye Terminator v3.1 Sequencing Buffer (Applied Biosystems) and 10 pmol primer, made up to 10 μ l with distilled water (dH₂O). Sequencing of pTZU6-shRNA clones was done with M13 reverse primer (5'-CAG GAA ACA GCT ATG AC-3') or the U6 forward primer; target primer (5'-CGA CGA TCT GCC TAA GAT GT-3') was used for psiCHECK-target clones. Thermal cycling conditions were as follows: 96°C for 1 minute, followed by 25 cycles of: 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes. The reaction product was purified by ethanol/EDTA precipitation (see Appendix B) and the pellet resuspended in Hi-Di™ Formamide (Applied Biosystems) for subsequent electrophoresis performed by Inqaba Biotec (Pretoria, SA) or internally on the ABI Prism 3100-*Avant* Genetic Analyzer (Applied Biosystems). Sequence data analysis was performed using the Sequencing Analysis V3.3 programs (Applied

Biosystems) and FinchTV v 1.4.0 (Geospiza, Seattle, WA, USA). Bulk preparations were made of all sequence-verified plasmids for use in molecular cloning and transfections. These preparations were made using the QIAGEN® Plasmid Maxi Kit (QIAGEN, Hilden, Germany) as detailed in Appendix B.

2.4 Mammalian cell culture

116 cells (human embryonic kidney cells expressing the T-antigen of SV40 virus and *Cre* Recombinase) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 4.5 g/L Glucose and 2 mM L-Glutamine (BioWhittaker®, Lonza, Walkersville, Maryland, USA) and 10% heat-inactivated fetal bovine serum, FBS (Gibco®, Invitrogen, CA, USA), referred to as complete medium. Cells were incubated at 37°C with 5% CO₂ and passaged at 80% confluency as described in Appendix B. TZM-bl cells (HeLa-derived cells expressing CD4, CCR5 and CXCR4 HIV receptors, as well as *luciferase* and *lacZ* reporter genes under control of the HIV Tat-inducible LTR promoter) were obtained through the NIH AIDS Research and Reference Reagent Program (NARRRP), Division of AIDS, NIAID, NIH (Catalogue number 8129) from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. TZM-bl cells were also cultured in complete medium (10% FBS) and passaged with 0.25% Trypsin / 1 mM EDTA (Gibco) (see Appendix B). SupT1 cells (NARRRP Catalogue Reagent 100, obtained from Dr. James Hoxie (Smith *et al.*, 1984)), were grown in suspension in complete medium (10% FBS). Their passaging is also described in Appendix B.

2.5 Transfection of DNA and RNA into cultured cells

For all transfections cells seeded the previous day were transfected at 50-80% confluency. The following protocols are for 24-well culture plates (2 cm² culture surface area). Transfections in 96-well culture plates (0.4 cm² surface area) were carried out in the same way but scaled down by a factor of 0.2.

2.5.1 Lipofectamine™ 2000 transfections

A maximum amount of 1 µg DNA was diluted with OptiMEM® Medium to a 50 µl volume. The required volume of Lipofectamine™ 2000 (Invitrogen, CA, USA) (using a ratio of 1 µl Lipofectamine™ 2000 to 1 µg DNA) was similarly diluted into 50 µl OptiMEM® Medium (Invitrogen). After five minutes incubation at room temperature, the dilutions were mixed and allowed to incubate for 20 minutes at room temperature to allow lipoplexes (DNA-lipid complexes) to form. Thereafter the total volume (100 µl) was added drop-wise to the cell culture medium (500 µl). The culture plate was gently rocked to distribute the complexes evenly and incubated for the required length of time at 37°C.

2.5.2 ESCORT™ V transfections

For this reagent, the culture medium was replaced with fresh medium (without antibiotics) from 30 minutes to two hours before the transfection. A maximum amount of 700 ng DNA was diluted with 60 µl ESCORT V Transfection Buffer (Sigma-Aldrich). As a ratio of 3 µl ESCORT V Transfection Reagent (Sigma-Aldrich) to 1 µg DNA was used, 2.1 µl of Transfection Reagent was diluted with 60 µl Transfection Buffer. The dilutions were mixed gently, combined and mixed again before incubating at room temperature for 20 minutes. The rest of the procedure is the same as described in Section 2.5.1.

2.5.3 DharmaFECT®-4 transfections

Transfections with this reagent were carried out using the same procedures described in Section 2.5.1, except that a 96-well format was used. siRNAs were used instead of DNA and precautions were therefore taken to avoid RNase contamination of the samples and the siRNAs were stored on ice when not being handled. Moreover, dilutions of the siRNA stocks to required final concentrations were done using the buffer described in Section 2.1.3. Transfections were optimised as explained in Section 2.9 and thereafter 0.4 µl of the transfection reagent was used per 100 nM siRNA, unless otherwise specified.

2.6 Dual-Luciferase reporter assays

To evaluate the ability of the shRNA expression cassettes to knock down their reporter targets, a dual luciferase reporter assay was performed. Because each shRNA's target sequence was cloned into the 3' UTR of the *Renilla (Renilla reniformis) luciferase* reporter gene, the level of knockdown could be determined by measuring *Renilla* Luciferase activity relative to that of control Firefly (*Photinus pyralis*) Luciferase (expressed separately on the same plasmid). The 116 cells were seeded 24 hours prior to transfection at 1.2×10^5 cells per well in 24-well culture plates (Nunclon™ Δ Surface, Thermo Fisher Scientific, Rochester, NY, USA). Cells were then transfected at 10:1 and 5:1 ratios of shRNA:target using Lipofectamine™ 2000 (see Section 2.5.1). In both cases a total of 1 µg of DNA was transfected, comprising: 800 ng shRNA with 80 ng target (for 10:1 ratio) and 750 ng shRNA with 150 ng target (5:1), as well as 100 ng of pCI-EGFP reporter plasmid (to monitor transfection efficiency). Mock (pTZU6+1) and non-specific controls (U6 shRNA 5, renamed shHBx-5) were included in both experiments.

Forty-eight hours post-transfection, a Dual-Luciferase® Reporter Assay (Promega, WI, USA) was performed. After aspirating the culture medium, cells were lysed in the recommended volume of 1 × passive lysis buffer (PLB) (Promega, proprietary formulation) and incubated at 37°C for 15-20 minutes. After resuspending the lysates to remove clumps, 12 µl of each sample were transferred to the wells of a white-walled 96-well plate (Corning® Costar®, Corning Inc., MA, USA) and loaded into the Veritas dual-injection luminometer (Turner Biosystems, CA, USA). Sufficient volumes (i.e. 50 µl per sample plus 500 µl for injector priming) of 1 × Luciferase Assay Reagent II (LAR II) and Stop & Glo® Reagent (Promega, proprietary formulations) were made up according to the instructions of the supplier. Luciferase activity readings were then taken (in relative light units, RLU): first Firefly luciferase, after addition of LAR II, followed by *Renilla* luciferase after Stop & Glo Reagent addition. The protocol used for measurements was adapted for 50 µl from the Promega protocol for 100 µl of reagent per sample.

2.7 qRT-PCR assays

Quantitative real-time reverse-transcription PCR (qRT-PCR) was performed in order to verify the knockdown efficacy of the shRNA constructs against their endogenous mRNA targets. qRT-PCR primers (see Table A-7 of Appendix A) were designed to amplify each of the 5 genes, as well as housekeeping genes *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* and *β-actin*. TZM-bl, HEK293T and 116 cells were seeded in 12-well (2.5×10^5 cells per well) or 24-well (1.2×10^5 cells per well) tissue culture plates (Nunclon™ Δ Surface, Thermo Fisher Scientific). Twenty-four hours later, the maximum amount of DNA was transfected for each well format (i.e. 24-well plates: 950 ng of shRNA-expressing plasmid or control plasmid and 50 ng pCI-EGFP; 12-well plates: 1.9 µg shRNA or control plasmid with 100 ng pCI-EGFP). Lipofectamine™ 2000 was used for

116 and HEK293T cells (as described in Section 2.5.1), while ESCORT™ V transfection reagent (Sigma-Aldrich) was used to transfect TZM-bl cells (see Section 2.5.2).

RNA was extracted 48 hours post-transfection using TRI-Reagent® (Sigma-Aldrich). Culture medium was aspirated and the cells lysed using the recommended amount of TRI-Reagent (1 ml per 10 cm² of culture dish area). After resuspension and 5 minutes incubation at room temperature, chloroform (200 µl per ml TRI-Reagent) was added to the homogenate, vortexed until thoroughly mixed and the phases allowed to separate before centrifugation at 12 000 × g for 15 minutes at 4°C. The upper aqueous phase (containing the RNA) was then transferred to a clean microfuge tube and isopropanol added (500 µl per ml TRI-Reagent) before storing at -70°C overnight. The following day (or when needed) the RNA was pelleted by centrifugation at 12 000 × g for 30 minutes at 4°C. The supernatant was discarded, 75% ethanol added (1 ml per ml TRI-Reagent) and the RNA washed by brief vortexing. After centrifugation at 7 500 × g for 5 minutes, the pellet was allowed to air-dry for ~5 minutes before resuspension in diethyl pyrocarbonate (DEPC)-treated water (Sigma-Aldrich) and incubation at 55°C for 10 minutes. Thereafter the RNA was stored on ice and used directly in reverse transcription before long-term storage at -70°C.

The QuantiTect® Reverse Transcription kit (QIAGEN, Hilden, Germany) was used for reverse transcription of RNA to cDNA. The reaction was scaled down so that 500 ng or 1 µg of RNA was incubated with 1 µl gDNA Wipeout buffer in a 7 µl reaction volume at 42°C for two minutes and then placed on ice. Thereafter 0.5 µl Quantiscript® Reverse Transcriptase (a proprietary mixture of the QIAGEN® products Omniscript® Reverse Transcriptase and Sensiscript® Reverse Transcriptase that also contains RNase inhibitor), 0.5 µl RT Primer mix (a blend of oligo-dT and random hexamer primers including Mg²⁺ ions and dNTPs) and 1 × Quantiscript RT buffer were added to the first reaction to a final volume of 10 µl and incubated at 42°C for 20 minutes before heat-

inactivation at 95°C for three minutes and placing on ice. The resulting cDNA (4 µl) was used in subsequent qPCR with 10 pmol of the designed primers (Table A-7, Appendix A) and 1 × LightCycler® FastStart DNA Master^{PLUS} SYBR Green I (Roche Applied Science, Mannheim, Germany) (proprietary formulation comprising FastStart *Taq* DNA Polymerase, reaction buffer, MgCl₂, SYBR Green I dye and dNTP mix) in a 20 µl reaction volume. The Roche LightCycler® 2.0 instrument was used for the PCR using the following parameters: a hotstart at 95°C for 10 minutes was followed by 35-50 cycles of denaturation (95°C for 10 seconds), annealing (60°C for 10 seconds) and elongation (72°C for 10 seconds). Quantification occurred during the elongation stage, while melting curve analysis (95°C for 30 seconds, 65°C for 30 seconds, followed by slow (ramp of 0.2) heating to 95°C with continuous quantification) ensured PCR product specificity. After PCR, the Relative Quantification (Monocolour) module of the LightCycler® LCS4 v 4.0.0.23 software (Roche Applied Science, Mannheim, Germany) was used for data analysis.

2.8 Electroporation

Electroporation of SupT1 cells with pCI-EGFP, was done on the CE Module of a GenePulser Xcell apparatus (Bio-Rad Laboratories Inc., Hercules, CA, USA) using variations of several protocols as outlined in Tables B-1 and B-2 of Appendix B. Buffers used included DMEM, with or without FBS (10%) and DMSO (1.25%) (Invitrogen), OptiMEM (Invitrogen), Gene Pulser® electroporation buffer (Bio-Rad) (patented formulation, International Publication Number WO 2008/134 200 A1, World Intellectual Property Organization), phosphate-buffered (PB) sucrose (272 mM sucrose (Saarchem Merck), 7 mM K₃PO₄ (pH 7.4) (Sigma-Aldrich), 1 mM MgCl₂) and HEPES-buffered (HB) dextrose (20 mM HEPES (pH 7.3) (BDH Chemicals), 137 mM NaCl (Saarchem Merck),

0.7 mM Na₂HPO₄ (Saarchem Merck) and 6 mM dextrose (Saarchem Merck)) (Chu *et al.*, 1987; Baum *et al.*, 1994). Transfection efficacy (i.e. the proportion of cells that fluoresce green) was assessed by fluorescence microscopy (Axiovert 100 M, Carl Zeiss AG, Germany) after 24 hours of outgrowth post-electroporation. The total number of cells and the number of fluorescing cells were counted in a field of view approximately 2 cm × 2 cm under 200 × magnification. The viability of the cells was also assessed using 0.4% Trypan-blue stain (Biowhittaker). While dead or dying cells are permeable to the blue dye and thus stain blue, viable cells exclude it and appear colourless. To stain the cells, they were resuspended in an equal volume of the stain and loaded onto a haemocytometer slide for counting (see Appendix B).

2.9 Delivery of DNA and RNA to SupT1 cells by cationic lipid-based transfection reagents

Two siRNA pools and a recommended reagent for siRNA transfection, DharmaFECT® 4, were purchased from Thermo Scientific Dharmacon® (Thermo Fisher Scientific Inc., Lafayette, CO, USA). Delivery of siRNA to SupT1 cells using DharmaFECT® 4 transfection reagent was optimised as follows: SupT1 cells were seeded in 100 µl of medium at 5×10^3 , 1×10^4 and 2.5×10^4 cells per well of a 96-well tissue culture plate (Techno Plastic Products AG, TPP®, Switzerland). Twenty-four hours later, 100 nM siRNA was transfected in duplicate with 0.05, 0.1, 0.2, 0.3, 0.4 or 0.5 µl DharmaFECT®-4 (20 µl volume transfection mix). Forty-eight hours later, cells were examined using a fluorescence microscope (Axiovert 100 M, Carl Zeiss AG, Germany) for detection of the siRNAs (labelled with the sulfoindocyanine fluorescent probe, Cy3) within cells. Delivery of the siRNAs to TZM-bl cells using DharmaFECT®-4 was assessed similarly: cells were seeded in 100 µl of medium at 10 000 and 25 000 cells per well of a

96-well tissue culture plate (TPP®). Twenty-four hours later, 100 nM Cy3-labelled siRNA was transfected in duplicate with 0.2, 0.4 or 0.6 µl DharmaFECT®-4 (20 µl volume transfection mixes) or 0.4 µl Lipofectamine™ 2000. Forty-eight hours later, cells were examined by fluorescence microscopy for Cy3 fluorescence within cells. shRNAs were transfected into SupT1 cells and TZM-bl cells using ESCORT™ V transfection reagent (Sigma-Aldrich) as explained in Section 2.5.2.

2.10 Cytotoxicity assays

Various assays exist for determining the metabolic and physical condition of cells. A colorimetric assay was used here that measures the ability of mitochondrial Reductase enzymes to convert the yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) substrate to purple Formazan (Mosmann 1983). The activity of these enzymes is reduced in cells that are experiencing metabolic dysfunction - for example, as a result of treatment with a cytotoxic agent like Trichostatin A, TSA. This organic compound selectively inhibits the class I and II mammalian HDAC enzyme families (Yoshida *et al.*, 1990) and activates expression of apoptotic genes (Henderson *et al.*, 2003).

For the MTT assay, 5×10^3 TZM-bl cells per well were seeded in DMEM containing 10% FBS in a 96-well tissue culture plate (TPP®). Eighteen hours later, cells were treated with 0.4 µl ESCORT™ V for shRNA transfections (100 ng of shRNA or control plasmid and 10 ng pCI-EGFP) or 0.4 µl DharmaFECT® 4 for 100 nM siRNA transfections. Controls wells (in triplicate) included untransfected and untreated cells, as well as cells treated with three concentrations (1000 nM, 500 nM and 100 nM) of TSA (Sigma-Aldrich). Culture medium was replaced after 5 hours of transfection (siRNA- and

shRNA-treated wells). After 48 hours of transfection, 10 μ l of MTT (5 mg/ml in PBS, 0.2 μ m filter-sterilised) (Sigma-Aldrich) was added per well containing 100 μ l and incubated at 37°C with 5% CO₂ in the dark for 1 hour. Thereafter, the medium was removed and the black formazan precipitate dissolved by addition of 200 μ l dimethyl sulfoxide (DMSO). After mixing by gentle shaking for 2 minutes, the light absorbance of each well was measured at two wavelengths (570 nm, with 655 nm as the reference) using a Microplate reader (model 680, BioRad).

2.11 Virus production

Most of the viral work was done in the HIV Pathogenesis Research Laboratory with permission of Dr Maria Papathanasopoulos, while later work was carried out in our laboratory. For the initial challenge assay in TZM-bl cells, CAP210.2.00.E8 Env-pseudotyped virus was used (a gift from Maria Papathanasopoulos). The CAP210.2.00.E8 plasmid (NARRRP Catalogue Reagent 11317, available from Drs. L. Morris, K. Mlisana and D. Montefiori (Li *et al.*, 2006)) expresses HIV-1 Subtype C *env/rev*. The *env⁻/rev⁻* backbone plasmid, pSG3 Δ env (NARRRP Catalogue Reagent 11051, available from Drs. John C. Kappes and Xiaoyun Wu (Wei *et al.*, 2002; Wei *et al.*, 2003)), contains a defective *vpu* gene.

For the final challenge assay, HIV-1^{p81A-4} virus was used. The p81A-4 plasmid (NARRRP Catalogue Reagent 11440, available from Dr. Bruce Chesebro (Toohey *et al.*, 1995)) is a full length HIV-1 infectious molecular clone containing the V1-V3 envelope regions of the Ba-L HIV-1 strain in an NL4-3 (Subtype B) strain background. Infectious virions were produced by transfecting the plasmid into HEK293T cells, seeded the previous day at 2×10^6 cells in a 25 cm² flask (Corning® flask, Corning, NY, USA) in 5 ml medium. Four micrograms of p81A-4 plasmid was suspended in 150 μ l serum-free

DMEM, mixed with 40 µl PolyFect® transfection reagent (QIAGEN, Hilden, Germany), left at room temperature for five minutes and then added to the seeded cells' medium. Cells were incubated at 37°C with 5% CO₂ and medium changed 24 hours after transfection. A further 24 hours later, virus-containing supernatant was collected, centrifuged briefly (200 × g for five minutes) to remove cellular debris and filtered through a 0.2 µm sterile filter. Serum concentration was adjusted to 20% FBS and aliquots frozen at -70°C.

2.12 Viral titration

An end-point titration technique was used for viral titering, i.e. the TCID₅₀ (50% tissue culture infectious dose) was determined based on the protocol published by the ACTG Laboratory Technologist Committee of the HIV/AIDS Network Co-ordination (2004). Previous data from our laboratory has shown that the TCID₅₀ determined from LTR-luciferase activity does not differ greatly from the TCID₅₀ obtained by p24 ELISA (enzyme-linked immunosorbent assay). Thus, the TCID₅₀ was only determined by luciferase assay in this study. A more accurate titre involves calculating the multiplicity of infection (m.o.i.), which measures the average number of viral particles present per cell. However, as this was not technically feasible in this study, the TCID₅₀ method was used. A dosage of 500TCID₅₀ was used in all challenge assays as this dose did not cause cell death and yielded LTR-luciferase activity values within a reliable detection range.

Cells were seeded at 5×10^4 cells per well of a 96-well tissue culture plate (TPP®). The following day, the culture medium was removed and replaced with 50 µl DMEM containing 10% FBS and 15 µg/ml DEAE-dextran (GE Healthcare Life Sciences, Uppsala, Sweden). The virus stock was initially diluted in seven serial three-fold dilutions, using DEAE/dextran-containing medium (described above), a total volume of 750 µl and 250 µl transfers. To each column of three wells containing 50 µl medium, 150 µl of the

corresponding virus dilution was added per well (i.e. a 3:4 dilution). Thus the final titration consisted of seven serial four-fold dilutions (i.e. 4^{-2} ; 4^{-3} ; 4^{-4} ; ...; 4^{-8}). One column of wells served as a control and was treated with DEAE/dextran-containing medium without any added virus. The data obtained from the TCID₅₀ Luciferase assay were analyzed using the Spearman-Kärber formula detailed in Appendix B.

2.13 Viral challenge assays

The viral challenge assays were performed in TZM-bl cells as they are permissive for infection with viruses that are tropic for both T-cells and macrophages. In addition, TZM-bl cells support a full viral lifecycle while their integrated reporter genes provide a convenient and simple means of assessing changes in viral transcriptional activity. The Subtype C-enveloped pseudovirus (Section 2.11) was used as an initial screen for the effects of each gene's suppression during a single round of infection. This was followed by a challenge assay consisting of two parts that was based on the approach of Brass *et al.*, (2008) (Figure 2-4). In the first part, fully infectious virus (i.e. capable of generating virions that can infect new cells) was used to challenge cells in which *SPTBN1*, *SP110* and the control genes had been inhibited. The virus used was Subtype B virus produced from a full-length infectious molecular clone (p81A-4) that is similar to the NL4-3 strain except for the V1-V3 envelope region, which is of the macrophage-tropic BaL strain (Section 2.11). In the second part of the assay, the culture medium from the infected cells was transferred to uninfected, untransfected cells to assess the effect of knockdown on infectivity (i.e. virion production and infection of new cells).




Figure 2-4: Schematic of two-part viral challenge assay

The schematic for the two-part viral challenge assay was based on the approach used by Brass et al. (2008), with Part 1 measuring early-stage viral replication and Part 2 measuring later stages (assembly and budding). TzM-bl cells were transfected with pooled siRNAs and, after 72 hours of gene knockdown, infected with HIV-1. After 48 hours, integrated LTR-luciferase reporter gene expression was measured (Part 1) and the virus-containing supernatant transferred to fresh TzM-bl cells. After 24 hours infection, luciferase reporter activity was again measured for Part 2 of the assay. Figure adapted from Brass et al. (2008).

2.13.1 Env-pseudotyped viral challenge

For the CAP210.2.00.E8 Env-pseudotyped viral challenge assay, TzM-bl cells were seeded at 5×10^3 cells per well of a 96-well tissue culture plate (TPP®). The RNAi effectors were transfected the following day, using 0.4 μ l or 0.2 μ l DharmaFECT® 4 for siRNA transfections (for 100 nM and 50 nM siRNA, respectively) and 0.4 μ l ESCORT™ V for shRNA transfections (120 ng DNA : 100 ng of the relevant shRNA or control plasmid, 10 ng pCI-EGFP and 10 ng phRL-CMV). The Virus Control and No Virus control wells were not transfected. Medium (100 μ l) was replenished 30 minutes to two hours prior to ESCORT™ V transfection and again 4-6 hours after DharmaFECT® 4 and ESCORT™ V

transfections. After 72 hours of transfection (when knockdown is still operative), the cells were infected with 500TCID₅₀ of pseudovirus (i.e. 50 TCID₅₀'s in 100 µl) in medium containing 5% FBS and DEAE-dextran at a final concentration of 10 µg/ml. After 48 hours of infection, a luciferase assay was carried out (see Section 2.6), measuring Firefly (LTR) luciferase relative to *Renilla* luciferase activity for the shRNA-transfected wells and LTR-luciferase activity only for the siRNA-transfected wells. Data were normalised to the mean of the Non-specific control (siHBV).

2.13.2 Replication-competent viral challenge

As a result of several practical issues, Part 1 in this study was measured using LTR-Luciferase activity as opposed to p24 Gag production. For Part 1, cells were seeded and transfected with siRNA as was carried out for the pseudovirus challenge assays, with untransfected infected (Virus Control) and untransfected uninfected (No Virus) control wells included. After 72 hours of transfection, cells were infected with p81 virus at a TCID₅₀ of 500/ml in 200 µl medium containing 10% FBS and 15 µg/ml DEAE-dextran. The No Virus control wells received the same medium without virus added. After two hours incubation, the medium was removed and replaced with fresh complete medium before further incubation at 37 °C with 5% CO₂. After 48 hours of infection, Part 2 of the assay was initiated by transferring 80 µl of virus-containing supernatant to the wells of a replica plate seeded the previous day with 5.4×10^3 TZM-bl cells per well. These cells were cultured in medium containing 15 µg/ml DEAE-dextran to facilitate infection. A Dual-Luciferase reporter assay was performed (as described in Section 2.6) on the Part 1 cells after remaining supernatant had been discarded. After 20 hours of infection, the Part 2 cells were lysed for an assay of LTR-Luciferase activity (also using the Dual-Luciferase reporter assay, with only Firefly Luciferase activity measured for siRNA-treated wells).

2.14 Statistical analyzes

All data were analyzed using GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com). Non-parametric one-way analysis of variance (ANOVA) was used to assess the statistical significance of data. The post-tests performed are described with each reported result in Chapter 3.

CHAPTER 3 : RESULTS

This study aimed to verify whether several genes that have recently been implicated as being novel HIV-1 host factors are required for viral infection and replication. Five genes were selected from the published dataset (Brass *et al.*, 2008) as it was expected that some of these would be false positives (i.e. not true HIV-1 host factors) and also that some difficulties might arise during experiments to assess their effect on the virus and to inhibit their function by RNAi. Their selection was specifically made in an unbiased way, using criteria that would select for genes whose effect on HIV-1 replication was supported by good evidence and that could potentially be developed as novel drug/gene therapy targets.

3.1 Criteria-based selection of five genes

The five genes that were selected from the list of 237 novel HDFs published by Brass *et al.* (2008), as well as the criteria supporting their selection, are summarised in Table 3-1. A full portrayal of the selection process is shown in Appendix C. The first stage selected genes that caused a 75% or greater reduction in HIV-1 replication (see Table C-1). This cut-off value was high enough to narrow down the original gene list while ensuring a selection of genes remained that had scored in both early (Part 1) and late (Part 2) stages of the HIV-1 lifecycle.

The second stage selected for genes for which more than one siRNA caused a reduction in viral activity (Table C-2). The greater the number of individual siRNAs targeting the same gene that cause a significant decrease in viral activity, the more likely that the effect is gene-specific. From this stage onwards, the list of genes scoring in Part 1

and Part 2 were processed separately. The next stage considered the functional importance of the Part 1 genes. Six genes (see Table C-3) were excluded from the selection based on their biological function as recorded in the curated UniProt database. For example, WNT1 is a member of the Wnt signalling pathway, while NUP107 is an essential component of the nuclear pore complex. Knockdown of such genes would likely be toxic to the cell and thus not optimal target genes.

Of the five genes to be studied, three were chosen from the Part 1 list (involved in viral entry up until Gag translation) and two from the Part 2 list (involved in later stages such as assembly and budding). The final three Part 1 genes were chosen as the first three on the remaining sorted list (see Table C-4). The Part 2 genes were processed in the same way as explained above, with six genes being excluded based on functional importance (Table C-5). As the remaining list contained several more genes than the Part 1 list, an additional criterion was introduced to further focus the list: the number of gene homologues in other species (i.e. orthologues) was considered, as genes that are highly conserved across many species are more likely to have essential functions. A cut-off of five homologues was chosen that served to shorten the Part 2 gene list by ~30% (see Table C-6). The final selection (Table C-7) included one gene with three individual scoring siRNAs (*PRDM14*) and one with a published reference to interaction with pathogens (*SP110*) (see section 1.6.1.5). Thus, these two genes were selected to represent the late stage of HIV-1 replication in this study.

Table 3-1: The final five putative HDFs selected for validation in this study

Gene	NCBI GeneID	Extent of virus knockdown	Number of siRNAs	Involvement in protein complexes and/or molecular pathways	Function	References to HIV-1 interaction
SPTBN1 (spectrin, beta, non-erythrocytic 1)	6711	76%	3 (Part 1)	None	May be involved in calcium-dependant movement of the cytoskeleton at the membrane, through its interaction with calmodulin	(Shoeman <i>et al.</i> , 2002)
TMED2 (transmembrane emp24 domain trafficking protein 2)	10959	82%	3 (Part 1); 1 (Part 2)	Interacts with ARFGAP1	May be involved in the budding of coatomer-coated and other coated vesicles. Could bind and collect cargo molecules into budding vesicles.	None
KIAA1012	22878	89%	4 (Part 1)	Part of the multisubunit TRAPP (transport protein particle) complex.	May be involved in vesicular transport from endoplasmic reticulum to Golgi.	None
PRDM14 (PR-domain containing 14)	63978	81%	3 (Part 2)	None	May be involved in transcriptional regulation.	None
SP110 (<i>SP110</i> nuclear body protein)	3431	84%	2 (Part 2)	None	Transcription factor. May be a nuclear hormone receptor co-activator. Enhances transcription of genes with retinoic acid response elements (RARE).	(Izmailova <i>et al.</i> , 2003)

3.2 Gene-specific knockdown by Pol III-expressed shRNAs

3.2.1 Design of shRNA expression cassettes

In order to validate the classification of SPTBN1, TMED2, KIAA1012, PRDM14 and SP110 as HDFs, as well as their role in early versus late stages of HIV-1 replication, their function was inhibited using RNAi effecters targeted to the coding region of each gene. Because gene knockdown using siRNAs is transient, shRNA expression cassettes were designed that would provide a constant supply of RNAi effecters for stabler suppressive effects. The U6 Pol III promoter is useful in this regard: shRNA-encoding sequences that have a G-residue at the 5' end and at least four terminating T-residues are efficiently expressed to form shRNAs with two-nucleotide 3' overhangs that allow Dicer processing into siRNAs (Paule and White 2000; Brummelkamp *et al.*, 2002; Paddison *et al.*, 2002; Paul *et al.*, 2002).

Initially, shRNAs targeting three different regions of each of the five genes (*SPTBN1*, *TMED2*, *KIAA1012*, *PRDM14* and *SP110*) were designed. Their design was based on the Broad Institute's online TRC MISSION shRNA Library (Section 2.1.1). However, several candidate sequences available on this database contained three or more T-residues in the guide sequence (which cannot be altered without affecting its targeting efficacy). To avoid risking premature termination of Pol III transcription, another approach was used for the design of these shRNA sequences. The difference in thermodynamic stability between the 5' and 3' ends of a siRNA duplex is largely responsible for ensuring correct selection of the guide strand for loading into the RISC (Khvorova *et al.*, 2003; Schwarz *et al.*, 2003) and an effective predictor of siRNA efficacy (Heale *et al.*, 2005). An online application which ranks candidate siRNA duplexes based on this difference was used to design the sequences encoding shTMED-2, shKIAA-3 and shPRDM-3 (Section 2.1.1).

The specificity of all shRNA sequences was assessed using BLAST (see Section 2.1.2) to detect off-target matches with other gene sequences. While partial matches were found in some instances (data not shown), no matches with the full seed region (nucleotides 2-8 of the guide strand) were found that might cause miRNA-like off-target translational suppression (Jackson *et al.*, 2003; Jackson *et al.*, 2006). Finally, the secondary structure of the shRNA sequences was assessed using the RNA Mfold program (Mathews *et al.*, 1999; Zuker 2003) (Section 2.1.2). This algorithm uses free energy predictions to calculate the hybridization and folding of a linear RNA sequence at 37°C. In all cases, the desired hairpin structure was most thermodynamically favourable and thus most likely to form under physiological conditions. This is important for efficient Dicer processing and subsequently effective RNAi silencing (Siolas *et al.*, 2005).

3.2.2 Cloning of shRNA expression cassettes and reporter targets

For each gene a set of three U6 Pol III shRNA expression cassettes and one plasmid consecutively encoding each shRNA's minimal target sequence were designed. Cloning of the shRNA cassettes used a rapid and simple PCR-based approach that is described in Section 2.3.1. The minimal target sequences were inserted by positional cloning into the 3' UTR of the *Renilla* luciferase reporter gene expressed from the psiCHECK-2.2 plasmid (see Sections 2.2 and 2.3.2). This plasmid separately expresses Firefly luciferase, providing a useful dual-reporter system whereby knockdown of the minimal target RNA can be detected by measuring *Renilla* luciferase activity relative to background Firefly luciferase.

Restriction digestions were performed with *Xba*I and *Hind*III, restriction enzymes whose sites flank the T/A cloning site of pTZ57R/T, to verify that individual clones had inserts of the correct size. Figure 3-1a (pg 60) shows the digestion products after gel electrophoresis: correctly inserted clones produced two bands, one of size 368 bp (the

insert) and another of 2840 bp (the backbone of pTZ57R/T). Insertion of the correct sequence was subsequently verified by sequencing the insert as shown in the partial electrophoretogram in Figure 3-1b. All five of the reporter target plasmids were correctly cloned (data not shown). Likewise, of the 15 designed shRNAs, 10 cloned correctly (verified by sequencing): shSPTBN-1, shSPTBN-2, shSPTBN-3, shTMED-2 (which was subsequently used as a positive control), shKIAA-1, shKIAA-2, shPRDM-1, shPRDM-3, shSP110-1 and shSP110-2. The five remaining shRNAs (shTMED-1, shTMED-3, shKIAA-3, shPRDM-2 and shSP110-3) proved difficult to clone, specifically at the second round of PCR-amplification. Nevertheless, sufficient shRNA expression cassettes were correctly cloned to continue.

3.2.3 Knockdown of luciferase reporter targets

The ability of each expressed shRNA to inhibit its respective target sequence was assessed by co-transfecting each shRNA (or a non-targeting control, shHBx-5 or an empty vector, Mock) with its respective reporter target plasmid into HEK293T cells. After 48 hours to allow for knockdown to occur, the cells were lysed and the relative luminescence of *Renilla* (reporter) versus Firefly luciferase activity measured (see Section 2.6). Figure 3-2 (pg 61) shows these ratios normalised to the Mock control, empty pTZU6+1 (see Section 2.2).




Figure 3-1: Example of restriction digest and sequence data used to verify correct clones.

a) Digestion of correctly inserted clones (lanes 2-17) with *Xba*I and *Hind*III restriction enzymes produced products of size 368 bp and 2840 bp after separation by ethidium bromide-stained agarose gel electrophoresis and visualisation under UV light. A previously sequence-verified shRNA clone, shTMED-2 was used as a positive control (when digested) (lane 19) and as a size reference for the larger digestion product when undigested (3208 bp) (lane 20). A molecular weight marker, O'GeneRuler™ 100 bp Plus DNA Ladder (Fermentas), was used as an additional band-size reference in lanes 1 and 21. b) Part of an electrophoretogram showing the sequence of the 3' end of the U6 promoter and the shRNA sequence for correctly cloned shTMED-2.

As shown in Figure 3-2, the non-specific shRNA control (shHBx-5) did not cause unwanted off-target knockdown of any of the reporter target sequences relative to the Mock control, which serves to normalise for effects of the Pol III promoter. Moreover, all correctly cloned shRNAs yielded highly effective knockdown (75% or more, $P < 0.01$) of the reporter targets. This indicates that these shRNAs are being correctly expressed and processed by the RNAi pathway for recognition and action on their target sequences.




Figure 3-2: Knockdown efficiency of shRNAs against luciferase reporter targets.

Dual Luciferase Reporter Assay data compiled from several experiments. Data represent *Renilla* Luciferase activity relative to background Firefly Luciferase. The percentage target knockdown relative to Mock is indicated above each shRNA column. The x-axis is divided into 5 groups: one for each gene's reporter target. Key to symbols: M is Mock; 1, 2 and 3 refer to the shRNAs targeting each gene (e.g. 2 in the TMED2 group is shTMED-2); NS is non-specific shRNA, shHBx-5. Sample values (n=3) were normalised to the Mock control, with error bars representing the standard error of the mean (SEM). ANOVA with Dunnett's post-test comparison with Mock: ns ($p > 0.05$); ** ($p < 0.01$).

3.3 Accurate detection of mRNA by quantitative RT-PCR

The ability of the shRNAs to suppress minimal target sequences does not necessarily translate into effective inhibition of the endogenous mRNA target. Frequently, secondary structure within the mRNA prevents effective RNAi knockdown (see Section 4.6.2). To accurately detect the level of mRNA suppression by each shRNA, qRT-PCR assays were set up for specific target RNA quantification relative to a stably expressed housekeeping gene.

3.3.1 Testing of non-targeting controls

qRT-PCR is an extremely sensitive technique that requires testing with several controls to ensure amplification is occurring correctly. Three non-targeting shRNAs (shHBx-5 and shHBx-10, both targeting HBV, and shLacZ, targeting the *lacZ* gene of *E. coli*) (see Section 2.2) were tested to ensure that non-specific knockdown effects were not detected for each gene. Knockdown of *SPTBN1* by shHBx-5, shHBx-10 and shLacZ is shown in Figure 3-3a. Figures 3-3b and c show knockdown of *TMED2*, *KIAA1012* and *SP110* by shHBx-5 and shLacZ. *GAPDH* was used as the reference gene for relative mRNA quantification in Figure 3-3a and b, while β -*Actin* was used in Figure 3-3c. Based on these data, shHBx-5 (from here on referred to as shHBx) was used as a non-specific control in subsequent experiments as it consistently showed no significant knockdown of the various genes tested.

Amplification of *PRDM14* showed extremely low expression levels in several cell lines tested (data not shown). The cycle threshold values (i.e. the point at which the PCR amplification rate becomes exponential) for amplification of cDNA and water blank samples with *PRDM14*-specific primers were indistinguishable. Since normal expression levels of this gene could not be accurately detected, it is unlikely that product would be detected in RNAi-suppressed samples. For this reason, this gene was not studied further.




Figure 3-3: Testing knockdown of SPTBN1, TMED2, KIAA1012 and SP110 by non-specific shRNA controls.

Non-specific knockdown of *SPTBN1*: a) shHBx-5, shHBx-10 and shLacZ were tested for non-specific knockdown of *SPTBN1* by qRT-PCR assay using *GAPDH* as housekeeping gene. Sample values (n=3, SEM) were normalised to Mock. One-way ANOVA with Dunnett's post-test comparison with Mock: Not significant, ns ($p > 0.05$). Non-specific knockdown of *TMED2*, *KIAA1012* and *SP110*: b) shHBx-5, shHBx-10 and shLacZ were tested for non-specific knockdown of *TMED2*, *KIAA1012* and *SP110* by qRT-PCR assay. *GAPDH* was used as housekeeping gene with values normalised to Mock (n=2, SEM). Two-way ANOVA with Bonferroni's post-test comparison with Mock: ns ($p > 0.05$). c) As in b) with β -Actin used as housekeeping gene and shHBx-10 not tested.

3.3.2 Testing of positive controls

As a positive control, shHTATSF-2, a verified shRNA targeting the *HTATSF1* gene involved in regulating HIV-1 transcript splicing (Section 1.2.6) was tested. As shown in Figure 3-4a, quantification of *HTATSF1* mRNA levels relative to *GAPDH* failed to show the expected knockdown. When repeated using β -actin as the reference gene (Figure 3-4b), the expected level of knockdown (50%, $P < 0.01$) was obtained. This effect was seen in several experiments (Figure 3-3b): where *GAPDH* was used as the reference gene there was high variability between triplicate sample values and between successive experiments; this was overcome by using β -actin instead (Figure 3-3c). Thus, subsequent experiments quantified gene expression relative to β -actin.




Figure 3-4: Knockdown of positive control *HTATSF1*.

Knockdown of positive control *HTATSF1* by qRT-PCR assay using *GAPDH* (a) and β -actin (b) as housekeeping genes. Sample values ($n = 3$, SEM) were normalised to Mock. ANOVA with Dunnett's post-test comparison with Mock: ns ($p > 0.05$); ** ($p < 0.01$).

Two more positive controls were tested that target viral genetic elements. The TZM-bl cell line contains a stably integrated Firefly *luciferase* reporter gene that is expressed by the HIV-1 LTR promoter. By transfecting these cells with a Tat expression cassette, transactivation of the Tat-responsive LTR promoter can be induced (Section 1.1.3), which in turn increases reporter gene expression several fold. As shown in Figure 3-5a and b, verified U6 promoter-expressed shRNAs targeting the *LTR* and *Tat* RNA of HIV-1 (shLTR and shTat, respectively - Section 2.2) were tested relative to a Mock control (an empty vector containing the U6 promoter). In addition, the experiment was tested in the presence and absence of Tat (expressed from a CMV promoter), with an empty vector containing the CMV promoter added in Tat's absence to control for promoter activity.

shLTR was designed to target a Subtype C virus LTR sequence. When this shRNA was tested previously as part of a long hairpin RNA (lhRNA) construct to knock down a Subtype C LTR-driven luciferase reporter (Barichievy *et al.*, 2007) it yielded 90% knockdown in the presence of Tat (which upregulates LTR expression). When tested using the same conditions against a Subtype B LTR-driven reporter, it yielded only 50% knockdown in the presence of Tat. The data obtained here for shLTR is comparable: Figure 3-5a shows the effect of Tat on upregulating luciferase levels. shLTR knockdown is only significant in the presence of Tat (representing an infection), matching the expected value of 50% knockdown ($P < 0.001$) of this integrated Subtype B LTR-driven reporter. Figure 3-5b shows similar results for the second positive control, shTat. This shRNA yielded ~30% knockdown ($P < 0.001$) when its target (Tat) was added. This is lower than expected (Scherer *et al.*, 2004), but may be due to higher target concentration in this system, where Tat was strongly expressed from a plasmid.




Figure 3-5: Knockdown of LTR-driven luciferase by positive controls shLTR and shTat.

Knockdown of integrated LTR-*luciferase* expression in TZM-bl cells by shLTR (a) and shTat (b), respectively, in the presence (+) or absence (-) of the HIV-1 transcriptional transactivator protein Tat. *Luciferase* expression was quantified by qRT-PCR assay using β -*Actin* as housekeeping gene. Values were normalised to Mock (the first column) with $n=3$, SEM. ANOVA with Bonferroni's post-test comparisons (see arrows): ns ($p > 0.05$); *** ($p < 0.0001$).

3.3.3 Other controls used in optimising qRT-PCR assays

Negative controls (without cDNA template) were included in every qRT-PCR assay for each primer set to control for contamination in the reaction. In addition, negative-RT controls (without Reverse transcriptase) were included regularly to check for DNA contamination during reverse transcription of RNA samples. Finally, the PCR product amplified by each set of primers (i.e. for *GAPDH*, *SPTBN1*, *TMED2*, *KIAA1012* and *SP110*) was cloned into T/A vector pTZ57R/T to create target plasmid standards. A \log_{10} dilution (from 0.1 pg to 10 ng) of each plasmid was then amplified by qPCR to create standard curves for each gene (Figure 3-6). As 10 ng of each target plasmid was amplified with a cycle threshold (Ct) value of 12, this amount was regularly included in assays as a standard to detect inter-assay variation. The standards continued to amplify

at this Ct value (even using *β-Actin* as reference gene), giving support for the reliability and consistency of the assays. With the necessary controls in place, verification of shRNA knockdown of the four remaining genes could be done.




Figure 3-6: Standard curve of plasmid standards for each primer set

The PCR product amplified by each gene's primer set was cloned into a T/A plasmid and used to create a log standard curve for each primer set. The Ct value represents the cycle threshold, the number of PCR cycles at which amplification becomes exponential.

3.4 shRNA-mediated knockdown of endogenous mRNA targets

The ability of the designed shRNAs to knock down their endogenous mRNA targets was verified in both 116 cells and TZM-bl cells by qRT-PCR. Representative data are shown in Figures 3-7a and b, 3-8, 3-9a and b and 3-10. Figure 3-7 shows knockdown of *SPTBN1* endogenous mRNA. Although the sample means of shSPTBN-1 and shHBx in Figure 3-7a show almost a two-fold decrease from the Mock, statistical analysis of intra- and inter-group variation made it clear that there is no significant knockdown ($p > 0.05$). Figure 3-7b (using *GAPDH* as housekeeping gene) provides support for the lack of significant knockdown of *SPTBN1*. Retrospective analysis of the sequences encoding shSPTBN-2 and shSPTBN-3 showed an error in design. As the luciferase reporter targets

were thus designed and cloned based on incorrect shRNA sequence information, knockdown of these targets could be obtained but not the endogenous mRNA.




Figure 3-7: Knockdown of endogenous *SPTBN1* mRNA by shRNAs.

a) *SPTBN1* knockdown in 116 cells by qRT-PCR assay using β -Actin as housekeeping gene. b) *SPTBN1* knockdown in TZM-bl cells by qRT-PCR assay using *GAPDH* as housekeeping gene. Data normalised to Mock (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$); _ (single data point, no statistical analysis done).

As shown in Figures 3-8 and 3-9a and b, statistically significant (i.e. $P < 0.05$) knockdown of *TMED2* and *KIAA1012* mRNA could not be achieved, though the shRNA design and sequence was correct. In all cases, the maximum amount of shRNA was transfected with good efficiency in either 116 cells or TZM-bl cells. *SP110* was the only gene that could be suppressed by a shRNA. *SP110* mRNA was decreased relative to controls by ~60% by shSP110-2 (Figure 3-10, pg 70). This was the only functional shRNA that could be taken forward.




Figure 3-8: Knockdown of endogenous *TMED2* mRNA by shRNAs.

TMED2 knockdown in 116 cells by qRT-PCR assay using β -Actin as housekeeping gene. Data normalised to Mock (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$).




Figure 3-9: Knockdown of endogenous *KIAA1012* mRNA by shRNAs.

a) *KIAA1012* knockdown in 293T cells by qRT-PCR assay using β -actin as housekeeping gene. b) *KIAA1012* knockdown in TZM-bl cells by qRT-PCR assay using *GAPDH* as housekeeping gene. Data normalised to Mock (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$).




Figure 3-10: Knockdown of endogenous *SP110* mRNA by shRNAs.

SP110 knockdown in TZM-bl cells by qRT-PCR assay using β -actin as housekeeping gene. Data normalised to Mock (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$); ** ($p < 0.01$).

3.5 Knockdown of endogenous mRNA by siRNA SMARTpools

As the majority of the designed shRNAs failed to effect significant knockdown of their endogenous targets, a different approach was required. Commercially available siRNA SMARTpools (Dharmacon, CO, USA) comprising four individual siRNAs per gene were purchased that are specially designed and modified for enhanced target specificity and are guaranteed to effect specific target knockdown of 75% or more (Section 4.6.4). Only siRNAs targeting *SPTBN1* and *SP110* were selected, as these genes seemed the most promising of the five originally chosen (Table 3-1). Figure 3-11 shows the knockdown efficacy of the SMARTpool siRNAs targeting *SPTBN1* (a) and *SP110* (b) over a range of siRNA concentrations, in comparison to a non-specific siRNA control (targeting HBV) (Section 2.1.3). The SMARTpool siRNAs successfully knocked down both genes by 90% or more (at 100 nM concentration). Moreover, knockdown efficacy decreased in proportion to the amount of siRNA transfected. This dosage response supports RNAi as being the mechanism for the observed silencing.




Figure 3-11: Knockdown of endogenous *SPTBN1* mRNA by siRNA SMARTpools.

a) Knockdown of *SPTBN1* (a) and *SP110* (b), respectively, by qRT-PCR assay using β -actin as housekeeping gene. b) TZM-bl cells were transfected with Dharmacon® SMARTpool siRNAs at 100, 50, 25, 10 and 5 nM concentrations. Data normalised to Non-specific control siHBV (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$); * ($p < 0.05$); ** ($p < 0.01$).

3.6 Knockdown efficacy of shRNAs derived from pooled siRNAs

The knockdown described above was mediated by siRNAs that were introduced into the cell cytoplasm. The activity of siRNAs is typically potent but short-lived: they are diluted during cell division and degraded over time. In contrast, shRNAs can be constitutively expressed from plasmids at a high rate (e.g. using the U6 Pol III promoter). This ensures a constant, large supply of RNAi effectors that can mediate longer-lasting knockdown than siRNAs can. For this reason, new shRNAs were designed based on the sequences of the siRNA pools (designated with the suffixes A-D). Because of the difficulties encountered during cloning of the original shRNAs, reverse primers were designed that incorporated the entire shRNA sequence upstream of the primer binding site. All the shRNAs could be cloned correctly, except for shSP110-D that had a single incorrect base in the promoter region. The knockdown efficacy of these shRNAs is shown in Figure 3-12. Though knockdown of their endogenous targets was statistically highly significant ($P < 0.01$), the difference in efficacy (approximately two-fold less) between the pooled siRNAs and their individual shRNA versions is striking. The inability of shSPTBN-A to knock down its target mRNA may be a result of target site accessibility (Section 4.6.2) or inefficient processing by Dicer.




Figure 3-12: Knockdown of SPTBN1 and SP110 by shRNAs derived from SMARTpool siRNAs

Knockdown of *SPTBN1* (a) and *SP110* (b), respectively, by shRNAs derived from pooled siRNA target sequences. Gene expression quantified by qRT-PCR assay using *B-actin* as housekeeping gene. Data normalised to Mock (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$); ** ($p < 0.01$).

3.7 Delivery to SupT1 cells by electroporation

One of the objectives of this project involved optimising delivery of RNAi effecters to SupT1 cells, a T-cell line that grows in suspension. Suspension cells are notoriously difficult to transfect using conventional transfection reagents. Viral vectors offer one alternative for delivering shRNAs to T-cells. Various types of viral vectors, their advantages and drawbacks are discussed in Sections 4.6.7.2 and 4.6.7.3. Another delivery method is electroporation. This well-characterised technique is simple and rapid and widely used for introducing nucleic acids and protein molecules into primary cells, suspension cells and other cell types that are refractory to transfection. Electroporation entails delivering a pulsed electrical field across the cellular membrane, creating water-filled pores that rapidly open to allow a highly charged molecule like DNA a short period of time (~ 20 ms) to enter the cell before resealing (Langridge *et al.*, 1987).

Electroporation of SupT1 cells was attempted with eGFP-expressing plasmid using various protocols as outlined in Section 2.8 and Tables B-1 and B-2 (Appendix B). The efficacy of each experiment is summarised in Table 3-2, with values representing the average of three data points. The number of dead cells (staining blue) and the number of transfected cells (expressing GFP) are shown as a proportion of the total number of cells. In some cases very few cells survived the procedure – even after 24 hours outgrowth their numbers were too few for accurate quantification of cell viability or electroporation efficacy. While the different protocols tested resulted in varying levels of cell toxicity, the overall efficacy of the technique was disappointingly low. Thus, this technique was not used in this study.

Table 3-2: Results of electroporation experiments (average of data in triplicate)

Protocol	Average cell death	Average transfection efficacy
Jurkat/1	Accurate quantifications not possible – cells too sparse.	
Jurkat/2		
Jurkat/3	17%	2.6%
Jurkat/4	24%	2.5%
Jurkat/5	0 %	0%
Jurkat/6	0%	0%
1/1	91%	5 %
1/2	100%	0%
2/1	47%	1%
2/2	45%	2%
3	Accurate quantifications not possible.	
4		
5		

3.8 Delivery to SupT1 cells by transfection reagents

When DharmaFECT-4 transfection reagent was tested for its ability to deliver a Cy3 fluorescently-labelled siRNA to SupT1 cells at three different cell densities (Section 2.9), a moderate fluorescent signal could be observed that co-localised with individual cells (Figure 3-13b). Moreover, ESCORT-V transfection reagent could deliver GFP-expressing plasmid DNA to SupT1 cells, as shown in Figure 3-13a.




Figure 3-13: Delivery of plasmid DNA and siRNA to SupT1 cells

SupT1 cells transfected with GFP-expressing plasmid by ESCORT-V transfection reagent (a) and with Cy3-labelled siRNA by DharmaFECT-4 transfection reagent (b) were visualised by fluorescence microscopy 48 hours after transfection. The images represent 100 × magnification, except for the first picture in a) at 200 × magnification, with scale bars indicated in white for each magnification.

Though the viability of the samples was not directly measured, there were no visible detrimental effects compared to untreated cells. The functionality of the siRNAs

and shRNAs transfected into SupT1 cells was subsequently tested by qRT-PCR. Neither the siRNA SMARTpools (that had yielded impressive knockdown in TZM-bl and 293T cells), nor the two best shRNAs targeting each gene gave any significant knockdown in the SupT1 cell line (Figures 3-14 and 3-15). This indicates that the intracellular delivery of both RNAi effectors by transfection reagent is not high enough to yield functional knockdown.




Figure 3-14: Knockdown by siRNA SMARTpools in SupT1 cells

Knockdown of *SPTBN1* (a) and *SP110* (b), respectively, in SupT1 cells transfected with siRNA SMARTpools at 100 nM and 50 nM concentrations using DharmaFECT-4 transfection reagent. Gene expression quantified by qRT-PCR assay using *B-actin* as housekeeping gene. Data normalised to siHBV non-specific control (n=2, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$).




Figure 3-15: Knockdown of *SPTBN1* and *SP110* by siRNA-derived shRNAs in SupT1 cells.

The best shRNAs targeting *SPTBN1* (shSPTBN-D) and *SP110* (shSP110-2) were tested for their knockdown ability after delivery to SupT1 cells by ESCORT-V transfection reagent. Gene expression quantified by qRT-PCR assay using *B-actin* as housekeeping gene and normalised to Mock (n=3, SEM). ANOVA with Dunnett's post-test comparison: ns ($p > 0.05$).

As the RNAi effectors could not be functionally introduced (by either electroporation or transfection reagent) into a cell line that can be infected by HIV-1 and that is also closely related to the virus' natural host cell type (CD4+ T helper cells), the rest of this study focused on validating the data produced by Brass *et al.* (2008) in TZM-bl cells. However, before proceeding with viral challenges of the transfected cells, it was important to ascertain whether the shRNAs and siRNAs developed produced any cytotoxic effects when introduced into cells.

3.9 Cytotoxicity assay

All the functional RNAi effectors used in this study, as well as their respective controls, were transfected into TZM-bl cells and the resultant cytotoxicity measured relative to untreated cells (Section 2.10). In addition, cells were treated with several concentrations of TSA as a positive control. As shown in Figures 3-16, none of the shRNAs nor their controls showed significant toxicity when compared to untreated

controls. However, the siRNA non-specific control (siHBV) showed highly significant toxicity ($P < 0.01$), comparable to the lowest concentration of the positive control (TSA 100 nM). As the siRNA SMARTpools do not show a significant difference in toxicity to siHBV, this implies that siRNA treatment in general is causing cytotoxicity. This is further supported by the qualitative observation that the cells transfected with siRNAs appeared to grow slower (data not shown) than those transfected with shRNAs. As the toxicity associated with siRNA transfection appeared to be slight and not specific to an individual siRNA's effects, we decided that sufficient controls were in place to continue with viral challenge assays.




Figure 3-16: MTT assay for RNAi-related cytotoxicity

TZM-bl cells were treated with HDAC inhibitor Trichostatin A (TSA) at various concentrations as a positive control and transfected with the siRNA-derived shRNAs, siRNA pools and their respective controls. Mitochondrial Reductase activity was measured as solubilised formazan production (absorbance at 570 nm) relative to background absorbance (655 nm). Data were normalised to the mean of the untreated samples ($n=3$, SEM). ANOVA with Dunnett's post-test comparisons with the untreated control (dashed lines) or with Mock and siHBV (solid lines): ns ($p > 0.05$), ** ($p < 0.01$).

3.10 The effect of SPTBN1 and SP110 knockdown on HIV-1 replication

3.10.1 Single-round challenge of transfected cells with pseudovirus

An initial screen was set up in TZM-bl cells after 72 hours of gene knockdown by shRNAs (Figure 3-17) and siRNAs (Figure 3-18, pg 82) targeting *SPTBN1* and *SP110*, as well as their respective controls (Section 2.13.1). As shown in Figure 3-17a, the control shRNAs shLTR and shTat (targeting the viral LTR promoter and Tat transactivator-encoding genes) and shHTATSF-2 and shLEDGF (targeting verified HIV-1 host factors, *HTATSF1* (Section 1.2.6) and *LEDGF* (Section 1.2.4)) inhibit the virus to their respective expected levels. shLEDGF does not show significant viral inhibition as incomplete gene knockdown ensures sufficient gene product remains for HIV-1 to replicate unhindered (Vandekerckhove *et al.*, 2006).

The effects of shRNA-mediated knockdown on pseudovirus infection shown in Figure 3-17b are not statistically significant. This was confirmed by additional statistical analysis excluding the variable samples shSP110-B and shSP110-C (data not shown). This result is not surprising considering the weaker knockdown efficacy of the shRNAs compared to the siRNA pools. For this reason, the shRNAs were not used in the subsequent viral challenge assay. The challenge assay described above included samples transfected with siRNA (Figure 3-18). As the siRNA- and shRNA-treated cells were part of the same experiment, the shRNA controls (Figure 3-17a) provided support for the validity of the siRNA challenge data in the absence of corresponding siRNA controls. In contrast to the shRNA-treated cells, the data in Figure 3-18 show a significant decrease in viral activity when *SPTBN1* is knocked down, though only at the highest siRNA concentration (100 nM). There was a significant difference between the untransfected Virus Control samples and those treated with the non-specific control siRNA targeting

HBV. This indicates some repressive effect of the siRNA transfection procedure on virus replication and/or on cell viability, as indicated by the MTT assay (Figure 3-16).




Figure 3-17: Changes in pseudovirus activity in cells transfected with shRNA

a) TZM-bl cells were transfected with shRNA controls and infected 72 hours later with HIV-1 pseudovirus (expressing a Subtype C envelope). Forty-eight hours later, LTR-Luciferase activity was measured relative to background *Renilla* Luciferase. Virus Control and No Virus control wells were not transfected and only assayed for LTR-Luciferase activity. All data were normalised to non-specific shRNA control, shHBx, and analyzed by ANOVA with Dunnett's post-test comparison (n=3, SEM): ns ($p > 0.05$), * ($p < 0.05$), ** ($p < 0.01$). b) The same experiment as in a) showing the shRNA data.




Figure 3-18: Changes in pseudovirus activity in cells transfected with siRNAs

TZM-bl cells were transfected with siRNA SMARTpools (at 100 nM and 50 nM concentrations) and siHBV control. After 72 hours of knockdown, cells were infected with pseudovirus (except for No Virus control wells). Forty-eight hours later, LTR-Luciferase activity was measured. All data (n=3, SEM) normalised to siHBV. ANOVA with Dunnett's post-test comparison with siHBV: ns (p > 0.05), ** (P < 0.01).

3.10.2 Two-part challenge of transfected cells with replication-competent virus

After the initial screen for the requirement of each gene for pseudovirus activity, siRNA-transfected cells were challenged with fully replicating virus. The assay was set up in two parts (Figure 3-19) to mimic as closely as possible the experiments carried out by Brass *et al.* (2008). The virus used, HIV-1^{p81A-4} (derived from the molecular clone p81A-4) is capable of a full round of replication, producing assembled virions (during Part 1) that can infect fresh cells in a second round of infection (Part 2) (Sections 2.11 and 2.13.2). As shown in Figure 3-19b, only *SPTBN1* was shown to have a significant effect on viral infection. This effect was only seen at the highest siRNA concentration (100 nM) and supports the pseudovirus challenge data (Figure 3-18). In addition, the gene appears to be required during a later stage of infection as only the Part 2 data shows a statistically

significant ($P < 0.01$) effect. However the sample means in Part 1 and 2 follow the same trend (compare Figure 3-19a and b). *SP110* knockdown did not negatively affect TZM-bl cell infection by HIV-1^{p81A-4} (during either Part 1 or 2). This also supports the data from the pseudovirus challenge assay. Thus, in summary, SPTBN1 knockdown decreases HIV-1 replication by 60-75% ($P < 0.01$), seemingly during the late stage of infection. While Brass *et al.* (2008) showed a similar decrease in viral activity (76%), they indicated an early-stage role for SPTBN1. In addition, this study found no indication for SP110 as a HIV-1 host factor, while Brass *et al.* showed that SP110 knockdown caused a 84% virus reduction during the later stages of the viral lifecycle.




Figure 3-19: Changes in HIV-1^{p81A-4} activity in cells transfected with siRNAs

a) TZM-bl cells transfected with siRNA SMARTpools targeting *SPTBN1* and *SP110*, challenged with HIV-1^{p81A-4} 72 hours post-transfection, and assayed for LTR-Luciferase activity 48 hours later (Part 1). b) Fresh TZM-bl cells infected with viral supernatant from Part 1 cells and assayed for LTR-Luciferase activity 20 hours later (Part 2). All data (n=3, SEM) normalised to siHBV. ANOVA with Dunnett's post-test comparison with siHBV: ns ($p > 0.05$), * ($P < 0.05$).

CHAPTER 4 : DISCUSSION

4.1 The possible roles of *SPTBN1* in HIV-1 replication

This study has shown that *SPTBN1*, but not *SP110*, is required for infection and early-stage replication of a pseudovirus expressing Subtype C envelope in TZM-bl reporter cells. An early role in viral replication is supported by Brass *et al.* (2008) who showed viral suppression of 76% during Part 1 of their assay by 2 individual siRNAs. In contrast, this study's subsequent challenge assay with fully replicating virus showed a greater requirement during the later stages (post-translation up to assembly and budding of new virions). An important difference between this study and that published by Brass *et al.* (2008) is that Part 1 of their study was assessed by p24 assay (i.e. from viral entry to Gag translation), while this study measured LTR-Luciferase activity (which covers viral entry to Tat-induced transcription and reporter translation). Thus post-transcriptional modifications, export and translation of viral transcripts (apart from Tat and Rev) is not included in this study's Part 1. A "late-stage" classification in this study could translate into an "early-stage" role in terms of Brass *et al.*'s delineation of the lifecycle. In addition, the Part 2 data of Brass *et al.* (2008) was normalized to the number of Part 1 donor cells. This was not possible in this study and could affect the correlation between Part 1 and 2 samples. In spite of the above complications, the detection of this gene in all three challenge assays merits some discussion on its potential role(s) in HIV-1 replication.

As mentioned in Section 1.6.1.1, spectrins crosslink actin, organize transmembrane proteins and regulate stability and shape of the plasma membrane. β -spectrins interact with a wide array of membrane proteins to form a junctional complex and a major attachment site for the cytoskeleton to the cell membrane (Mouro-Chanteloup *et al.*, 2003; Nicolas *et al.*, 2003). These interactions occur via direct binding of various

forms of phospholipids (Diakowski *et al.*, 1999). In addition, spectrins may bind calmodulin to cause calcium-dependant movement of the cytoskeleton at the membrane. As described in Sections 1.2.1, 1.2.3 and 1.2.10, multiple associations occur between the cytoskeleton and HIV-1 during both entry and exit from the cell, as well as during trafficking to and from the nucleus [reviewed by (Naghavi and Goff 2007)]. Thus, both early and late roles for *SPTBN1* in HIV-1 replication are plausible.

4.2 *SP110* and HIV-1 replication

SP110 was not detected as a host factor in either of the two screens performed here (in spite of almost-complete knockdown in the same cell line used by Brass *et al.*, (2008). As mentioned in Section 1.6.1.5, this gene is recruited by EBV and stabilizes *A. phagocytophilum* gene expression. Thus a possible role in HIV-1 replication is not unlikely. As a retinoic acid receptor transcriptional co-activator, with a C-terminal region that is homologous to the Transcription Intermediary Factor 1 (TIF1) family of proteins, it's most likely role would be during viral transcription (i.e. Part 1). In contrast, Brass *et al.* (2008) found only a post-Gag translation requirement for *SP110*.

SP110 is also induced by the Interferon response (Regad and Chelbi-Alix 2001). This innate immune pathway functions to inactivate viral replication. In response, several viruses, including HIV-1 (Gunnery *et al.*, 1990; Martinand *et al.*, 1999) have evolved means to inhibit this cellular process. Possibly, HIV-1 interacts with *SP110* to further regulate this response. Apart from these factors, high *SP110* expression is restricted to peripheral blood leukocytes (PBLs) and the spleen. Although its expression in HeLa and 293T cells could be detected by qRT-PCR in this study, this gene's involvement in the Interferon response, specifically during HIV-1 infection, may only be active in immune cells (e.g. PBLs (peripheral blood leukocytes), which interestingly are also the natural

targets of HIV-1). Thus, the inconclusive data reported for this gene in this study and by Brass *et al.* (2008) highlights the risks of using cellular models that do not represent the biological context of the process being studied.

4.3 Comparison of viruses used in this study and by Brass *et al.* (2008)

As TZM-bl reporter cells and siRNA SMARTpools were used in both studies, the discrepancy in results seems to reflect differences between the viruses. As the CAP210.2.00.E8 pseudovirus and HIV-IIIB (HTLV-IIIB/H9 from Dr Robert Gallo, NARRRP Catalogue Reagent 398, used by Brass *et al.*, 2008) data agree on an early requirement for *SPTBN1*, while the HIV-1^{p81A-4} data indicate a later stage of involvement, we would expect the pseudovirus and HIV-IIIB to have common properties (particularly regarding cellular entry) that differ from those of HIV-1^{p81A-4}. In contrast, HIV-IIIB is T-cell tropic (i.e. using CXCR4 as entry co-receptor) while both the Env-pseudotyped virus and HIV-1^{p81A-4} are macrophage-tropic (i.e. using CCR5 co-receptor), the latter due to the insertion of a BaL strain V3 loop region into the envelope of NL4-3 virus (Chesebro *et al.*, 1992). Moreover, HIV-IIIB and HIV-1^{p81A-4} are both Subtype B viruses while the pseudovirus has a Subtype C envelope. Thus these aspects of the viruses do not account for the results. Other differences between the viruses include the fact that the lab-adapted strain of HIV-IIIB used by Brass *et al.* (2008) is deficient for the viral accessory genes *nef* and *vpu*, while a molecular clone (HXBc2, Genbank accession number K03455) derived from this strain encodes a truncated form of Vpr. It is interesting that the pseudovirus in this study is also lacking *vpu*, while HIV-1^{p81A-4} has an intact genome, except for the V1-V3 region substitution that changes its cell tropism. Since a Vpu-deficiency is common to the pseudovirus and HIV-IIIB, this loss-of-function may explain the pattern of results obtained.

Vpu has several functions in viral pathogenesis [recently reviewed by (Nomaguchi *et al.*, 2008)]. Briefly, Vpu is required for virus maturation and release (Klimkait *et al.*, 1990). Deletion of *vpu* was shown to cause retention of virus at the plasma membrane, as a result of host Tetherin that is normally degraded by Vpu (Neil *et al.*, 2008), and increased cytopathic effects (Iwatani *et al.*, 1997). These cytopathic effects were found to result from association between virions / envelope protein with abnormally high levels of surface CD4 receptor, which is normally degraded by Vpu (Willey *et al.*, 1992). Down-regulation of CD4 has several functions, one being to prevent superinfection of infected cells (Wildum *et al.*, 2006). Loss of these functions may have had significant implications on the pseudovirus data obtained in this study and the findings of Brass *et al.* (2008). While their study reported no change in CD4 surface expression after Rab6 gene knockdown, they did not take into account the effect of HIV-IIIB infection on CD4 levels. Tetherin-mediated membrane retention of virus (in the absence of Vpu) could mask a late-acting function of *SPTBN1* (and other membrane proteins) in aiding the release of virus particles. Alternatively, superinfection (resulting from increased CD4 levels) would place a greater burden on viral entry pathways, possibly making an early requirement for *SPTBN1* more pronounced than during a Vpu-regulated infection.

As Nef also functions in down-regulating CD4 surface expression, the lack of both *vpu* and *nef* in HIV-IIIB may explain the stronger requirement for *SPTBN1* observed by Brass *et al.* (2008). Nef also directly interacts with the Actin cytoskeleton to aid post-fusion trafficking (Campbell *et al.*, 2004). Thus the loss of a putative *SPTBN1* function at the membrane during entry may not be as debilitating in the presence of Nef (as observed in the pseudovirus data). Finally, cytopathic effects induced by *vpu* deletion could have diverse effects on cellular functions, making the interpretation of any one gene's role in cellular or viral processes inaccurate.

4.4 Gene selection

The criteria comprising the selection process used in this study to compile a list of individual genes representing both the early and late stages of the HIV lifecycle are logically and biologically sound. However, as three of the five selected genes could not be fully studied (*PRDM14* because of low expression levels in the cell lines used; *KIAA1012* and *SP110* because of target mRNA inaccessibility to the shRNAs) in viral challenge assays, their status as HDFs is inconclusive. Such obstacles may be prevented in future studies by using online databases such as the NCBI Gene Expression Omnibus (GEO) Dataset that provides sequence- and microarray-based expression data in a range of cellular types. Moreover, bioinformatic measures of target site accessibility should be incorporated into the shRNA design process (see Section 4.6.2) or genes selected for which effective RNAi effectors (at the mRNA or protein level) have been published.

4.5 Broader perspectives

4.5.1 Large-scale lentiviral shRNA transduction of T-cells

A recent study by Yeung *et al.* (2009) used a lentiviral shRNA library to transduce Jurkat T-cells before infection with full-length NL4-3 virus. Such a study is far more valuable in representing a natural T-cell infection than siRNA screens in HeLa or 293T cells using lab-adapted viral strains. This study (Yeung *et al.*, 2009) identified 252 host genes whose knockdown did not affect T-cell viability (over 3 weeks of selection) and that protected the cell from lytic viral replication. The candidates identified by Yeung *et al.* (2009) have great potential as future drug targets since cytotoxic effects resulting from long-term knockdown has already been ruled out, while the ability of each gene to completely protect the cell from virus-induced lysis (over 4 weeks of infection) has also

been shown. In addition, reversal of viral suppression could be achieved by reconstituting the inhibited gene product (for three genes), thus proving the direct and specific effects of the knockdown. A disadvantage of such an experiment is the incomplete genome coverage resulting from incomplete transduction efficiency. Also, Yeung *et al.* (2009) acknowledge several factors that can result in false negative and false positive results. However, by repeating such a screen several times, both coverage and accuracy can be improved. Moreover, by repeating such a screen in primary T-cells and macrophages (that are refractory to siRNA transfection but not lentiviral transduction), a shortlist of candidates can be assembled that can be confirmed by detailed studies of specific viral processes.

On comparing their data with the three siRNA genomic screen datasets (Brass *et al.*, 2008; Konig *et al.*, 2008; Zhou *et al.*, 2008), Yeung *et al.* found that their 252 genes were mostly distinct. However, the cellular pathways used by HIV-1 seem to be conserved across the studies. This is interesting, considering the differences in cell lines, viral strains, study design and detection assays used. They suggest that further study of these common cellular pathways may be more informative than focusing on individual genes identified. This confirms the need for using microarray analyzes of total gene expression profile changes, as well as robust and powerful bioinformatic algorithms that take into account protein interactions and molecular pathway networks in order to detect overlaps and patterns that might easily be missed when dealing with such large datasets. This study has shown that there are many reasons for which study of an individual gene might be discontinued. By studying the interacting proteins and functional gene networks of such a gene in parallel, such obstacles would have little impact on the investigative potential of the study. In addition, the results would be more robust and informative, with data on multiple interacting genes providing a biological context that does not exist in single gene studies.

4.5.2 Alternative techniques for characterizing the viral/cellular interactome

The task of documenting the viral/cellular interactome is vast and complex. By combining the data obtained from a wide variety of approaches, there is a greater likelihood that the final picture will be a true reflection of such a dynamic process. Moreover, because these interactions are dynamic, using only two time-points for measurements (as used in this study and in all four genomic RNAi screens mentioned) would not detect subtle and transient changes. Thus kinetic analyzes of several viral markers (for example, LTR-expression, p24-Gag levels, CD4 receptor levels and total viral load) over time would be more informative.

Several novel technologies have been developed for high-throughput analysis of protein interactions that are useful in biochemically validating the interaction data from standard yeast-two-hybrid (Y2H) screens. These technologies [reviewed by (Bailer and Haas 2009)] include: nucleic acid programmable protein arrays, NAPPA (Ramachandran *et al.*, 2004), that transcribe and translate DNA printed on array chips for co-immunoprecipitation (CoIP) assays; luminescence-based mammalian interactome mapping, LUMIER (Barrios-Rodiles *et al.*, 2005), that uses luciferase-fusion proteins to detect protein interactions; protein fragment complementation assays, PCA (Nyfeler *et al.*, 2005), based on the reconstitution of a fluorescent protein when its domains (fused to the proteins of interest) interact and finally, mammalian protein-protein interaction trapping, MAPPIT (Eyckerman *et al.*, 2001), to detect the transcriptional activity of an endogenous reporter gene that is activated by a signaling cascade when the proteins of interest (fused to the membrane receptor and signal molecule, respectively) interact.

Other approaches to mapping the viral/cellular interactome include microarray analyzes of HIV-induced changes in the host transcriptome and proteome (Geiss *et al.*, 2000), shotgun liquid chromatography-tandem mass spectrometry (Chan *et al.*, 2009), as

well as high-resolution microscopy techniques. The many applications of the latter are particularly exciting for viral research (Arhel *et al.*, 2006; Brandenburg *et al.*, 2007). PALM/STORM (photoactivation localization microscopy/stochastic optical reconstruction microscopy) combines super-resolution microscopy with superior algorithms for visualizing molecules at the nanometer scale and detecting individual fluorescent signals in three dimensions over time (Bates *et al.*, 2007; Huang *et al.*, 2008). In addition, single particle tracking and new molecular beacons have been used to study RNA localization and trafficking as effectively as the GFP reporter allows protein visualization (Bratu *et al.*, 2003; Mhlanga *et al.*, 2005). The application of such technologies to future studies of viral replication and infection will enable the real-time detection of individual reporter signals in single live cells. This will greatly reduce the inaccuracies of previous experiments where averaged static signals across cell populations were used, potentially masking multiple subtle variations that can now be more fully explored.

4.6 Factors of RNAi experiments highlighted by this study

4.6.1 Primer design in PCR-based cloning of shRNAs

The variable ease with which each shRNA could be cloned (using the two-step PCR approach) may be because of specific sequence combinations that make hairpin formation thermodynamically more favorable than template/primer binding. The second-round PCR reverse primers were designed to bind the loop region as well as part of the sense strand of the first-round product, allowing hairpin formation to occur in both the primer and the template. In retrospect, the original primer design suggested by (Castanotto *et al.*, 2002), using reverse primers that are complementary to each other over the loop region only, would have avoided this hairpin formation. The comparatively greater success at cloning the siRNA-based shRNAs (using single-round PCR with full-

length primers, where the template did not contain hairpin-forming sequences) gives support for using this approach in future, as no optimization or additional reagents was required for efficient PCR amplification.

4.6.2 Target mRNA accessibility to the RNAi machinery

The ability of the original set of shRNAs to knock down Luciferase reporter targets by at least 75% (with most affording over 90% knockdown) indicates efficient Dicer processing of the guide strand and RISC activation. In addition, the fact that a non-targeting shRNA showed no effect on each reporter target supports this knockdown as being sequence-specific. The fact that such efficiently processed and highly functional shRNAs had no significant effect on their endogenous mRNA targets (excepting shSP110-2) is likely to be a result of the inherent properties of the target mRNA. Both bioinformatic modeling and experimental studies have shown that the local secondary structure of target mRNAs affects the biological activity of siRNAs by preventing loaded RISCs from accessing the site (Bohula *et al.*, 2003; Kretschmer-Kazemi Far and Sczakiel 2003; Overhoff *et al.*, 2005). Indeed, one way in which HIV-1 can evade RNAi is by altering its secondary structure to hinder target site accessibility, which in turn lowers the stability of the siRNA/target duplex (Westerhout *et al.*, 2005). Moreover, a bioinformatic analysis of 100 siRNAs and 101 shRNAs targeted to 103 endogenous human genes (Shao *et al.*, 2007) predicted that siRNA/shRNA efficacy could be improved by 40% just by ensuring target accessibility. Shao *et al.* (2007) described a measure of target structural accessibility (termed $\Delta G_{\text{disruption}}$) that was found to be the most important predictor of RNAi efficacy. Such factors would be given more attention in future shRNA designs.

4.6.3 The importance of reliable reference genes and controls in qRT-PCR assays

Target site accessibility cannot be predicted by assays like the Dual Luciferase Reporter Assay used in this study. The oligodeoxyribonucleotide/RNase H method has been used effectively to give a direct indication of target accessibility (Scherr and Rossi 1998; Lee *et al.*, 2002), though it cannot measure overall knockdown efficacy. A simpler alternative to assess the RNAi activity on the endogenous mRNA is to use qRT-PCR (used here to address the second objective of the study). This technique (if set up correctly) is both sensitive and accurate, allowing the detection of changes in RNA levels over a large dynamic range.

The qRT-PCR data obtained in this study clearly shows the importance of having the correct controls in place. In this study, several negative and positive controls were tested: the no-template and negative-RT controls, target plasmid standards, as well as melting curve analysis, all served to ensure that the correct template (cDNA) was being amplified during each assay, with no contamination and with the same efficiency. Apart from these, two different housekeeping genes (*β -actin* and *GAPDH*) were compared for their reliability as references for normalizing mRNA levels. *β -actin* and *GAPDH* have been used as single reference genes in more than 90% of studies (Vandesompele *et al.*, 2002). In spite of this, several studies on the reliability of commonly used housekeeping genes have shown that neither are in fact optimal reference genes (Zhong and Simons 1999; Selvey *et al.*, 2001; Glare *et al.*, 2002; Watson *et al.*, 2007). Their expression varies across several tissue types tested and are affected by cell cycle activation (Radonic *et al.*, 2004). This is of concern as the requirement for a reference gene in mRNA detection is that the gene's expression is as constant as biologically possible, without being affected by experimental procedures.

In this study, where RNA was amplified by qRT-PCR from two cell lines, *β -actin* consistently proved to be more reliable than *GAPDH*, with the data normalized to *β -actin*

showing very little variation between replicate samples and assays. The suitability of β -*actin* is further supported by the fact that the knockdown efficacies of the positive control shRNAs (that were previously determined by qRT-PCR) matched the data obtained in this study. The only discrepancy observed (for shTat) is due to differences in experimental setup, with the weaker knockdown observed here being attributable to the far higher target concentration (expressed from a plasmid) than was present when originally tested (expressed endogenously from a stable cell line). Moreover, the levels of LTR-driven reporter gene expression in the absence of Tat are so low that any knockdown would not be detected in comparison to the decrease detected when Tat was added.

4.6.4 Off-target effects and the benefits of Dharmacon's ON-TARGET^{plus} SMARTpool technology

An important aspect of any RNAi study is non-specific or off-target effects. The only comprehensive way to rule this out is to use microarrays to assess changes in the gene expression profile before and after RNAi treatment. As this option was not feasible in this project, non-specific control shRNAs (targeting the HBV genome and a host gene, *lacZ*) and a control siRNA (also targeting HBV) were tested for their effects against each of the genes studied. Once their reliability had been ascertained, these were included in every qRT-PCR assay to indicate whether knockdown effects were shRNA/siRNA-specific or not. Finally, the online BLAST tool was useful in screening each shRNA for non-specific matches between the guide sequence and other human gene sequences.

Several aspects of Dharmacon's ON-TARGET^{plus} SMARTpool technology ensure specific silencing by the siRNAs used in this study. Firstly, chemical modifications in both strands (Jackson *et al.*, 2006; Chen *et al.*, 2008) serve to ensure that the antisense (guide) strand is processed and loaded into RISC and to stabilize target specificity. Secondly, the effect of pooling not only increases knockdown efficacy but also minimizes

off-target silencing by decreasing the concentration of each individual siRNA. Seed region filters and seed frequency analyzes (Birmingham *et al.*, 2006; Anderson *et al.*, 2008) have also been incorporated into the design of each siRNA to prevent miRNA-like off-target silencing of genes with seed sequence matches in their 3'-UTRs. Finally, microarray analyzes of the number of genes' expression affected by these siRNAs (Anderson *et al.*, 2008) show a marked decrease in off-target effects.

The SMARTselection™ design algorithm, combined with the dual-strand modifications and pooling, not only decrease off-target silencing but are also responsible for the impressive knockdown efficacy of the siRNAs. The increase in knockdown of both genes at the lowest concentration (5 nM - Figure 3-11) is unexpected. A possible explanation is that the siRNA/lipid charge ratio at such a low concentration favours lipoplex formation (lipid molecules complexed with DNA or RNA), enhancing transfection and thus knockdown efficacy. The comparatively weaker knockdown efficacy of the shRNAs derived from the siRNA pools is unsurprising. Not only is the pooling effect lost, as well as the chemical modifications that enhanced both specificity and efficiency in the SMARTpools, but potential variability in Dicer cleavage sites (Vermeulen *et al.*, 2005) could produce guides sequences of slightly different lengths, affecting the ultimate seed sequence of the guide and thus its targets for knockdown. While shRNAs provide stabler, longer-term silencing, with Dicer processing increasing the efficiency of RISC loading (Kim *et al.*, 2005; Siolas *et al.*, 2005), the siRNA ON-TARGET_{plus} SMARTpool technology provides more potent knockdown with fewer off-target effects, which was important for achieving the viral knockdown objective of the study.

4.6.5 siRNA-related cytotoxicity

The third aim of this project was to confirm that no significant toxicity was induced in the treated cells. Trypan-blue exclusion (the classical standard for measuring the

proportion of viable cells in a sample) detects only late apoptotic and necrotic cells where the plasma membrane is sufficiently damaged to allow uptake of the dye, whereas the MTT assay used in this study can detect apoptotic cells and distinguish them from viable and dead cells (Feng *et al.*, 2002). The MTT assay assesses metabolic activity (and thus cell viability) by measuring mitochondrial enzyme activity and cytoplasmic NADH reduction. It is important to ensure that the cells to be tested have a uniform baseline metabolic rate. The cells tested in this study were healthy, proliferating well and not subjected to any extreme environmental changes before the test. They were seeded uniformly from one population and transfected in the same way as during previous knockdown assays. The only observed toxicity (relating to siRNA transfection) may be related to siRNA-induced activation of the innate immune response when certain sequence motifs are recognized by Toll-like Receptor 7/8 (Hornung *et al.*, 2005; Judge *et al.*, 2005). This ultimately leads to sequence-independent suppression of protein synthesis and enhanced mRNA degradation through the activation of many host defense genes (Kariko *et al.*, 2004). However, this is unlikely as siHBV has previously tested negative for Interferon induction (data not shown) while the design and construction of the SMARTpools ensures that such motifs are excluded while including chemical modifications that can avoid such an effect (Sioud 2008).

Alternatively off-target silencing may have down-regulated essential gene functions. As described previously, several preventative measures serve to significantly decrease the number of off-target effects in the ON-TARGET^{plus} SMARTpool siRNAs. Another possibility is that the targeted genes' loss of function is responsible for the toxicity. In spite of the care taken during selection of these genes, very few of the protein interactions and molecular pathway interactions of the selected genes have been described. As with any study where relatively unknown human genes are targeted, in-depth characterization of the gene in several cell lines would need to be done and more sensitive techniques than the MTT assay used to assess the exact cellular system that is

affected by the knockdown. However, in light of the fact that both siRNA pools and the siRNA control affected cell viability to a similar degree suggests a more general cause of toxicity.

The transfection procedure is a likely candidate for siRNA-associated toxicity. One study, comparing a number of commercially available cationic liposome/lipid-based systems used for siRNA delivery, found that the doses required for maximum transfection efficiency and target knockdown also caused non-specific down-regulation of cellular protein expression (Spagnou *et al.*, 2004). One of these transfection reagents is widely used in RNAi studies because of its high transfection efficiencies across a broad range of cells. In contrast, the siRNA transfection reagent used in this study (DharmaFECT 4) claims to have very low toxicity. Alamar blue viability assays on transfected cells (matching the exact conditions used in this study excepting the cell line) indicated 80% viability post-transfection (data unpublished, Dharmacon). The alamar blue assay is comparable in sensitivity (if not slightly more sensitive) to the MTT assay used here (Hamid *et al.*, 2004).

The only remaining explanation for the observed toxicity is that the untransfected, untreated control sample wells contained more cells than the siRNA-transfected wells because of cells lifting off during the two changes of culture medium in the latter. For the shRNA-transfected wells, the transfection mix was added directly to the medium, which is less disruptive to the cell monolayer. This explanation is supported by the difference in LTR-activity observed between the Virus Control and siHBV-treated samples in the viral challenge assays (Figure 3-18 for an example). In summary, it is unlikely that the siRNA transfection conditions are cytotoxic, with the data probably reflecting unequal baseline signals as a result of the transfection process.

4.6.6 Delivery of RNAi effectors to a T-cell line by electroporation and lipid-based reagents

Another objective of this study was to determine whether shRNAs or siRNAs could be delivered to a T-cell line (that is permissive to natural infection by HIV) using reagents and tools available to us. Unfortunately, electroporation is clearly too harsh a delivery technique, with insufficient cells remaining for several of the tested protocols. If delivery of the RNAi effectors significantly affects cell viability (altering several cellular pathways' normal functioning), this would severely limit our ability to accurately detect these pathways' interactions with HIV. Apart from the adverse effects on viability, the delivery efficiency of the protocols tested here was also disappointing. In contrast, the DharmaFECT 4 and ESCORT-V transfection reagents showed better delivery (of siRNA and DNA, respectively) with no visible effects on cell viability. However, delivery was still inadequate for achieving the knockdown potential of the RNAi effectors. To infer the involvement of a gene product in viral replication very good knockdown of gene expression must be achieved and thus highly efficient delivery of the RNAi effectors is an absolute requirement.

4.6.7 Alternative delivery methods

Two alternatives to the delivery methods tested in this study are nucleofection and lentiviral transduction. Both have been reported to be successfully applied (Schroers *et al.*, 2002; Zhou *et al.*, 2003; Maasho *et al.*, 2004; Anderson *et al.*, 2007; ter Brake *et al.*, 2008), however they are considerably expensive. Generation of recombinant lentiviral vectors is also time-consuming and requires some experience.

4.6.7.1 Nucleofection

Nucleofection™ is an adaptation of electroporation that delivers any nucleic acid directly to the nucleus (and cytoplasm) without requiring cells to be dividing. This technique, developed by the Amaxa biotechnology company (Lonza, Cologne, Germany), specializes in delivery to difficult-to-transfect cell types, including primary cells, stem cells, suspension cells and non-dividing cells. Nucleofection™ uses both electrical parameters (which can only be used on the Nucleofector™ device) and a buffer specially formulated for each cell type. The company's website (www.lonzabio.com) has reports of 5 independent researchers that have successfully transfected SupT1 cells using their technology, with delivery ranging from 30 to 65% and 75-98% cell viability. This technique is promising for transient transfection as it is simple and rapid, with a cell-type specific buffer and existing protocols that have been proven to work. However, in the HIV-1 gene therapy setting stable transfection of cells is important, thus limiting the application of this technique.

4.6.7.2 Lentiviral transduction

Lentiviral transduction has been developing for many years and has been used in a wide variety of settings including delivery of potential gene therapies to inhibit HIV-1 [reviewed by (Escors and Breckpot 2010)]. Lentiviral vectors are attractive for gene therapy because stable integration of the transgene into the genome occurs, allowing permanent knockdown of targeted genes. Moreover, as with nucleofection, transduction of non-dividing, primary and stem cells is possible (Hamilton *et al.*, 2009). Finally, these vectors have low immunogenic properties, making them useful for long-term challenge assays to detect viral resistance and changes in replication kinetics over time [reviewed by (Nayak and Herzog 2009)].

Their great potential in the gene therapy field is illustrated by a triple-therapy vector comprising a TAR decoy, a ribozyme targeted to *CCR5* and a shRNA against *rev/tat*. This gene therapy has proved to be both safe and highly effective against HIV-1 in T-cells/PBMCs (peripheral blood mononuclear cells) (Li *et al.*, 2003), hematopoietic stem cells, HSCs (Li *et al.*, 2005) and in SCID-hu (severe combined immune deficient human) mouse-derived T-cells (Anderson *et al.*, 2007). Effective delivery of this vector to the HSCs is particularly exciting, as these cells give rise to the lymphocytes and other cells of the humoral immune system, many of which are targets of HIV-1 infection. This therapy has been approved by the FDA for participation in two planned human clinical trials.

The drawback of using any integrating viral vector is the risk of insertional mutagenesis occurring - a concern enhanced after three X-SCID (X-linked severe combined immunodeficiency) patients developed leukemia during a gene therapy trial due to onco-retroviral vector integration adjacent to a proto-oncogene promoter (Hacein-Bey-Abina *et al.*, 2003). Since then most studies use lentiviral vectors, as they tend to integrate distally from promoters in introns, lowering the oncogenic risk (Wu *et al.*, 2003) or non-integrating lentiviral vectors [reviewed by (Philpott and Thrasher 2007)] that remove this risk entirely while retaining their high transduction efficiency (particularly in non-dividing cells). Lentiviral vectors have been extensively developed for increased safety (Pauwels *et al.*, 2009). However, in spite of these safety precautions there is always a chance that recombination between the vector and wildtype virus may occur, potentially mobilizing the vector and rendering it replication-competent. However, this risk may be used to our advantage by ensuring that the vector is spread to every cell that becomes infected (Morris and Rossi 2004).

4.6.7.3 Other viral delivery vectors

Apart from lentiviral vectors, other popular viral vectors have been developed from Adenovirus (AdV), and Adeno-associated virus (AAV). AdV vectors (usually derived from serotypes 2 or 5) have a broad tissue-tropism [reviewed by (Lipiec *et al.*, 2009)], can transduce quiescent and proliferating cells and rapidly induce strong transgene expression – important in infectious disease settings. Vector toxicity and immunogenicity (leading to rapid clearance of transduced cells) has been overcome by the generation of “gutless” AdV vectors, from which all adenovirus coding sequences (excepting the inverted terminal repeats, ITRs, and packaging signal, ψ) are deleted (McCaffrey *et al.*, 2008).

AAVs have long-term *in vivo* stability, up to 6 years (Bankiewicz *et al.*, 2006) in spite of mostly remaining episomal (i.e. non-integrating), which lowers concerns of insertional mutagenesis. The drawback of slow onset of transgene expression by single-stranded AAVs was overcome by generation of self-complementary (sc) double-stranded AAVs that reach maximal expression within several days (McCarty *et al.*, 2003; Wang *et al.*, 2003). The maximum insert size of scAAV vectors (~2.2 Kb), while being prohibitive for most applications, is ideal for expression of RNAi triggers like shRNAs.

In brief, while cloning and packaging high-titer viral vector preparations is a relatively lengthy process requiring specific resources and skills, the many developments and options in this field allow highly efficient transgene delivery to almost any target cell desired, allowing stable expression with few side effects. Moreover, while there are significant concerns relating to safety of these vectors, these continue to be addressed in each new generation of vector development. As a result, viral vectors are the most promising and widely used vectors for delivery of gene therapies.

CHAPTER 5 : CONCLUSIONS

In summary, this study has verified that *SPTBN1* is required for HIV-1 replication in a HeLa-derived cell line. However, unlike Brass *et al.* (2008), we have shown a later (post-transcriptional) stage of involvement. In addition, *SP110* (implicated by Brass *et al.* (2008) as a late-acting HDF) does not appear to have any involvement in the viral lifecycle. These discrepancies between our findings and those of Brass *et al.* (2008) may reflect the absence of several important viral accessory genes from the virus used in the latter study. As both studies used a HeLa-derived reporter cell line rather than CD4+ T-cells, the need for using physiologically representative viral and cellular models when using RNAi to study virus-host interactions has been highlighted. Moreover, a set of viral markers that represent the viral replication cycle should be measured over several time-points, to ensure that experiments are comprehensive and maximally informative.

This study has accentuated several factors regarding RNAi-based knockdown experiments. Firstly, accessibility of the mRNA target site to RNAi activity is essential. Secondly, off-target knockdown effects, as well as cytotoxicity arising from the RNAi process, the transfection conditions or target knockdown must be carefully considered. Thirdly, while qRT-PCR is an immensely sensitive and powerful technique, it can give misleading results if reliable reference genes and controls are not used. Finally, while T-cells appear to be refractory to efficient transfection by lipid-based reagents and electroporation, advances in viral delivery systems, as well as the development of newer approaches (like Nucleofection), have made RNAi-based research in difficult-to-transfect cells possible.

Future prospects are promising as there have been major advances in our ability to directly visualize any host/viral molecular interaction in high resolution and in real-time within single live cells. These technologies are continually improving, enhancing our

understanding of the complex and dynamic processes that occur during a cellular HIV-1 infection. By complementing existing approaches to confirm and characterize the hundreds of newly identified candidate host factors, the goal of developing novel effective antiviral therapies will be more easily reached.

APPENDIX A: Sequence information

Table A-1: Genomic location of shRNA target sequences

Gene targeted	RNAi effector	Transcript code	Target location
SPTBN1	shSPTBN-1	NM_003128.2 (transcript variant 1, TV1) NM_178313.2 (transcript variant 2, TV2)	4864-4884 4961-4981
	shSPTBN-2	TV1 TV2	6121-6141* 6218-6238*
	shSPTBN-3	TV1 TV2	1896-1916* 1993-2013*
TMED2	shTMED-1 shTMED-2 shTMED-3	NM_006815.3	584-604 153-173 162-182
KIAA1012	shKIAA-1 shKIAA-2 shKIAA-3	NM_014939.3	4394-4414 536-556 1151-1171
PRDM14	shPRDM-1 shPRDM-2 shPRDM-3	NM_024504.2	303-323 1544-1564 691-711
SP110	shSP110-1	NM_004509.3 (TV1) NM_080424.2 (TV3)	2162-2182 2234-2254
	shSP110-2	TV1 + NM_004510.3(TV2) + TV3	348-368
	shSP110-3	TV1 + TV2 + TV3	471-491

* These sequences were the intended targets but were not actually targeted due to incorrect insertion of the sense (anti-guide) sequence in the position of the guide sequence during design of shRNAs shSPTBN-2 and -3.

Table A-2: Genomic location of siRNA-derived shRNA target sequences

Gene targeted	RNAi effector	Transcript code	Target location
SPTBN1	shSPTBN-A	NM_003128.2 (transcript variant 1, TV1)	5239-5257
		NM_178313.2 (transcript variant 2, TV2)	5336-5354
	shSPTBN-B	TV1	1664-1682
		TV2	1761-1779
	shSPTBN-C	TV1	4146-4164
		TV2	4243-4261
	shSPTBN-D	TV1	5876-5894
		TV2	5973-5991
SP110	shSP110-A	NM_004509.3 (TV1)	1530-1548
		NM_004510.3 (TV2)	
		NM_080424.2 (TV3)	
	shSP110-B	TV1 + TV2 + TV3	499-517
	shSP110-C	TV1 + TV2 + TV3	1714-1732
shSP110-D	TV1 + TV2 + TV3	1204-1222	

Table A-3: Primer sequences used in two-step PCR-amplification of shRNA expression cassettes for *SPTBN1*, *TMED2* and *KIAA1012*

Universal U6F	GGATCC <i>GATTC</i> AAGGTCGGGCAGGAAGAGGGCCT
SPTBN_1 R1	CTTT TGGGTCAGG <i>A</i> GAGATGTGTCAATGCGAGG CGGTGTTTCGTCCTTTCCACAA
SPTBN_1 R2	<u>AAAAAA</u> CCTCGCATTGACGACATCTTT TGGGTCAGG <i>A</i> GAGATG
SPTBN_2 R1	ATTA TGGGTCAGG <i>A</i> TAATGCACGTAGTTAGAGTCG CGGTGTTTCGTCCTTTCCACAA
SPTBN_2 R2	<u>AAAAAA</u> CGACTTTAACTACGTGCATTA TGGGTCAGG <i>A</i> TAATGCA
SPTBN_3 R1	TGAT TGGGTCAGG <i>A</i> TCAGAACTCTGTTATGATCG CGGTGTTTCGTCCTTTCCACAA
SPTBN_3 R2	<u>AAAAAA</u> TAGTCTTGAGACAATACTAGC TGGGTCUGG <i>A</i> TCAGAA
TMED_1 R1	CACAA TGGGTCAGG <i>T</i> TGTGTTGTCGTTGATGGCT CGGTGTTTCGTCCTTTCCACAA
TMED_1 R2	<u>AAAAAA</u> GAGCCATCAACGACAACACAA TGGGTCAGG <i>T</i> TGTGTT
TMED_2 R1	TATTT TGGGTCAGG <i>A</i> CATAGCACGAGACCGTGGC CGGTGTTTCGTCCTTTCCACAA
TMED_2 R2	<u>AAAAAA</u> GGCCACGGTCTCGGGCTATTT TGGGTCAGG <i>A</i> CATAG
TMED_3 R1	GCAT TGGGTCAGG <i>A</i> TGCTAACGAGATAGCACGAG CGGTGTTTCGTCCTTTCCACAA
TMED_3 R2	<u>AAAAAA</u> CTCGGGCTATTTCTGTTAGCAT TGGGTCAGG <i>A</i> TGCTAA
KIAA_1 R1	TAGTT TGGGTCAGG <i>A</i> ACTATGACATCTACATCAG CGGTGTTTCGTCCTTTCCACAA
KIAA_1 R2	<u>AAAAAA</u> GCTGATGTAGATGTCATAGTT TGGGTCAGG <i>A</i> ACTAT
KIAA_2 R1	CGTA TGGGTCAGG <i>A</i> CAGTGAAGTTGATTATTAGG CGGTGTTTCGTCCTTTCCACAA
KIAA_2 R2	<u>AAAAAA</u> CCTAATAATCAACTTCACGTA TGGGTCAGG <i>A</i> CAGTGA
KIAA_3 R1	CTGAT TGGGTCAGG <i>T</i> GAAGTTATAGTACAAGAGC CGGTGTTTCGTCCTTTCCACAA
KIAA_3 R2	<u>AAAAAA</u> CGATCATAACAGAGTTCTGAT TGGGTCAGG <i>T</i> GAAGT

Key: **Bold:** *Bam*HI; **Italic:** *Eco*RI; **Bold Italic:** Loop; **Red:** Guide sequence; **Blue:** U6 promoter priming; Underlined: Termination signal

Table A-4: Primer sequences used in two-step PCR-amplification of shRNA expression cassettes for *PRDM14* and *SP110*

PRDM_1 R1	AGAA <i>TGGGTCAGG</i> TTCTGTAGTGTCCATAGGACG CGGTGTTTCGTCCTTTCCACAA
PRDM_1 R2	<u>AAAAAA</u> CGTCCTATGGACACTACAGAA <i>TGGGTCAGG</i> TTCTGTA
PRDM_2 R1	TGTT <i>TGGGTCAGG</i> AACATGAAGAATGTGGATCCG CGGTGTTTCGTCCTTTCCACAA
PRDM_2 R2	<u>AAAAAA</u> CGGATCCACATTCTTCATGTT <i>TGGGTCAGG</i> AACATGA
PRDM_3 R1	TTATT <i>TGGGTCAGG</i> AATAACTGAGAGGTCCTCAG CGGTGTTTCGTCCTTTCCACAA
PRDM_3 R2	<u>AAAAAA</u> GCTGAGGACCTCCCAGTTATT <i>TGGGTCAGG</i> AATAAC
SP110_1 R1	CCATA <i>TGGGTCAGG</i> TATGGTTGCGAGACATCAGG CGGTGTTTCGTCCTTTCCACAA
SP110_1 R2	<u>AAAAAA</u> GCCTGATGTTTCGCAACCATA <i>TGGGTCAGG</i> TATGGT
SP110_2 R1	TCATT <i>TGGGTCAGG</i> ATGATGGAGTTGTCTAGGAGG CGGTGTTTCGTCCTTTCCACAA
SP110_2 R2	<u>AAAAAA</u> CCTCCTAGACAACCTCCATCAT <i>TGGGTCAGG</i> ATGATGGAGT
SP110_3 R1	CATT <i>TGGGTCAGG</i> AATGTCACCAGAAGAGACAGG CGGTGTTTCGTCCTTTCCACAA
SP110_3 R2	<u>AAAAAA</u> CCTGTCTCTTCTGGTGACATT <i>TGGGTCAGG</i> AATGTCA

Key: **Bold:** *Bam*HI; *Italic:* *Eco*RI; **Bold Italic:** Loop; **Red:** Guide sequence; **Blue:** U6 promoter priming; Underlined: Termination signal

Table A-5: Primer sequences used in single-round PCR-amplification of siRNA-derived shRNA expression cassettes

Universal U6F	5' - GGATC CTCGAG CGGGCC G TAGCAAGGTCGGGCAGGAAGAGGGCC - 3'
SPTBN_A R	5' - <u>AAAAAA</u> GCCTGAARGTGAGCGCATTAT TGGGTCAGG GATAATACGCTCACTTTCAGGC GGTGTTCGTCCTTTCCACAA - 3'
SPTBN_B R	5' - <u>AAAAAA</u> CCGCATACGAGGAGCGTGTAT TGGGTCAGG ATATACGCTCCTCGTATGCGGC GGTGTTCGTCCTTTCCACAA - 3'
SPTBN_C R	5' - <u>AAAAAA</u> GGACATGTCTTACGATGAATT TGGGTCAGG AATCCATCGTAAGACATGTCC GGTGTTCGTCCTTTCCACAA - 3'
SPTBN_D R	5' - <u>AAAAAA</u> GTGACAAGGCCGACGATATAT TGGGTCAGG ATACATCGTCGGCCTTGTCAC GGTGTTCGTCCTTTCCACAA - 3'
SP110_A R	5' - <u>AAAAAA</u> GGAGAARGATATCTGTTCATTT TGGGTCAGG AATGAACAGATATCTTTCTCC GGTGTTCGTCCTTTCCACAA - 3'
SP110_B R	5' - <u>AAAAAA</u> CRAATTAACCTGCGTGAATAT TGGGTCAGG ATACTCACGCAGGTTAATTTGC GGTGTTCGTCCTTTCCACAA - 3'
SP110_C R	5' - <u>AAAAAA</u> GAGGATGGA ACTTGGTTAATT TGGGTCAGG AATCAACCAAGTTCCATCCTC GGTGTTCGTCCTTTCCACAA - 3'
SP110_D R	5' - <u>AAAAAA</u> GAAGATGACTCAACTTGTATT TGGGTCAGG AACACAAGTTGAGTCATCTTC GGTGTTCGTCCTTTCCACAA - 3'

Key: Orange: *Bam*HI; Purple: *Xho*I; Dark Red: *Not*I; Green: *Nhe*I; **Bold**: Overlapping restriction sites; **Bold Italic**: Loop; **Red**: Guide sequence; **Blue**: U6 promoter priming; Underlined: Termination signal; R: Purine (A or G); Y: Pyrimidine (C or T)

Table A-6: shRNA Target Oligonucleotide Sequences

SPTBN1 F1	5' - <u>TCGAGATAT</u> CCCTCGCATTGACGACATCTTTGACT - 3'
SPTBN1 F2	5' - TTA ACTACGTGCATTACGATCATAACAGAGTTCTGAT GC - 3'
SPTBN1 R1	5' - GTTAAAGTCGAAAGATGTCGTC AATGCGAGG GATATC - 3'
SPTBN1 R2	5' - GGCCGC ATCAGAACTCTGTTATGATCGTAATGCACGTA - 3'
TMED2 F1	5' - <u>TCGAGATAT</u> CGAGCCATCAACGACAACACAAGGCCA - 3'
TMED2 F2	5' - CGGTCTCGGGCTATTTCTCGGGCTATTTCTGTTAGCAT GC - 3'
TMED2 R1	5' - GACCGTGGCCTTGTGTTGTCGTTGATGGCTC GATATC - 3'
TMED2 R2	5' - GGCCGC ATGCTAACGAAATAGCCCGAGAAATAGCCCGA - 3'
KIAA1012 F1	5' - <u>TCGAGATAT</u> CGCTGATGTAGATGTCATAGTTCTCTAA - 3'
KIAA1012 F2	5' - TAATCAACTTCACGTAGGCCCTTGTACTATAACTTCAG GC - 3'
KIAA1012 R1	5' - GATTATTAGGAACTATGACATCTACATCAGC GATATC - 3'
KIAA1012 R2	5' - GGCCGCT GAAGTTATAGTACAAGGGCCTACGTGAAGTT - 3'
PRDM14 F1	5' - <u>TCGAGATAT</u> CCGTCCTATGGACACTACAGAACGGAT - 3'
PRDM14 F2	5' - CCACATTCTTCATGTTGCTGAGGACCTCCCAGTTATT GC - 3'
PRDM14 R1	5' - TGTGGATCCGTTCTGTAGTGTCCATAGGACG GATATC - 3'
PRDM14 R2	5' - GGCCGCA ATAACTGGGAGGTCCTCAGCAACATGAAGAA - 3'
SP110 F1	5' - <u>TCGAGATAT</u> CGCCTGATTTCTCGCAACCATACCTCC - 3'
SP110 F2	5' - TAGACA ACTCCATCATCCTGTCTCTTCTGGTGACATT GC - 3'
SP110 R1	5' - GTCTAGGAGGTATGGTTGCGAGAAATCAGGC GATATC - 3'
SP110 R2	5' - GGCCGCA ATGTCACCAGAAGAGACAGGATGATGGAGTT - 3'

Key: Underlined: XhoI site; **Bold**: EcoRV; **Bold, italic**: NotI

Table A-7: qRT-PCR primers

GENE	PRIMER	SEQUENCE (5'-3')
GAPDH	Forward (F)	CAT GAG AAG TAT GAC AAC AGC CT
	Reverse (R)	AGT CCT TCC ACG ATA CCA AAG T
β -ACTIN	F	AGG TCA TCA CCA TTG GCA ATG AG
	R	TCT TTG CGG ATG TCC ACG TCA
SPTBN1	F	CCT CTG ATC GTA AAG CCA AGA C
	R	CCA CTC GTG TTT CCG ATT GAG
TMED2	F	AGC TCA CCA GAA CAA GCT AGA
	R	GTC GTT GAT GGC TCT GTG TAT T
KIAA1012	F	ACT TTC GGT GGT AAT ACT GCT G
	R	GAA GCT GAT GAT ATG AGT GCT GT
PRDM14	F	CAG GAC AAG GTG TGC TAC CC
	R	GCT GCC GGA AAG GTT GGA A
SP110	F	TCG GAA TGA GGA TGG AAC TTG G
	R	CAG AGC AAA AGT CCA CTC TTC AG

Table A-8: Control siRNA/shRNAs and target primers

siRNA/shRNA GUIDE SEQUENCE (5'-3')	TARGET Q-PCR PRIMERS (5'-3')
<p>siHBV: UUGAAGUAUGCCUCAAGGUCdG¹ shHBx-5: CAG AGG TGA AGC GAA GTG CAC ACG G shHBx-10: CCA AGG CAC AGC TTG GAG GCT TGA A</p>	<p>N/A</p>
<p>shHTATSF-2: TTG CGG TAG AAC TAG ATG CGC shLEDGF: TCG CTT CCT CAT GCT GTC T</p>	<p>HTATSF1 F: AGT GGG ACC TGG ACA AAA AGG HTATSF1 R: GTT CCG GGG CTT TTT CTT GTG LEDGF: N/A</p>
<p>shLTR: TCT GAG GGA TCT CTA GTT ACT T shTat: GCT CTT CGT CGC TGT CTC CGC</p>	<p>Firefly Luc F: (<i>EcoRI</i> site in bold) ATT AGA ATT CAT GGA AGA CGC CAA AAA C Firefly Luc R: (<i>HindIII</i> site in bold) ATT AGG GCC CAC TAG TAA GCT TAC CAC ATT TGT AGA GGT TTT AC</p>

¹ This represents the antisense sequence (guide) of the siRNA and was labeled at the 3' end with the Cy3 fluorescent dye. The sense sequence is as follows: 5'-ACCUUGAAGCAUACUUCAAdTdT-3' (d: deoxy).

APPENDIX B: Experimental procedures

1) Ethanol/EDTA precipitation

After addition of 2.5 μ l 125 mM EDTA and 30 μ l of absolute ethanol, the reaction was incubated for 15 minutes in the dark at room temperature. Centrifugation at 12 000 \times g for 15 minutes ensued, after which the supernatant was discarded. Finally, 30 μ l of 70% ethanol was added before centrifugation at 12 000 \times g for 10 minutes, after which the supernatant was again discarded.

2) Bacterial cell culturing

Using aseptic technique and working near a gas flame, a scraping of frozen bacterial cells (e.g. DH5 α *E. coli* cells) were inoculated into Luria Bertani (LB) broth (10 g/L bacto-tryptone, 5 g/L yeast extract, 5 g/L sodium chloride in distilled water and autoclaved), such that the final volume did not exceed 1/10th of the flask's volume. The flask was incubated overnight (approximately 16 hours or until growth was in the log phase) at 37°C in a shaking incubator. To control for contamination, a flask was inoculated as described above but with 1 \times ampicillin: any turbidity after overnight culture indicated growth of contaminants (i.e. ampicillin-resistant bacteria or fungi).

3) Agar bacterial plates

Agar plates were made by adding 1% w/v agar to LB broth (see Bacterial cell culturing (section 2)) and autoclaving. After cooling (without setting), 100 μ g/ml ampicillin was added if necessary and 30-50 ml agar poured into each sterile bacterial plate (Greiner Bio-One, GmbH, Kremsmunster, Austria) using aseptic technique near a gas flame. After setting, the plates were stored at 4°C.

4) Chemically competent bacterial cells

A 1 in 50 dilution of overnight bacterial culture in fresh LB broth (see Bacterial cell culturing (section 2)) was made and allowed to incubate at 37°C with moderate shaking. During incubation, the transformation buffer (100 mM CaCl₂, 10 mM PIPES HCl, 15% v/v Glycerol) was allowed to thaw on ice. After two hours, growth was arrested by placing the cultures on ice for five minutes. The cultured cells were then pelleted by centrifugation at 1200 × g for 15 minutes. Working aseptically and on ice, the supernatant was discarded and the pellet gently resuspended in 1 ml of transformation buffer. The volume was then made up to 20 ml with transformation buffer and incubated on ice for 30 minutes. Thereafter, the cells were pelleted by centrifugation at 500 – 700 × g for 10 minutes. The supernatant was carefully removed, the pellet gently resuspended in 1.5 – 2 ml transformation buffer and aliquots of 100 µl stored at -70°C.

5) Small-scale preparations of plasmid DNA

Bacterial cells transformed with plasmid DNA were cultured overnight (12-16 hours) in 4 ml LB (see Bacterial cell culturing (section 2)) at 37°C before DNA purification using the High Pure Plasmid Isolation kit (Roche, Mannheim, Germany). The culture was pelleted at 13 000 × g for 30 seconds and the pellet resuspended in 250 µl Suspension Buffer/RNase (50 mM Tris-HCl, 10 mM EDTA, pH 8, 0.1 mg/ml RNase A). Thereafter, 250 µl Lysis Buffer was added, mixed gently and incubated for five minutes at room temperature. Next 350 µl chilled Binding Buffer was added, gently mixed and incubated for 5 minutes on ice before centrifugation at 13 000 × g for 10 minutes. The supernatant containing the DNA was transferred to a High Pure filter tube, centrifuged at 13 000 × g for one minute and the flow-through discarded. The resin/filter binding the DNA was washed of contaminants using 700 µl Wash Buffer II and centrifuged at 13 000 × g for one minute and an additional minute after discarding the flow-through. Finally the pure DNA was eluted by applying 100 µl Elution Buffer to the centre of the filter and centrifuging after one minute at 13 000 × g for a minute. The quantity and quality of the DNA was then measured at 260 nm relative to 280 nm using the NanoDrop™ 1000 spectrophotometer (Thermo Scientific).

6) Bulk preparations of plasmid DNA

A scraping was taken from a 60% glycerol stock of bacterial cells transformed with the desired plasmid and used to inoculate 200 ml of LB supplemented with 100 µg/ml ampicillin for overnight culture. After approximately 16 hours of growth, the cells were pelleted by centrifugation at 3 040 × g for 30 minutes. During the centrifugation step, Qiagen HiSpeed Maxi Tips (one for each plasmid preparation) were equilibrated by filling with dH₂O, followed by 20 ml equilibration buffer (QBT) (750 mM NaCl, 50 mM MOPS (pH 7.0), 15% v/v isopropanol, 0.15% v/v Triton® X-100) and allowing to empty by gravity flow through the resin into a waste container. After centrifugation, the supernatant was discarded and the pellet gently resuspended in 10 ml chilled resuspension buffer (P1) (50 mM Tris-chloride (pH 8.0), 10 mM EDTA, 100 µg/ml RNase A). The cells were lysed by addition of 10 ml lysis buffer (P2) (200 mM NaOH, 1% w/v SDS), mixed by inversion and incubated for 5 minutes at room temperature. Thereafter, 10 ml chilled neutralization buffer (P3) (3 M potassium acetate, pH 5.5) was added, mixed by inversion and incubated for 5 minutes on ice. Centrifugation at 3 040 × g for 20 minutes followed, after which the supernatant (free of cellular debris) was carefully poured into the equilibrated HiSpeed (Qiagen) tips and allowed to filter through the resin. The low salt and pH conditions allow the DNA to bind to the anion-exchange resin. The HiSpeed tips were washed with 60 ml wash buffer (QC) (1 M NaCl, 50 mM MOPS (pH 7.0), 15% v/v isopropanol). The DNA was then eluted into a clean tube containing 10 ml isopropanol by addition of 15 ml elution buffer (QF) (1.25 M NaCl, 50 mM Tris-chloride (pH 8.5), 15% v/v isopropanol), mixed and stored at -20°C overnight. The following day, the precipitated DNA was pelleted (by centrifugation at 10 000 × g for 1 hour), washed by resuspension in 70% v/v ethanol and again centrifuged for 15 minutes. The final pellet was air-dried before resuspension in 200 µl dH₂O.

7) Mammalian cell culture

All mammalian cell culture (including transfections) was done in a separate tissue culture room using sterile techniques. Handling of cultures was performed inside a biological laminar flow cabinet, decontaminated with Virkon® disinfectant and 70% ethanol, before incubation in sterile incubators fitted with HEPA (high efficiency particulate air) filters, warmed to 37 °C and ventilated with 5% CO₂ gas.

i. Passage of 116, HEK293 and 293T cells

When cells reached 80% confluency (i.e. ~80% of the culture vessel's surface area is covered with an even monolayer of cells) they were passaged. This involved lifting the adherent cells from the surface of the culture vessel by gently washing with pre-warmed phosphate buffered saline, PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.76 mM KH₂PO₄, pH 7.4) supplemented with 0.01% w/v EDTA. Once all the cells were in suspension a fraction of the volume (generally one quarter) was returned to the culture vessel (or transferred to a fresh one) and the appropriate culture volume made up with fresh warmed complete medium.

ii. Passage of TZM-bl cells

These cells were also passaged at 80% confluency. After removing culture medium, the cells were gently rinsed of residual serum with pre-warmed PBS/EDTA, being careful not to lift off any cells, and the rinse fluid discarded. After rinsing, sufficient 0.25% Trypsin / 1 mM EDTA (GIBCO, Invitrogen, CA, USA) was added to cover the monolayer of cells. The cells were returned to the 37 °C incubator for 4 minutes or until the cells easily lifted from the culture vessel surface. Thereafter, fresh medium was added to the cell suspension (at a 3 : 1 volume ratio of medium to Trypsin), before returning one quarter to the culture vessel with fresh warmed complete medium.

iii. Passage of SupT1 cells

Unlike the 116 and TZM-bl adherent cell lines, SupT1 cells grow in suspension and were passaged when cell density reached ~5 × 10⁵ cells/ml. The cell suspension was pelleted by centrifugation at 500 × g for 5 minutes, after which the supernatant was removed and the pelleted cells washed by resuspending in 1 × PBS (no EDTA added). The washed cells were again pelleted by centrifugation and resuspended in PBS. Thereafter 1/10th of the cell suspension was returned to the culture flask with fresh warmed complete medium.

8) Cell counting with a haemocytometer

Cells were resuspended in PBS (4-5 ml) and a 50 µl sample diluted 1:2 with Trypan-blue. After gently mixing, the sample was loaded by capillary action into both chambers of a haemocytometer (Hausser Scientific, Horsham, PA) covered with a 22 × 26 mm glass coverslip (Marienfeld, Germany). After focusing on the grid under a light microscope, the number of white cells in four quadrants and the centre square were counted. The total number of cells was divided by the number of quadrants counted (i.e. 5), multiplied by the dilution factor (i.e. 2) and by 10^4 . This calculation gives the approximate number of cells per ml and can be used to calculate the dilutions needed to seed the required number of cells per well.

9) Algorithm for TCID50 calculation

The Spearman-Kärber formula for calculating 50% tissue culture infectious dose (TCID50) is given as:

$$M = xk + d[0.5 - (1/n)(r)]$$

where **xk** is the dose of the highest dilution, **r** is the sum of negative responses, **d** is the spacing between dilutions and **n** represents the number of wells per dilution (Schmidt and Emmons 1989).

Example of TCID50 calculation

The following viral dilutions were used in triplicate: 4^{-2} ; 4^{-3} ; 4^{-4} ; 4^{-5} ; 4^{-6} ; 4^{-7} ; 4^{-8} . There are 9 negative responses out of the 21 total responses (i.e. nine samples' means are statistically significant ($P < 0.05$) from the mean of the No Virus control). The volume per well is 200 µl.

Then: $xk = 8$ (because 4^{-8} was the highest dilution); $r = 9$; $d = 1$ and $n = 3$

Thus: $M = 8 + 1[0.5 - (1/3)(9)] = -5.5$

The 50% endpoint is 4^M , thus $10^x = 4^{-5.5}$

Thus the titre, x , is 3.31 TCID50s per 200 µl.

The TCID50/ml is the above value multiplied by 5: **$1.02 \times 10^4 / \text{ml}$**

10) Electroporation protocols (two tables)

Table B-1: Preset electroporation protocols

PROTOCOL	Preset – Mammalian 11 (Jurkat)					
Volume (µl)	400		200		100	
Number of Cells	1 × 10 ⁵					
Buffer	OptiMEM	DMEM	OptiMEM	DMEM	OptiMEM	DMEM
DNA (ng)	40					
Cuvette size (cm)	0.4		0.2			
Temperature (°C)	25 (room temperature)					
Outgrowth	2 ml medium (10% FBS)				500 µl medium (10% FBS)	
Waveform	Exponential					
Voltage (V)	140					
Capacitance (µF)	1000					
Number of pulses	Single					

Table B-2: Electroporation protocols from the literature

PROTOCOL	1 ^a		2 ^b		3 ^c	4 ^d	5 ^e
Volume (µl)	300		400	200	250		
Number of Cells	7 × 10 ⁶		5 × 10 ⁶		2 × 10 ⁶	1 × 10 ⁶	2 × 10 ⁶
Buffer	DMEM + 10% FBS	DMEM + 10% FBS + 1.25% DMSO	GenePulser		Phosphate-buffered sucrose	OptiMEM	HEPES-buffered dextrose
DNA (µg)	30		2		5	25	5
Cuvette size (cm)	0.2		0.4	0.2	0.4		
Temperature (°C)	25 (room temperature)				0 (ice)		
Outgrowth	10 ml DMEM + 10% FBS	10 ml DMEM + 10% FBS + 1.25% DMSO	500,000 fresh cells in 27.5 ml medium		1 ml DMEM + 10% FBS		
Waveform	Exponential				Square	Exponential	
Voltage (V)	250				100	250	
Capacitance (µF)	960				N/A	950	900
Number of pulses	Single				10	Single	
Pulse duration (ms)	N/A				2	N/A	
Pulse interval (ms)	N/A				100	N/A	

a (Melkonyan *et al.*, 1996); b (Beerens *et al.*, 2000); c (Maroun *et al.*, 2006); d (Chow and Gawler 1999; Jason *et al.*, 2004); e (Chu *et al.*, 1987; Baum *et al.*, 1994; Eksioglu-Demiralp *et al.*, 2003).

11) Safety precautions when handling Ethidium Bromide

Avoid inhalation or ingestion, as well as contact with the eyes or skin. Use gloves, separate pipettes and glassware and dispose of waste appropriately. This dye intercalates into nucleic acid bases and may be mutagenic and thus carcinogenic.

APPENDIX C: Selection of genes

This appendix contains tables listing the genes that were excluded or selected during selection of the genes to be studied. The title of each table describes each stage of the process, where Part 1 and 2 refers to the early and late stages, respectively, of the HIV-1 lifecycle as defined by Brass *et al.* (2008). In addition, the tables themselves are adapted from Supplementary Table 2 published by Brass *et al.* (2008). The original table of genes was successively sorted according to criteria explained in Section 3-1.

Table C-1: Genes that decreased HIV-1 activity by 75% or more

Symbol	SMARTpools, percent versus controls (part one, p24, or part two, RLU)
KIAA1012	11% p24
ATP6V0A1	12% RLU
FLJ90680	12% RLU
STAC2	12% RLU
ZNF512B	13% RLU
CXorf50	14% RLU
DIMT1L	15% p24
ASXL2	15% RLU
DDX55	15% RLU
CXCR4	16% p24
CACNG1	16% RLU
FLJ10154	16% RLU
SP110	16% RLU
GABARA PL2 (ATG8)	17% RLU
STT3A	17% RLU
NUP107	18% p24
THOC2	18% p24
TMED2	18% p24
SPCS3	18% RLU
TUBAL3	18% RLU
C20orf174	19% p24
C9orf131	19% RLU
PRDM14	19% RLU
AGBL5	20% p24
PNRC1	20% p24

Symbol	SMARTpools, percent versus controls (part one, p24, or part two, RLU)
FAM76B	20% RLU
NDUFB7	20% RLU
NMT1	20% RLU
ADAM10	21% p24
RICS	22% p24
EDNRA	22% RLU
MPHOSPH6	22% RLU
OST48 (DDOST)	22% RLU
PDIA6	22% RLU
C3orf56	23% p24
TNPO3	23% p24
ATG16L2	23% RLU
JHDM1D	23% RLU
DKFZp686O24 166	24% p24
SPTBN1	24% p24
WNT1	24% p24
LOC285550	24% RLU
PPP2R2A	24% RLU
C8orf14	25% p24
GCN5L2	25% p24
TIMM8A	25% RLU
UBQLN4	25% RLU

Table C-2: Genes that scored with two or more siRNAs in Part 1 (left) and Part 2 (right)

Symbol	p24 siRNAs (part one)
KIAA1012	4
DIMT1L	4
TNPO3	4
TMED2	3
SPTBN1	3
WNT1	3
C8orf14	3
CXCR4	2
NUP107	2
AGBL5	2
ADAM10	2
RICS	2

Symbol	Beta-gal siRNAs (scored in part two only)
DDX55	3
PRDM14	3
NMT1	3
OST48 (DDOST)	3
DKFZp686O24166	2
ATP6V0A1	2
FLJ90680	2
STAC2	2
CXorf50	2
FLJ10154	2
SP110	2
STT3A	2
SPCS3	2
EDNRA	2
PDIA6	2
ATG16L2	2
PPP2R2A	2
TIMM8A	2

Table C-3: Part 1 genes excluded due to important cellular functions

Symbol	UniProt function
OST48 (DDOST)	Essential subunit of N-oligosaccharyl transferase enzyme which catalyzes the transfer of a high mannose oligosaccharide to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains.
ATP6V0A1	Required for assembly and activity of the vacuolar ATPase. Potential role in differential targeting and regulation of the enzyme for a specific organelle (By similarity).
STT3A	Component of the N-oligosaccharyl transferase enzyme which catalyzes the transfer of a high mannose oligosaccharide from a lipid-linked oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains. N-glycosylation occurs cotranslational and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). SST3A seems to be involved in complex substrate specificity (By similarity).
SPCS3	Component of the microsomal signal peptidase complex which removes signal peptides from nascent proteins as they are translocated into the lumen of the endoplasmic reticulum (By similarity).
EDNRA	Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.
TIMM8A	Mitochondrial intermembrane chaperone that participates in the import and insertion of some multi-pass transmembrane proteins into the mitochondrial inner membrane. Also required for the transfer of beta-barrel precursors from the TOM complex to the sorting and assembly machinery (SAM complex) of the outer membrane. Acts as a chaperone-like protein that protects the hydrophobic precursors from aggregation and guide them through the mitochondrial intermembrane space. The TIMM8-TIMM13 complex mediates the import of proteins such as TIMM23, SLC25A12/ARALAR1 and SLC25A13/ARALAR2, while the predominant TIMM9-TIMM10 70 kDa complex mediates the import of much more proteins. Probably necessary for normal neurologic development.

Table C-4: Final Part 1 gene selection

Symbol	p24 siRNAs (part one)	Beta-gal siRNAs (scored in part two only)	SMARTpools, percent versus controls (part one, p24, or part two, RLU)	Description	UniProt function
KIAA1012	4		11% p24	KIAA1012	May play a role in vesicular transport from endoplasmic reticulum to Golgi.
TMED2	3	1	18% p24	transmembrane emp24 domain trafficking protein 2	Could have a role in the budding of coatomer-coated and other species of coated vesicles. Could bind cargo molecules to collect them into budding vesicles.
SPTBN1	3		24% p24	spectrin, beta, non-erythrocytic 1	Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane.
C8orf14	3		25% p24	chromosome 8 open reading frame 14	
AGBL5	2		20% p24	ATP/GTP binding protein-like 5	non TM
RICS	2		22% p24	Rho GTPase-activating protein	

Table C-5: Part 2 genes excluded due to important cellular functions

Symbol	Homologs
FLJ90680	
STAC2	Stac2 (Mus musculus); Stac2_predicted (Rattus norvegicus); STAC2 (Canis lupus familiaris); STAC2 (Homo sapiens)
CXorf50	CXorf50 (Homo sapiens); LOC653687 (Homo sapiens)
FLJ10154	9430010O03Rik (Mus musculus); FLJ10154 (Homo sapiens)
SP110	Sp110 (Rattus norvegicus); Sp110 (Mus musculus); SP110 (Pan troglodytes); SP110 (Homo sapiens)
PRDM14	Prdm14 (Mus musculus); LOC563151 (Danio rerio); PRDM14 (Canis lupus familiaris); LOC464224 (Pan troglodytes); PRDM14 (Homo sapiens)
ATG16L2	Atg16l2 (Mus musculus); LOC100007282 (Danio rerio); ATG16L2 (Canis lupus familiaris); ATG16L2 (Homo sapiens)
DKFZp686O24166	

Table C-1: Part 2 genes with five or fewer homologs

Symbol	UniProt function
DIMT1L	Specifically dimethylates two adjacent adenosines in the loop of a conserved hairpin near the 3'-end of 18S rRNA in the 40S particle (By similarity).
WNT1	Ligand for members of the frizzled family of seven transmembrane receptors. Probable developmental protein. May be a signaling molecule important in CNS development. Is likely to signal over only few cell diameters.
CXCR4	Receptor for the C-X-C chemokine CXCL12/SDF-1. Transduces a signal by increasing the intracellular calcium ions level. Involved in haematopoiesis and in cardiac ventricular septum formation. Plays also an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Could be involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus.
NUP107	Essential component of nuclear pore complex. Required for the assembly of peripheral proteins into the nuclear pore complex.
ADAM10	Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala- -Val-77' to its mature soluble form. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis (By similarity).
TNPO3	Seems to function in nuclear protein import as nuclear transport receptor. In vitro, mediates the nuclear import of splicing factor SR proteins SFRS1 and SFRS2, by recognizing phosphorylated RS domains.

Table C-2: Final Part 2 gene selection

Symbol	p24 siRNAs (part one)	Beta-gal siRNAs (scored in part two only)	SMARTpools, percent versus controls (part one, p24, or part two, RLU)	Description	UniProt function	curated keywords
FLJ90680		2	12% RLU	FLJ90680 protein		
STAC2		2	12% RLU	SH3 and cysteine rich domain 2		
CXorf50		2	14% RLU	chromosome X open reading frame 50		
FLJ10154		2	16% RLU	hypothetical protein FLJ10154		
SP110		2	16% RLU	SP110 nuclear body protein	Transcription factor. May be a nuclear hormone receptor coactivator. Enhances transcription of genes with retinoic acid response elements (RARE).	Response to pathogen (Jenner & Young)
PRDM14		3	19% RLU	PR domain containing 14	May be involved in transcriptional regulation.	
ATG16L2		2	23% RLU	ATG16 autophagy related 16-like 2 (S. cerevisiae)		
DKFZp686O24166	1	2	24% p24	hypothetical protein DKFZp686O24166		

REFERENCES

- AIDSinfo. (2008). "AIDSinfo: Offering information on HIV/AIDS treatment, prevention, and research / Vaccines." < <http://aidsinfo.nih.gov/default.aspx>> [Retrieved 20 Jan 2010].
- Altschul, S. F., W. Gish, W. Miller, *et al.* (1990). "Basic local alignment search tool." J Mol Biol 215(3): 403-10.
- Anderson, E. M., A. Birmingham, S. Baskerville, *et al.* (2008). "Experimental validation of the importance of seed complement frequency to siRNA specificity." Rna 14(5): 853-61.
- Anderson, J., M. J. Li, B. Palmer, *et al.* (2007). "Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells." Mol Ther 15(6): 1182-8.
- Angeletti, P. C., L. Zhang and C. Wood (2008). "The viral etiology of AIDS-associated malignancies." Adv Pharmacol 56: 509-57.
- Arhel, N., A. Genovesio, K. A. Kim, *et al.* (2006). "Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes." Nat Methods 3(10): 817-24.
- Arien, K. K., Y. Gali, A. El-Abdellati, *et al.* (2006). "Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones." Virology 347(1): 65-74.
- Arthos, J., C. Cicala, E. Martinelli, *et al.* (2008). "HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells." Nat Immunol 9(3): 301-9.
- Ashihara, E., E. Kawata and T. Maekawa (2009). "Future Prospect of RNA Interference for Cancer Therapies." Curr Drug Targets.
- Bailer, S. M. and J. Haas (2009). "Connecting viral with cellular interactomes." Curr Opin Microbiol 12(4): 453-9.
- Bala, S., M. Marcos and G. Szabo (2009). "Emerging role of microRNAs in liver diseases." World J Gastroenterol 15(45): 5633-40.

- Bankiewicz, K. S., J. Forsayeth, J. L. Eberling, *et al.* (2006). "Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC." Mol Ther 14(4): 564-70.
- Barichievy, S., S. Saayman, P. Arbuthnot, *et al.* (2009). "RNA interference-based gene expression strategies aimed at sustained therapeutic inhibition of HIV." Curr Top Med Chem 9(12): 1065-78.
- Barichievy, S., S. Saayman, K. J. von Eije, *et al.* (2007). "The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5' long terminal repeat." Oligonucleotides 17(4): 419-31.
- Barr, S. D., J. R. Smiley and F. D. Bushman (2008). "The interferon response inhibits HIV particle production by induction of TRIM22." PLoS Pathog 4(2): e1000007.
- Barre-Sinoussi, F., J. C. Chermann, F. Rey, *et al.* (1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)." Science 220(4599): 868-71.
- Barrero-Villar, M., J. R. Cabrero, M. Gordon-Alonso, *et al.* (2009). "Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin redistribution, membrane fusion and viral infection in lymphocytes." J Cell Sci 122(Pt 1): 103-13.
- Barrios-Rodiles, M., K. R. Brown, B. Ozdamar, *et al.* (2005). "High-throughput mapping of a dynamic signaling network in mammalian cells." Science 307(5715): 1621-5.
- Bates, M., B. Huang, G. T. Dempsey, *et al.* (2007). "Multicolor super-resolution imaging with photo-switchable fluorescent probes." Science 317(5845): 1749-53.
- Baum, C., P. Forster, S. Hegewisch-Becker, *et al.* (1994). "An optimized electroporation protocol applicable to a wide range of cell lines." Biotechniques 17(6): 1058-62.
- Beerens, N., F. Groot and B. Berkhout (2000). "Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription." Nucleic Acids Res 28(21): 4130-7.
- Bengtsson, L. and K. L. Wilson (2006). "Barrier-to-autointegration factor phosphorylation on Ser-4 regulates emerlin binding to lamin A in vitro and emerlin localization in vivo." Mol Biol Cell 17(3): 1154-63.

- Bennasser, Y., M. L. Yeung and K. T. Jeang (2006). "HIV-1 TAR RNA subverts RNA interference in transfected cells through sequestration of TAR RNA-binding protein, TRBP." J Biol Chem 281(38): 27674-8.
- Bernstein, E., A. A. Caudy, S. M. Hammond, *et al.* (2001). "Role for a bidentate ribonuclease in the initiation step of RNA interference." Nature 409(6818): 363-6.
- Bhattacharya, J., A. Repik and P. R. Clapham (2006). "Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes." J Virol 80(11): 5292-300.
- Bieniasz, P. D., T. A. Grdina, H. P. Bogerd, *et al.* (1998). "Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat." Embo J 17(23): 7056-65.
- Bilodeau, P. S., J. K. Domsic, A. Mayeda, *et al.* (2001). "RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element." J Virol 75(18): 8487-97.
- Birmingham, A., E. M. Anderson, A. Reynolds, *et al.* (2006). "3' UTR seed matches, but not overall identity, are associated with RNAi off-targets." Nat Methods 3(3): 199-204.
- BLASTn. (1990). "BLASTn programs search nucleotide databases using a nucleotide query." < <http://blast.ncbi.nlm.nih.gov/Blast.cgi>> [Retrieved 5 Mar 2008].
- Blot, G., K. Janvier, S. Le Panse, *et al.* (2003). "Targeting of the human immunodeficiency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env incorporation into virions and infectivity." J Virol 77(12): 6931-45.
- Blum, R., F. Pfeiffer, P. Feick, *et al.* (1999). "Intracellular localization and in vivo trafficking of p24A and p23." J Cell Sci 112 (Pt 4): 537-48.
- Boden, D., O. Pusch, F. Lee, *et al.* (2003). "Human immunodeficiency virus type 1 escape from RNA interference." J Virol 77(21): 11531-5.
- Boden, D., O. Pusch and B. Ramratnam (2004). "HIV-1-specific RNA interference." Curr Opin Mol Ther 6(4): 373-80.

- Boese, A., P. Sommer, D. Holzer, *et al.* (2009). "Integrase interactor 1 (Ini1/hSNF5) is a repressor of basal human immunodeficiency virus type 1 promoter activity." J Gen Virol 90(Pt 10): 2503-12.
- Bogerd, H. P., R. A. Fridell, S. Madore, *et al.* (1995). "Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins." Cell 82(3): 485-94.
- Bohula, E. A., A. J. Salisbury, M. Sohail, *et al.* (2003). "The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript." J Biol Chem 278(18): 15991-7.
- Bolz, D. D., J. L. Tenor and A. Aballay (2010). "A conserved PMK-1/p38 MAPK is required in caenorhabditis elegans tissue-specific immune response to Yersinia pestis infection." J Biol Chem 285(14): 10832-40.
- Bour, S., C. Perrin and K. Strebel (1999). "Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity." J Biol Chem 274(47): 33800-6.
- Braaten, D., C. Aberham, E. K. Franke, *et al.* (1996). "Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A." J Virol 70(8): 5170-6.
- Brandenburg, B., L. Y. Lee, M. Lakadamyali, *et al.* (2007). "Imaging poliovirus entry in live cells." PLoS Biol 5(7): e183.
- Brasey, A., M. Lopez-Lastra, T. Ohlmann, *et al.* (2003). "The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle." J Virol 77(7): 3939-49.
- Brass, A. L., D. M. Dykxhoorn, Y. Benita, *et al.* (2008). "Identification of host proteins required for HIV infection through a functional genomic screen." Science 319(5865): 921-6.
- Bratu, D. P., B. J. Cha, M. M. Mhlanga, *et al.* (2003). "Visualizing the distribution and transport of mRNAs in living cells." Proc Natl Acad Sci U S A 100(23): 13308-13.
- Bray, M., S. Prasad, J. W. Dubay, *et al.* (1994). "A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent." Proc Natl Acad Sci U S A 91(4): 1256-60.

- Brenchley, J. M., T. W. Schacker, L. E. Ruff, *et al.* (2004). "CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract." J Exp Med 200(6): 749-59.
- Brummelkamp, T. R., R. Bernards and R. Agami (2002). "A system for stable expression of short interfering RNAs in mammalian cells." Science 296(5567): 550-3.
- Buck, C. B., X. Shen, M. A. Egan, *et al.* (2001). "The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site." J Virol 75(1): 181-91.
- Bugelski, P. J., B. E. Maleeff, A. M. Klinkner, *et al.* (1995). "Ultrastructural evidence of an interaction between Env and Gag proteins during assembly of HIV type 1." AIDS Res Hum Retroviruses 11(1): 55-64.
- Bukrinskaya, A., B. Brichacek, A. Mann, *et al.* (1998). "Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton." J Exp Med 188(11): 2113-25.
- Bukrinskaya, A. G., A. Ghorpade, N. K. Heinzinger, *et al.* (1996). "Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA." Proc Natl Acad Sci U S A 93(1): 367-71.
- Bukrinsky, M. I., N. Sharova, M. P. Dempsey, *et al.* (1992). "Active nuclear import of human immunodeficiency virus type 1 preintegration complexes." Proc Natl Acad Sci U S A 89(14): 6580-4.
- Bukrinsky, M. I., N. Sharova, T. L. McDonald, *et al.* (1993). "Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection." Proc Natl Acad Sci U S A 90(13): 6125-9.
- Bushman, F. D., N. Malani, J. Fernandes, *et al.* (2009). "Host cell factors in HIV replication: meta-analysis of genome-wide studies." PLoS Pathog 5(5): e1000437.
- Campbell, E. M., R. Nunez and T. J. Hope (2004). "Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity." J Virol 78(11): 5745-55.
- Carmona, S., A. Ely, C. Crowther, *et al.* (2006). "Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs." Mol Ther 13(2): 411-21.

- Castanotto, D., H. Li and J. J. Rossi (2002). "Functional siRNA expression from transfected PCR products." Rna 8(11): 1454-60.
- Castanotto, D. and J. J. Rossi (2009). "The promises and pitfalls of RNA-interference-based therapeutics." Nature 457(7228): 426-33.
- Chan, B. and K. Musier-Forsyth (1997). "The nucleocapsid protein specifically anneals tRNA^{Lys}-3 onto a noncomplementary primer binding site within the HIV-1 RNA genome in vitro." Proc Natl Acad Sci U S A 94(25): 13530-5.
- Chan, E. Y., J. N. Sutton, J. M. Jacobs, *et al.* (2009). "Dynamic host energetics and cytoskeletal proteomes in human immunodeficiency virus type 1-infected human primary CD4 cells: analysis by multiplexed label-free mass spectrometry." J Virol 83(18): 9283-95.
- Chang, L. J., X. Liu and J. He (2005). "Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1." Gene Ther 12(14): 1133-44.
- Chatterji, U., M. D. Bobardt, P. Gaskill, *et al.* (2006). "Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry." J Biol Chem 281(48): 37025-33.
- Chen, B. K., R. T. Gandhi and D. Baltimore (1996). "CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef." J Virol 70(9): 6044-53.
- Chen, H. and A. Engelman (1998). "The barrier-to-autointegration protein is a host factor for HIV type 1 integration." Proc Natl Acad Sci U S A 95(26): 15270-4.
- Chen, P., W. Hubner, M. A. Spinelli, *et al.* (2007). "Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses." J Virol 81(22): 12582-95.
- Chen, P. Y., L. Weinmann, D. Gaidatzis, *et al.* (2008). "Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity." Rna 14(2): 263-74.
- Chen, R. L., Y. C. Chou, Y. J. Lan, *et al.* (2010). "Developmental silencing of human zeta-globin gene expression is mediated by the transcriptional repressor RREB1." J Biol Chem 285(14): 10189-97.

- Chendrimada, T. P., R. I. Gregory, E. Kumaraswamy, *et al.* (2005). "TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing." Nature 436(7051): 740-4.
- Cherepanov, P., G. Maertens, P. Proost, *et al.* (2003). "HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells." J Biol Chem 278(1): 372-81.
- Chertova, E., O. Chertov, L. V. Coren, *et al.* (2006). "Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages." J Virol 80(18): 9039-52.
- Chesebro, B., K. Wehrly, J. Nishio, *et al.* (1992). "Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism." J Virol 66(11): 6547-54.
- Chow, A. and D. Gawler (1999). "Mapping the site of interaction between annexin VI and the p120GAP C2 domain." FEBS Lett 460(1): 166-72.
- Chu, G., H. Hayakawa and P. Berg (1987). "Electroporation for the efficient transfection of mammalian cells with DNA." Nucleic Acids Res 15(3): 1311-26.
- Cihlar, T. and A. S. Ray (2010). "Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine." Antiviral Res 85(1): 39-58.
- Ciuffi, A., M. Llano, E. Poeschla, *et al.* (2005). "A role for LEDGF/p75 in targeting HIV DNA integration." Nat Med 11(12): 1287-9.
- Clark, J. M. (1988). "Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases." Nucleic Acids Res 16(20): 9677-86.
- Coburn, G. A. and B. R. Cullen (2002). "Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference." J Virol 76(18): 9225-31.
- Connell, B. J., K. Michler, A. Capovilla, *et al.* (2008). "Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa." Aids 22(7): 896-9.

- Coolen, M. and L. Bally-Cuif (2009). "MicroRNAs in brain development and physiology." Curr Opin Neurobiol 19(5): 461-70.
- Das, A. T., T. R. Brummelkamp, E. M. Westerhout, *et al.* (2004). "Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition." J Virol 78(5): 2601-5.
- de Bethune, M. P. (2010). "Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009)." Antiviral Res 85(1): 75-90.
- de la Fuente, J., R. Manzano-Roman, E. F. Blouin, *et al.* (2007). "Sp110 transcription is induced and required by Anaplasma phagocytophilum for infection of human promyelocytic cells." BMC Infect Dis 7: 110.
- de la Fuente, J., R. Manzano-Roman, V. Naranjo, *et al.* (2010). "Identification of protective antigens by RNA interference for control of the lone star tick, Amblyomma americanum." Vaccine 28(7): 1786-1795.
- Deeks, S. G. (2006). "Antiretroviral treatment of HIV infected adults." Bmj 332(7556): 1489.
- Deng, L., C. de la Fuente, P. Fu, *et al.* (2000). "Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones." Virology 277(2): 278-95.
- Diakowski, W., A. Prychidny, M. Swistak, *et al.* (1999). "Brain spectrin (fodrin) interacts with phospholipids as revealed by intrinsic fluorescence quenching and monolayer experiments." Biochem J 338 (Pt 1): 83-90.
- Doench, J. G. and P. A. Sharp (2004). "Specificity of microRNA target selection in translational repression." Genes Dev 18(5): 504-11.
- Dong, X., H. Li, A. Derdowski, *et al.* (2005). "AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly." Cell 120(5): 663-74.
- Doranz, B. J., J. F. Berson, J. Rucker, *et al.* (1997). "Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1)." Immunol Res 16(1): 15-28.

- Douglas, J. L., K. Viswanathan, M. N. McCarroll, *et al.* (2009). "Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a β TrCP-dependent mechanism." J Virol 83(16): 7931-47.
- Earl, P. L., B. Moss and R. W. Doms (1991). "Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein." J Virol 65(4): 2047-55.
- Ebina, H., J. Aoki, S. Hatta, *et al.* (2004). "Role of Nup98 in nuclear entry of human immunodeficiency virus type 1 cDNA." Microbes Infect 6(8): 715-24.
- Eksioglu-Demiralp, E., S. Kitada, D. Carson, *et al.* (2003). "A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis." J Immunol Methods 275(1-2): 41-56.
- El-Atrouni, W., E. Berbari and Z. Temesgen (2006). "HIV-associated opportunistic infections. Bacterial infections." J Med Liban 54(2): 80-3.
- Elbashir, S. M., J. Harborth, W. Lendeckel, *et al.* (2001). "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells." Nature 411(6836): 494-8.
- Emiliani, S., A. Mousnier, K. Busschots, *et al.* (2005). "Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication." J Biol Chem 280(27): 25517-23.
- Escors, D. and K. Breckpot (2010). "Lentiviral vectors in gene therapy: their current status and future potential." Arch Immunol Ther Exp (Warsz) 58(2): 107-19.
- Eugen-Olsen, J., A. K. Iversen, P. Garred, *et al.* (1997). "Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals." Aids 11(3): 305-10.
- Everett, R. D. and M. K. Chelbi-Alix (2007). "PML and PML nuclear bodies: implications in antiviral defence." Biochimie 89(6-7): 819-30.
- Eyckerman, S., A. Verhee, J. V. der Heyden, *et al.* (2001). "Design and application of a cytokine-receptor-based interaction trap." Nat Cell Biol 3(12): 1114-9.
- Farah, M. H. (2007). "RNAi silencing in mouse models of neurodegenerative diseases." Curr Drug Deliv 4(2): 161-7.

- Farnet, C. M. and W. A. Haseltine (1991). "Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex." J Virol 65(4): 1910-5.
- Farsad, K., N. Ringstad, K. Takei, *et al.* (2001). "Generation of high curvature membranes mediated by direct endophilin bilayer interactions." J Cell Biol 155(2): 193-200.
- Fassati, A., D. Gorlich, I. Harrison, *et al.* (2003). "Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7." Embo J 22(14): 3675-85.
- Feng, C. Q., W. L. Ma, Y. B. Song, *et al.* (2002). "[Detection of cell apoptosis by MTT assay]." Di Yi Jun Yi Da Xue Xue Bao 22(3): 262-3.
- Fire, A., S. Xu, M. K. Montgomery, *et al.* (1998). "Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*." Nature 391(6669): 806-11.
- Fisher, A. G., M. B. Feinberg, S. F. Josephs, *et al.* (1986). "The trans-activator gene of HTLV-III is essential for virus replication." Nature 320(6060): 367-71.
- Franke, E. K., H. E. Yuan and J. Luban (1994). "Specific incorporation of cyclophilin A into HIV-1 virions." Nature 372(6504): 359-62.
- Fridell, R. A., H. P. Bogerd and B. R. Cullen (1996). "Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway." Proc Natl Acad Sci U S A 93(9): 4421-4.
- Gallo, R. C., S. Z. Salahuddin, M. Popovic, *et al.* (1984). "Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS." Science 224(4648): 500-3.
- Gao, Y., W. Liu, H. Gao, *et al.* (2008). "Effective inhibition of infectious bursal disease virus replication in vitro by DNA vector-based RNA interference." Antiviral Res 79(2): 87-94.
- Garred, P., J. Eugen-Olsen, A. K. Iversen, *et al.* (1997). "Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group." Lancet 349(9069): 1884.

- Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, *et al.* (2001). "Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding." Cell 107(1): 55-65.
- Gatignol, A., A. Buckler-White, B. Berkhout, *et al.* (1991). "Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR." Science 251(5001): 1597-600.
- Gautier, V. W., L. Gu, N. O'Donoghue, *et al.* (2009). "In vitro nuclear interactome of the HIV-1 Tat protein." Retrovirology 6: 47.
- Geijtenbeek, T. B., R. Torensma, S. J. van Vliet, *et al.* (2000). "Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses." Cell 100(5): 575-85.
- Geiss, G. K., R. E. Bumgarner, M. C. An, *et al.* (2000). "Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays." Virology 266(1): 8-16.
- Glare, E. M., M. Divjak, M. J. Bailey, *et al.* (2002). "beta-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels." Thorax 57(9): 765-70.
- Goff, S. P. (2007). "Host factors exploited by retroviruses." Nat Rev Microbiol 5(4): 253-63.
- Gottwein, E. and H. G. Krausslich (2005). "Analysis of human immunodeficiency virus type 1 Gag ubiquitination." J Virol 79(14): 9134-44.
- Gould, S. J., A. M. Booth and J. E. Hildreth (2003). "The Trojan exosome hypothesis." Proc Natl Acad Sci U S A 100(19): 10592-7.
- Gregory, R. I., T. P. Chendrimada, N. Cooch, *et al.* (2005). "Human RISC couples microRNA biogenesis and posttranscriptional gene silencing." Cell 123(4): 631-40.
- Gregory, R. I., K. P. Yan, G. Amuthan, *et al.* (2004). "The Microprocessor complex mediates the genesis of microRNAs." Nature 432(7014): 235-40.
- Griffiths-Jones, S., H. K. Saini, S. van Dongen, *et al.* (2008). "miRBase: tools for microRNA genomics." Nucleic Acids Res 36(Database issue): D154-8.

- Grimson, A., K. K. Farh, W. K. Johnston, *et al.* (2007). "MicroRNA targeting specificity in mammals: determinants beyond seed pairing." Mol Cell 27(1): 91-105.
- Grinberg, D. (2008). "Recent patents relating to siRNAs and therapeutic strategies for genetic diseases." Recent Pat DNA Gene Seq 2(1): 40-3.
- Gunnery, S., A. P. Rice, H. D. Robertson, *et al.* (1990). "Tat-responsive region RNA of human immunodeficiency virus 1 can prevent activation of the double-stranded-RNA-activated protein kinase." Proc Natl Acad Sci U S A 87(22): 8687-91.
- Gurer, C., A. Cimarelli and J. Luban (2002). "Specific incorporation of heat shock protein 70 family members into primate lentiviral virions." J Virol 76(9): 4666-70.
- Hacein-Bey-Abina, S., C. Von Kalle, M. Schmidt, *et al.* (2003). "LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1." Science 302(5644): 415-9.
- Hamid, R., Y. Rotshteyn, L. Rabadi, *et al.* (2004). "Comparison of alamar blue and MTT assays for high through-put screening." Toxicol In Vitro 18(5): 703-10.
- Hamilton, B., Q. Feng, M. Ye, *et al.* (2009). "Generation of induced pluripotent stem cells by reprogramming mouse embryonic fibroblasts with a four transcription factor, doxycycline inducible lentiviral transduction system." J Vis Exp(33).
- Hammarstedt, M. and H. Garoff (2004). "Passive and active inclusion of host proteins in human immunodeficiency virus type 1 gag particles during budding at the plasma membrane." J Virol 78(11): 5686-97.
- Han, J., D. Kim and K. V. Morris (2007). "Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells." Proc Natl Acad Sci U S A 104(30): 12422-7.
- Han, J., Y. Lee, K. H. Yeom, *et al.* (2004). "The Drosha-DGCR8 complex in primary microRNA processing." Genes Dev 18(24): 3016-27.
- Han, J., Y. Lee, K. H. Yeom, *et al.* (2006). "Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex." Cell 125(5): 887-901.
- Hao, L., A. Sakurai, T. Watanabe, *et al.* (2008). "Drosophila RNAi screen identifies host genes important for influenza virus replication." Nature 454(7206): 890-3.

- Harrich, D., J. Garcia, F. Wu, *et al.* (1989). "Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat." J Virol 63(6): 2585-91.
- Hawkins, P. G., S. Santoso, C. Adams, *et al.* (2009). "Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells." Nucleic Acids Res 37(9): 2984-95.
- Hazenbergh, M. D., S. A. Otto, B. H. van Benthem, *et al.* (2003). "Persistent immune activation in HIV-1 infection is associated with progression to AIDS." Aids 17(13): 1881-8.
- Heale, B. S., H. S. Soifer, C. Bowers, *et al.* (2005). "siRNA target site secondary structure predictions using local stable substructures." Nucleic Acids Res 33(3): e30.
- Heikkila, O., P. Susi, T. Tevaluoto, *et al.* (2010). "Internalization of coxsackievirus A9 is mediated by {beta}2-microglobulin, dynamin, and Arf6 but not by caveolin-1 or clathrin." J Virol 84(7): 3666-81.
- Henderson, C., M. Mizzau, G. Paroni, *et al.* (2003). "Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)." Journal of Biological Chemistry 278(14): 12579-12589.
- Hirsch, A. J. (2010). "The use of RNAi-based screens to identify host proteins involved in viral replication." Future Microbiol 5: 303-11.
- Hoffmann, M., C. Segbert, G. Helbig, *et al.* (2009). "Intestinal tube formation in *Caenorhabditis elegans* requires vang-1 and egl-15 signaling." Dev Biol.
- Hogg, R. S., B. Yip, K. J. Chan, *et al.* (2001). "Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy." Jama 286(20): 2568-77.
- Holton, T. A. and M. W. Graham (1991). "A simple and efficient method for direct cloning of PCR products using ddT-tailed vectors." Nucleic Acids Res 19(5): 1156.
- Hornung, V., M. Guenther-Biller, C. Bourquin, *et al.* (2005). "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7." Nat Med 11(3): 263-70.

- HPCDispatcher. (2010). "HPCDispatcher siRNA submission form." < <http://www1.infosci.coh.org/hpcdispatcher/siRNA.aspx>> [Retrieved 28 Feb 2008].
- Hu, G. (1993). "DNA polymerase-catalyzed addition of nontemplated extra nucleotides to the 3' end of a DNA fragment." DNA Cell Biol 12(8): 763-70.
- Hu, W. Y., C. P. Myers, J. M. Kilzer, *et al.* (2002). "Inhibition of retroviral pathogenesis by RNA interference." Curr Biol 12(15): 1301-11.
- Hu, Z. J., Y. Liao, L. Y. Hu, *et al.* (2009). "Effects of antiatherosclerosis in carotid artery by RNAi-mediated silencing of MCP-1 expression." Ann Vasc Surg 23(5): 652-62.
- Huang, B., S. A. Jones, B. Brandenburg, *et al.* (2008). "Whole-cell 3D STORM reveals interactions between cellular structures with nanometer-scale resolution." Nat Methods 5(12): 1047-52.
- Huang, H. Y. and B. L. Chiang (2009). "siRNA as a therapy for asthma." Curr Opin Mol Ther 11(6): 652-63.
- Huang, K. J. and D. P. Wooley (2005). "A new cell-based assay for measuring the forward mutation rate of HIV-1." J Virol Methods 124(1-2): 95-104.
- Hutter, G., D. Nowak, M. Mossner, *et al.* (2009). "Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation." N Engl J Med 360(7): 692-8.
- Hutvagner, G., J. McLachlan, A. E. Pasquinelli, *et al.* (2001). "A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA." Science 293(5531): 834-8.
- IAVI. (2010). "State of the Field." < <http://www.iavi.org/research-development/Pages/state-of-field/>> [Retrieved 20 Jan 2010].
- Iorio, M. V. and C. M. Croce (2009). "MicroRNAs in cancer: small molecules with a huge impact." J Clin Oncol 27(34): 5848-56.
- Iwatani, Y., S. K. Song, L. Wang, *et al.* (1997). "Human immunodeficiency virus type 1 Vpu modifies viral cytopathic effect through augmented virus release." J Gen Virol 78 (Pt 4): 841-6.
- Iyengar, S., J. E. Hildreth and D. H. Schwartz (1998). "Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells." J Virol 72(6): 5251-5.

- Izmailova, E., F. M. Bertley, Q. Huang, *et al.* (2003). "HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages." Nat Med 9(2): 191-7.
- Jackson, A. L., S. R. Bartz, J. Schelter, *et al.* (2003). "Expression profiling reveals off-target gene regulation by RNAi." Nat Biotechnol 21(6): 635-7.
- Jackson, A. L., J. Burchard, D. Leake, *et al.* (2006). "Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing." Rna 12(7): 1197-205.
- Jacque, J. M., K. Triques and M. Stevenson (2002). "Modulation of HIV-1 replication by RNA interference." Nature 418(6896): 435-8.
- Jason, P., R. Mercedes and W. Junru (2004). "Experimental comparison of sonoporation and electroporation in cell transfection applications." Acoustics Research Letters Online 5(2): 62-67.
- Jolly, C., K. Kashefi, M. Hollinshead, *et al.* (2004). "HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse." J Exp Med 199(2): 283-93.
- Jolly, C., I. Mitar and Q. J. Sattentau (2007). "Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells." J Virol 81(24): 13916-21.
- Jolly, C. and Q. J. Sattentau (2004). "Retroviral spread by induction of virological synapses." Traffic 5(9): 643-50.
- Jolly, C. and Q. J. Sattentau (2007). "Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains." J Virol 81(15): 7873-84.
- Judge, A. D., V. Sood, J. R. Shaw, *et al.* (2005). "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA." Nat Biotechnol 23(4): 457-62.
- Kalpana, G. V., S. Marmon, W. Wang, *et al.* (1994). "Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5." Science 266(5193): 2002-6.

- Kalter, D. C., H. E. Gendelman and M. S. Meltzer (1991). "Monocytes, dendritic cells, and Langerhans cells in human immunodeficiency virus infection." Dermatol Clin 9(3): 415-28.
- Kang, H. (1998). "Direct structural evidence for formation of a stem-loop structure involved in ribosomal frameshifting in human immunodeficiency virus type 1." Biochim Biophys Acta 1397(1): 73-8.
- Kariko, K., P. Bhuyan, J. Capodici, *et al.* (2004). "Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3." J Immunol 172(11): 6545-9.
- Karlas, A., N. Machuy, Y. Shin, *et al.* (2010). "Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication." Nature 463(7282): 818-22.
- Kaur, G. and N. Mehra (2009). "Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes." Tissue Antigens 74(5): 373-85.
- Kawakami, K., C. Scheidereit and R. G. Roeder (1988). "Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro." Proc Natl Acad Sci U S A 85(13): 4700-4.
- Khvorova, A., A. Reynolds and S. D. Jayasena (2003). "Functional siRNAs and miRNAs exhibit strand bias." Cell 115(2): 209-16.
- Kim, D. H., M. A. Behlke, S. D. Rose, *et al.* (2005). "Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy." Nat Biotechnol 23(2): 222-6.
- Kim, D. H., P. Saetrom, O. Snove, Jr., *et al.* (2008). "MicroRNA-directed transcriptional gene silencing in mammalian cells." Proc Natl Acad Sci U S A 105(42): 16230-5.
- Kjems, J., M. Brown, D. D. Chang, *et al.* (1991). "Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element." Proc Natl Acad Sci U S A 88(3): 683-7.
- Klatzmann, D., F. Barre-Sinoussi, M. T. Nugeyre, *et al.* (1984). "Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes." Science 225(4657): 59-63.

- Kleiman, L., R. Halwani and H. Javanbakht (2004). "The selective packaging and annealing of primer tRNA^{Lys3} in HIV-1." Curr HIV Res 2(2): 163-75.
- Klimkait, T., K. Strebel, M. D. Hoggan, *et al.* (1990). "The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release." J Virol 64(2): 621-9.
- Kok, K. H., M. H. Ng, Y. P. Ching, *et al.* (2007). "Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA." J Biol Chem 282(24): 17649-57.
- Komano, J., K. Miyauchi, Z. Matsuda, *et al.* (2004). "Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses." Mol Biol Cell 15(12): 5197-207.
- Konig, R., Y. Zhou, D. Elleder, *et al.* (2008). "Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication." Cell 135(1): 49-60.
- Kretschmer-Kazemi Far, R. and G. Sczakiel (2003). "The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides." Nucleic Acids Res 31(15): 4417-24.
- Krishnan, M. N., A. Ng, B. Sukumaran, *et al.* (2008). "RNA interference screen for human genes associated with West Nile virus infection." Nature 455(7210): 242-5.
- Lambeth, L. S., Y. Zhao, L. P. Smith, *et al.* (2009). "Targeting Marek's disease virus by RNA interference delivered from a herpesvirus vaccine." Vaccine 27(2): 298-306.
- Langridge, W. H., B. J. Li and A. A. Szalay (1987). "Uptake of DNA and RNA into cells mediated by electroporation." Methods Enzymol 153: 336-50.
- Lapidot, T. and O. Kollet (2002). "The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice." Leukemia 16(10): 1992-2003.
- Laurent-Crawford, A. G., B. Krust, S. Muller, *et al.* (1991). "The cytopathic effect of HIV is associated with apoptosis." Virology 185(2): 829-39.
- Lecossier, D., F. Bouchonnet, F. Clavel, *et al.* (2003). "Hypermutation of HIV-1 DNA in the absence of the Vif protein." Science 300(5622): 1112.

- Lee, K. K., T. Haraguchi, R. S. Lee, *et al.* (2001). "Distinct functional domains in emerlin bind lamin A and DNA-bridging protein BAF." J Cell Sci 114(Pt 24): 4567-73.
- Lee, M. S. and R. Craigie (1994). "Protection of retroviral DNA from autointegration: involvement of a cellular factor." Proc Natl Acad Sci U S A 91(21): 9823-7.
- Lee, N. S., T. Dohjima, G. Bauer, *et al.* (2002). "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells." Nat Biotechnol 20(5): 500-5.
- Lee, Y., C. Ahn, J. Han, *et al.* (2003). "The nuclear RNase III Drosha initiates microRNA processing." Nature 425(6956): 415-9.
- Lee, Y., M. Kim, J. Han, *et al.* (2004). "MicroRNA genes are transcribed by RNA polymerase II." Embo J 23(20): 4051-60.
- Lehmann, M., M. P. Milev, L. Abrahamyan, *et al.* (2009). "Intracellular transport of human immunodeficiency virus type 1 genomic RNA and viral production are dependent on dynein motor function and late endosome positioning." J Biol Chem 284(21): 14572-85.
- Lehmann, M. J., N. M. Sherer, C. B. Marks, *et al.* (2005). "Actin- and myosin-driven movement of viruses along filopodia precedes their entry into cells." J Cell Biol 170(2): 317-25.
- Levesque, K., Y. S. Zhao and E. A. Cohen (2003). "Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells." J Biol Chem 278(30): 28346-53.
- Levy, J. A., J. Shimabukuro, H. Hollander, *et al.* (1985). "Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms." Lancet 2(8455): 586-8.
- Li, J., H. Tang, T. M. Mullen, *et al.* (1999). "A role for RNA helicase A in post-transcriptional regulation of HIV type 1." Proc Natl Acad Sci U S A 96(2): 709-14.
- Li, M., J. F. Salazar-Gonzalez, C. A. Derdeyn, *et al.* (2006). "Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa." J Virol 80(23): 11776-90.

- Li, M. J., G. Bauer, A. Michienzi, *et al.* (2003). "Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs." Mol Ther 8(2): 196-206.
- Li, M. J., J. Kim, S. Li, *et al.* (2005). "Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy." Mol Ther 12(5): 900-9.
- Liang, T. J. and C. Y. Qin (2009). "The emerging role of microRNAs in immune cell development and differentiation." Apmis 117(9): 635-43.
- Liao, Z., L. M. Cimasky, R. Hampton, *et al.* (2001). "Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1." AIDS Res Hum Retroviruses 17(11): 1009-19.
- Lin, C. W. and A. Engelman (2003). "The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes." J Virol 77(8): 5030-6.
- Lindwasser, O. W. and M. D. Resh (2001). "Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains." J Virol 75(17): 7913-24.
- Lingappa, J. R., J. E. Dooher, M. A. Newman, *et al.* (2006). "Basic residues in the nucleocapsid domain of Gag are required for interaction of HIV-1 gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly." J Biol Chem 281(7): 3773-84.
- Lipiec, A., M. Malecki and K. Hajdukiewicz (2009). "[Serotypes of adeno-associated viruses]." Postepy Biochem 55(1): 95-102.
- Llano, M., S. Delgado, M. Vanegas, *et al.* (2004). "Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase." J Biol Chem 279(53): 55570-7.
- Llano, M., D. T. Saenz, A. Meehan, *et al.* (2006a). "An essential role for LEDGF/p75 in HIV integration." Science 314(5798): 461-4.
- Llano, M., M. Vanegas, N. Hutchins, *et al.* (2006b). "Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75." J Mol Biol 360(4): 760-73.

- Lodge, R., J. P. Lalonde, G. Lemay, *et al.* (1997). "The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells." Embo J 16(4): 695-705.
- Lu, Y. Y., Y. Koga, K. Tanaka, *et al.* (1994). "Apoptosis induced in CD4+ cells expressing gp160 of human immunodeficiency virus type 1." J Virol 68(1): 390-9.
- Luban, J., K. L. Bossolt, E. K. Franke, *et al.* (1993). "Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B." Cell 73(6): 1067-78.
- Lund, E., S. Guttinger, A. Calado, *et al.* (2004). "Nuclear export of microRNA precursors." Science 303(5654): 95-8.
- Luo, W., Y. Wang and G. Reiser (2007). "p24A, a type I transmembrane protein, controls ARF1-dependent resensitization of protease-activated receptor-2 by influence on receptor trafficking." J Biol Chem 282(41): 30246-55.
- Ma, C., Y. Liu and L. He (2009). "MicroRNAs - powerful repression comes from small RNAs." Sci China C Life Sci 52(4): 323-30.
- Maasho, K., A. Marusina, N. M. Reynolds, *et al.* (2004). "Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system." J Immunol Methods 284(1-2): 133-40.
- Macatonia, S. E., R. Lau, S. Patterson, *et al.* (1990). "Dendritic cell infection, depletion and dysfunction in HIV-infected individuals." Immunology 71(1): 38-45.
- Majoul, I., M. Straub, S. W. Hell, *et al.* (2001). "KDEL-cargo regulates interactions between proteins involved in COPI vesicle traffic: measurements in living cells using FRET." Dev Cell 1(1): 139-53.
- Makeyev, E. V. and T. Maniatis (2008). "Multilevel regulation of gene expression by microRNAs." Science 319(5871): 1789-90.
- Malim, M. H., J. Hauber, S. Y. Le, *et al.* (1989). "The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA." Nature 338(6212): 254-7.
- Manes, S., G. del Real, R. A. Lacalle, *et al.* (2000). "Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection." EMBO Rep 1(2): 190-6.

- Mangeat, B., G. Gers-Huber, M. Lehmann, *et al.* (2009). "HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation." PLoS Pathog 5(9): e1000574.
- Mangeat, B., P. Turelli, G. Caron, *et al.* (2003). "Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts." Nature 424(6944): 99-103.
- Marchuk, D., M. Drumm, A. Saulino, *et al.* (1991). "Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products." Nucleic Acids Res 19(5): 1154.
- Mariani, R., D. Chen, B. Schrofelbauer, *et al.* (2003). "Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif." Cell 114(1): 21-31.
- Maroun, M., O. Delelis, G. Coadou, *et al.* (2006). "Inhibition of early steps of HIV-1 replication by SNF5/Ini1." J Biol Chem 281(32): 22736-43.
- Martinand, C., C. Montavon, T. Salehzada, *et al.* (1999). "RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells." J Virol 73(1): 290-6.
- Martinez, J. and Z. Temesgen (2006). "Opportunistic infections in patients with HIV and AIDS. Fungal and parasitic infections." J Med Liban 54(2): 84-90.
- Martinez, M. A., A. Gutierrez, M. Armand-Ugon, *et al.* (2002). "Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication." Aids 16(18): 2385-90.
- Mathews, D. H., J. Sabina, M. Zuker, *et al.* (1999). "Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure." J Mol Biol 288(5): 911-40.
- McCaffrey, A. P., P. Fawcett, H. Nakai, *et al.* (2008). "The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver." Mol Ther 16(5): 931-41.
- McCarty, D. M., H. Fu, P. E. Monahan, *et al.* (2003). "Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo." Gene Ther 10(26): 2112-8.

- McColl, D. J. and X. Chen (2010). "Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy." Antiviral Res 85(1): 101-18.
- McDonald, D., M. A. Vodicka, G. Lucero, *et al.* (2002). "Visualization of the intracellular behavior of HIV in living cells." J Cell Biol 159(3): 441-52.
- McDonald, D., L. Wu, S. M. Bohks, *et al.* (2003). "Recruitment of HIV and its receptors to dendritic cell-T cell junctions." Science 300(5623): 1295-7.
- Mead, D. A., N. K. Pey, C. Herrnstadt, *et al.* (1991). "A universal method for the direct cloning of PCR amplified nucleic acid." Biotechnology (N Y) 9(7): 657-63.
- Meiling-Wesse, K., U. D. Epple, R. Krick, *et al.* (2005). "Trs85 (Gsg1), a component of the TRAPP complexes, is required for the organization of the preautophagosomal structure during selective autophagy via the Cvt pathway." J Biol Chem 280(39): 33669-78.
- Melkonyan, H., C. Sorg and M. Klempt (1996). "Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO)." Nucleic Acids Res 24(21): 4356-7.
- Mette, M. F., W. Aufsatz, J. van der Winden, *et al.* (2000). "Transcriptional silencing and promoter methylation triggered by double-stranded RNA." Embo J 19(19): 5194-201.
- Mhlanga, M. M., D. Y. Vargas, C. W. Fung, *et al.* (2005). "tRNA-linked molecular beacons for imaging mRNAs in the cytoplasm of living cells." Nucleic Acids Res 33(6): 1902-12.
- Miller, H. B., K. O. Saunders, G. D. Tomaras, *et al.* (2009). "Tat-SF1 is not required for Tat transactivation but does regulate the relative levels of unspliced and spliced HIV-1 RNAs." PLoS One 4(5): e5710.
- Moffat, J., D. A. Grueneberg, X. Yang, *et al.* (2006). "A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen." Cell 124(6): 1283-98.
- Moore, J. P. (1997). "Coreceptors: implications for HIV pathogenesis and therapy." Science 276(5309): 51-2.

- Morlando, M., M. Ballarino, N. Gromak, *et al.* (2008). "Primary microRNA transcripts are processed co-transcriptionally." Nat Struct Mol Biol 15(9): 902-9.
- Morris, K. V., S. W. Chan, S. E. Jacobsen, *et al.* (2004). "Small interfering RNA-induced transcriptional gene silencing in human cells." Science 305(5688): 1289-92.
- Morris, K. V. and J. J. Rossi (2004). "Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection." Curr HIV Res 2(2): 185-91.
- Mosmann, T. (1983). "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays." J Immunol Methods 65(1-2): 55-63.
- Mothe, B., J. Ibarondo, A. Llano, *et al.* (2009). "Virological, immune and host genetics markers in the control of HIV infection." Dis Markers 27(3): 105-20.
- Mouro-Chanteloup, I., J. Delaunay, P. Gane, *et al.* (2003). "Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47." Blood 101(1): 338-44.
- Mulder, L. C., L. A. Chakrabarti and M. A. Muesing (2002). "Interaction of HIV-1 integrase with DNA repair protein hRad18." J Biol Chem 277(30): 27489-93.
- Naghavi, M. H. and S. P. Goff (2007). "Retroviral proteins that interact with the host cell cytoskeleton." Curr Opin Immunol 19(4): 402-7.
- Navia, B. A., E. S. Cho, C. K. Petito, *et al.* (1986). "The AIDS dementia complex: II. Neuropathology." Ann Neurol 19(6): 525-35.
- Nayak, S. and R. W. Herzog (2009). "Progress and prospects: immune responses to viral vectors." Gene Ther.
- Neil, S. J., T. Zang and P. D. Bieniasz (2008). "Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu." Nature 451(7177): 425-30.
- Nicewonger, J., G. Suck, D. Bloch, *et al.* (2004). "Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression." J Virol 78(17): 9412-22.
- Nicolas, V., C. Le Van Kim, P. Gane, *et al.* (2003). "Rh-RhAG/ankyrin-R, a new interaction site between the membrane bilayer and the red cell skeleton, is impaired by Rh(null)-associated mutation." J Biol Chem 278(28): 25526-33.

- Nishikawa, N., M. Toyota, H. Suzuki, *et al.* (2007). "Gene amplification and overexpression of PRDM14 in breast cancers." Cancer Res 67(20): 9649-57.
- Nomaguchi, M., M. Fujita and A. Adachi (2008). "Role of HIV-1 Vpu protein for virus spread and pathogenesis." Microbes Infect 10(9): 960-7.
- Novina, C. D., M. F. Murray, D. M. Dykxhoorn, *et al.* (2002). "siRNA-directed inhibition of HIV-1 infection." Nat Med 8(7): 681-6.
- Nyfeler, B., S. W. Michnick and H. P. Hauri (2005). "Capturing protein interactions in the secretory pathway of living cells." Proc Natl Acad Sci U S A 102(18): 6350-5.
- Okamura, K., J. W. Hagen, H. Duan, *et al.* (2007). "The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila." Cell 130(1): 89-100.
- Ono, A. and E. O. Freed (2001). "Plasma membrane rafts play a critical role in HIV-1 assembly and release." Proc Natl Acad Sci U S A 98(24): 13925-30.
- Orentas, R. J. and J. E. Hildreth (1993). "Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV." AIDS Res Hum Retroviruses 9(11): 1157-65.
- Ouellet, D. L., I. Plante, C. Barat, *et al.* (2009). "Emergence of a complex relationship between HIV-1 and the microRNA pathway." Methods Mol Biol 487: 415-33.
- Overhoff, M., M. Alken, R. K. Far, *et al.* (2005). "Local RNA target structure influences siRNA efficacy: a systematic global analysis." J Mol Biol 348(4): 871-81.
- Paddison, P. J., A. A. Caudy and G. J. Hannon (2002). "Stable suppression of gene expression by RNAi in mammalian cells." Proc Natl Acad Sci U S A 99(3): 1443-8.
- Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, *et al.* (1998). "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators." N Engl J Med 338(13): 853-60.
- Park, W. S., M. Hayafune, N. Miyano-Kurosaki, *et al.* (2003). "Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells." Gene Ther 10(24): 2046-50.
- Park, W. S., N. Miyano-Kurosaki, M. Hayafune, *et al.* (2002). "Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference." Nucleic Acids Res 30(22): 4830-5.

- Passman, M., M. Weinberg, M. Kew, *et al.* (2000). "In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells." Biochem Biophys Res Commun 268(3): 728-33.
- Paul, C. P., P. D. Good, I. Winer, *et al.* (2002). "Effective expression of small interfering RNA in human cells." Nat Biotechnol 20(5): 505-8.
- Paule, M. R. and R. J. White (2000). "Survey and summary: transcription by RNA polymerases I and III." Nucleic Acids Res 28(6): 1283-98.
- Pauwels, K., R. Gijssbers, J. Toelen, *et al.* (2009). "State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations." Curr Gene Ther 9(6): 459-74.
- Peng, C., B. K. Ho, T. W. Chang, *et al.* (1989). "Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity." J Virol 63(6): 2550-6.
- Perlman, M. and M. D. Resh (2006). "Identification of an intracellular trafficking and assembly pathway for HIV-1 gag." Traffic 7(6): 731-45.
- Petsch, K. A., C. Ma, M. J. Scanlon, *et al.* (2009). "Targeted forward mutagenesis by transitive RNAi." Plant J.
- Philpott, N. J. and A. J. Thrasher (2007). "Use of nonintegrating lentiviral vectors for gene therapy." Hum Gene Ther 18(6): 483-9.
- Pierson, T., J. McArthur and R. F. Siliciano (2000). "Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy." Annu Rev Immunol 18: 665-708.
- Posnien, N., J. Schinko, D. Grossmann, *et al.* (2009). "RNAi in the Red Flour Beetle (*Tribolium*)." CSH Protoc 2009(8): pdb prot5256.
- Pradhan, D. and J. Morrow (2002). "The spectrin-ankyrin skeleton controls CD45 surface display and interleukin-2 production." Immunity 17(3): 303-15.
- Purcell, D. F. and M. A. Martin (1993). "Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity." J Virol 67(11): 6365-78.

- Qiu, X. F., N. G. Dong, Z. Q. Sun, *et al.* (2009). "[Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts]." Zhonghua Yi Xue Za Zhi 89(41): 2938-42.
- Radonic, A., S. Thulke, I. M. Mackay, *et al.* (2004). "Guideline to reference gene selection for quantitative real-time PCR." Biochem Biophys Res Commun 313(4): 856-62.
- Ramachandran, N., E. Hainsworth, B. Bhullar, *et al.* (2004). "Self-assembling protein microarrays." Science 305(5680): 86-90.
- Rassouli, F. B. and M. M. Matin (2009). "Gene silencing in human embryonic stem cells by RNA interference." Biochem Biophys Res Commun 390(4): 1106-10.
- Reddy, T. R., H. Tang, W. Xu, *et al.* (2000). "Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA." Oncogene 19(32): 3570-5.
- Reddy, T. R., W. Xu, J. K. Mau, *et al.* (1999). "Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev." Nat Med 5(6): 635-42.
- Regad, T. and M. K. Chelbi-Alix (2001). "Role and fate of PML nuclear bodies in response to interferon and viral infections." Oncogene 20(49): 7274-86.
- Rehm, E. J., R. L. Hannibal, R. C. Chaw, *et al.* (2009). "The Crustacean *Parhyale hawaiiensis*: A New Model for Arthropod Development." CSH Protoc 2009(1): pdb emo114.
- Reyes-Darias, J. A., F. J. Sanchez-Luque and A. Berzal-Herranz (2008). "Inhibition of HIV-1 replication by RNA-based strategies." Curr HIV Res 6(6): 500-14.
- Reynolds, A., D. Leake, Q. Boese, *et al.* (2004). "Rational siRNA design for RNA interference." Nat Biotechnol 22(3): 326-30.
- Robinson, H. L. (2002). "New hope for an AIDS vaccine." Nat Rev Immunol 2(4): 239-50.
- Ruby, J. G., C. H. Jan and D. P. Bartel (2007). "Intronic microRNA precursors that bypass Drosha processing." Nature 448(7149): 83-6.

- Rudnicka, D., J. Feldmann, F. Porrot, *et al.* (2009). "Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses." J Virol 83(12): 6234-46.
- Ryzhova, E. V., R. M. Vos, A. V. Albright, *et al.* (2006). "Annexin 2: a novel human immunodeficiency virus type 1 Gag binding protein involved in replication in monocyte-derived macrophages." J Virol 80(6): 2694-704.
- Sacher, M., J. Barrowman, D. Schieltz, *et al.* (2000). "Identification and characterization of five new subunits of TRAPP." Eur J Cell Biol 79(2): 71-80.
- Sambrook, J. and D. Russell (2001). Molecular Cloning: A laboratory manual. New York, Cold Spring Harbour Laboratory Press.
- Samson, M., F. Libert, B. J. Doranz, *et al.* (1996). "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene." Nature 382(6593): 722-5.
- Scherer, L. J., Y. Yildiz, J. Kim, *et al.* (2004). "Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes." Mol Ther 10(3): 597-603.
- Scherr, M. and J. J. Rossi (1998). "Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts." Nucleic Acids Res 26(22): 5079-85.
- Schmidt, N. and R. Emmons (1989). Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Washington, D.C., American Public Health Association.
- Schroers, R., C. M. Davis, H. J. Wagner, *et al.* (2002). "Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection." Gene Ther 9(13): 889-97.
- Schwartz, S., B. K. Felber, D. M. Benko, *et al.* (1990). "Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1." J Virol 64(6): 2519-29.
- Schwarz, D. S., G. Hutvagner, T. Du, *et al.* (2003). "Asymmetry in the assembly of the RNAi enzyme complex." Cell 115(2): 199-208.
- Selvey, S., E. W. Thompson, K. Matthaei, *et al.* (2001). "Beta-actin--an unsuitable internal control for RT-PCR." Mol Cell Probes 15(5): 307-11.

- Shahbazian, D., A. Parsyan, E. Petroulakis, *et al.* (2010). "Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B." Mol Cell Biol 30(6): 1478-85.
- Shao, Y., C. Y. Chan, A. Maliyekkel, *et al.* (2007). "Effect of target secondary structure on RNAi efficiency." Rna 13(10): 1631-40.
- Sheehy, A. M., N. C. Gaddis, J. D. Choi, *et al.* (2002). "Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein." Nature 418(6898): 646-50.
- Sherer, N. M., M. J. Lehmann, L. F. Jimenez-Soto, *et al.* (2007). "Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission." Nat Cell Biol 9(3): 310-5.
- Sherer, N. M. and W. Mothes (2008). "Cytosomes and tunneling nanotubes in cell-cell communication and viral pathogenesis." Trends Cell Biol 18(9): 414-20.
- Shoeman, R. L., R. Hartig, C. Haues, *et al.* (2002). "Organization of focal adhesion plaques is disrupted by action of the HIV-1 protease." Cell Biol Int 26(6): 529-39.
- Shumaker, D. K., K. K. Lee, Y. C. Tanhehco, *et al.* (2001). "LAP2 binds to BAF.DNA complexes: requirement for the LEM domain and modulation by variable regions." Embo J 20(7): 1754-64.
- Shun, M. C., N. K. Raghavendra, N. Vandegraaff, *et al.* (2007). "LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration." Genes Dev 21(14): 1767-78.
- Siolas, D., C. Lerner, J. Burchard, *et al.* (2005). "Synthetic shRNAs as potent RNAi triggers." Nat Biotechnol 23(2): 227-31.
- Sioud, M. (2008). "Does the understanding of immune activation by RNA predict the design of safe siRNAs?" Front Biosci 13: 4379-92.
- Smith, S. D., M. Shatsky, P. S. Cohen, *et al.* (1984). "Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines." Cancer Res 44(12 Pt 1): 5657-60.

- Sodroski, J., C. Rosen, F. Wong-Staal, *et al.* (1985). "Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat." Science 227(4683): 171-3.
- Sokolskaja, E., D. M. Sayah and J. Luban (2004). "Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity." J Virol 78(23): 12800-8.
- Sowinski, S., C. Jolly, O. Berninghausen, *et al.* (2008). "Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission." Nat Cell Biol 10(2): 211-9.
- Spagnou, S., A. D. Miller and M. Keller (2004). "Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA." Biochemistry 43(42): 13348-56.
- Stein, B. S., S. D. Gowda, J. D. Lifson, *et al.* (1987). "pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane." Cell 49(5): 659-68.
- Stephens, J. L., S. H. Lee, K. S. Paul, *et al.* (2007). "Mitochondrial fatty acid synthesis in *Trypanosoma brucei*." J Biol Chem 282(7): 4427-36.
- Stoll, S., J. Delon, T. M. Brotz, *et al.* (2002). "Dynamic imaging of T cell-dendritic cell interactions in lymph nodes." Science 296(5574): 1873-6.
- Stoltzfus, C. M. and J. M. Madsen (2006). "Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing." Curr HIV Res 4(1): 43-55.
- Stopak, K., C. de Noronha, W. Yonemoto, *et al.* (2003). "HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability." Mol Cell 12(3): 591-601.
- Strack, B., A. Calistri, S. Craig, *et al.* (2003). "AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding." Cell 114(6): 689-99.
- Stremlau, M., M. Perron, M. Lee, *et al.* (2006). "Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor." Proc Natl Acad Sci U S A 103(14): 5514-9.

- Stremlau, M., M. Perron, S. Welikala, *et al.* (2005). "Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction." J Virol 79(5): 3139-45.
- Strunnikova, M., U. Schagdarsurengin, A. Kehlen, *et al.* (2005). "Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter." Mol Cell Biol 25(10): 3923-33.
- Studamire, B. and S. P. Goff (2008). "Host proteins interacting with the Moloney murine leukemia virus integrase: multiple transcriptional regulators and chromatin binding factors." Retrovirology 5: 48.
- Subramanya, S., S. S. Kim, N. Manjunath, *et al.* (2010). "RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?" Expert Opin Biol Ther 10(2): 201-13.
- Tang, H., G. M. Gaietta, W. H. Fischer, *et al.* (1997). "A cellular cofactor for the constitutive transport element of type D retrovirus." Science 276(5317): 1412-5.
- Taylor-Harris, P. M., L. E. Felkin, E. J. Birks, *et al.* (2005). "Expression of human membrane skeleton protein genes for protein 4.1 and beta1Sigma2-spectrin assayed by real-time RT-PCR." Cell Mol Biol Lett 10(1): 135-49.
- ter Brake, O., P. Konstantinova, M. Ceylan, *et al.* (2006). "Silencing of HIV-1 with RNA interference: a multiple shRNA approach." Mol Ther 14(6): 883-92.
- ter Brake, O., K. t Hooft, Y. P. Liu, *et al.* (2008). "Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition." Mol Ther 16(3): 557-64.
- Thomson, J. A., J. Itskovitz-Eldor, S. S. Shapiro, *et al.* (1998). "Embryonic stem cell lines derived from human blastocysts." Science 282(5391): 1145-7.
- Tilton, J. C. and R. W. Doms (2010). "Entry inhibitors in the treatment of HIV-1 infection." Antiviral Res 85(1): 91-100.
- Toohey, K., K. Wehrly, J. Nishio, *et al.* (1995). "Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread." Virology 213(1): 70-9.
- TRC. (2008). "The RNAi Consortium shRNA Library." <
<http://www.broadinstitute.org/rnai/trc/lib>> [Retrieved 26 Feb 2008].

- Tremblay, M. J., J. F. Fortin and R. Cantin (1998). "The acquisition of host-encoded proteins by nascent HIV-1." Immunol Today 19(8): 346-51.
- Tsigrelis, C., E. Berbari and Z. Temesgen (2006). "Viral opportunistic infections in HIV-infected adults." J Med Liban 54(2): 91-6.
- Tsuneyoshi, N., T. Sumi, H. Onda, *et al.* (2008). "PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells." Biochem Biophys Res Commun 367(4): 899-905.
- Turner, A. M., J. De La Cruz and K. V. Morris (2009). "Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression." Mol Ther 17(2): 360-8.
- UNAIDS. (2008). "2008 Report on the global AIDS epidemic." <
http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp> [Retrieved 15 Feb 2010].
- UNAIDS. (2009). "AIDS Epidemic Update 2009." <
<http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2009/default.asp>> [Retrieved 15 Feb 2010].
- Usami, Y., S. Popov, E. Popova, *et al.* (2009). "The ESCRT pathway and HIV-1 budding." Biochem Soc Trans 37(Pt 1): 181-4.
- Valenzuela-Fernandez, A., S. Alvarez, M. Gordon-Alonso, *et al.* (2005). "Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection." Mol Biol Cell 16(11): 5445-54.
- Vandekerckhove, L., F. Christ, B. Van Maele, *et al.* (2006). "Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus." J Virol 80(4): 1886-96.
- Vandesompele, J., K. De Preter, F. Pattyn, *et al.* (2002). "Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes." Genome Biol 3(7): RESEARCH0034.
- Ventoso, I., R. Blanco, C. Perales, *et al.* (2001). "HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation." Proc Natl Acad Sci U S A 98(23): 12966-71.

- Verdel, A., S. Jia, S. Gerber, *et al.* (2004). "RNAi-mediated targeting of heterochromatin by the RITS complex." Science 303(5658): 672-6.
- Vermeulen, A., L. Behlen, A. Reynolds, *et al.* (2005). "The contributions of dsRNA structure to Dicer specificity and efficiency." Rna 11(5): 674-82.
- Verner, Z., Z. Paris and J. Lukes (2010). "Mitochondrial membrane potential-based genome-wide RNAi screen of *Trypanosoma brucei*." Parasitol Res 106(5): 1241-4.
- VerPlank, L., F. Bouamr, T. J. LaGrassa, *et al.* (2001). "Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag)." Proc Natl Acad Sci U S A 98(14): 7724-9.
- von Eije, K. J., O. ter Brake and B. Berkhout (2009). "Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs." J Gene Med 11(6): 459-67.
- Wang, Z., H. I. Ma, J. Li, *et al.* (2003). "Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo." Gene Ther 10(26): 2105-11.
- Watkins, B. A., H. H. Dorn, W. B. Kelly, *et al.* (1990). "Specific tropism of HIV-1 for microglial cells in primary human brain cultures." Science 249(4968): 549-53.
- Watkins, D. I., D. R. Burton, E. G. Kallas, *et al.* (2008). "Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans." Nat Med 14(6): 617-21.
- Watson, S., S. Mercier, C. Bye, *et al.* (2007). "Determination of suitable housekeeping genes for normalisation of quantitative real time PCR analysis of cells infected with human immunodeficiency virus and herpes viruses." Virology 4: 130.
- Wei, X., J. M. Decker, H. Liu, *et al.* (2002). "Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy." Antimicrob Agents Chemother 46(6): 1896-905.
- Wei, X., J. M. Decker, S. Wang, *et al.* (2003). "Antibody neutralization and escape by HIV-1." Nature 422(6929): 307-12.
- Weinberg, M. S., L. M. Villeneuve, A. Ehsani, *et al.* (2006). "The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells." Rna 12(2): 256-62.

- Wensing, A. M., N. M. van Maarseveen and M. Nijhuis (2010). "Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance." Antiviral Res 85(1): 59-74.
- Westerhout, E. M., M. Ooms, M. Vink, *et al.* (2005). "HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome." Nucleic Acids Res 33(2): 796-804.
- Westermann, S. and K. Weber (2003). "Post-translational modifications regulate microtubule function." Nat Rev Mol Cell Biol 4(12): 938-47.
- Wildum, S., M. Schindler, J. Munch, *et al.* (2006). "Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection." J Virol 80(16): 8047-59.
- Willey, R. L., F. Maldarelli, M. A. Martin, *et al.* (1992). "Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4." J Virol 66(12): 7193-200.
- Wu, X., Y. Li, B. Crise, *et al.* (2003). "Transcription start regions in the human genome are favored targets for MLV integration." Science 300(5626): 1749-51.
- Yang, B. F., Y. J. Lu and Z. G. Wang (2009). "MicroRNAs and apoptosis: implications in the molecular therapy of human disease." Clin Exp Pharmacol Physiol 36(10): 951-60.
- Yang, G., G. M. Attardo, C. Lohs, *et al.* (2010). "Molecular characterization of two novel milk proteins in the tsetse fly (*Glossina morsitans morsitans*)." Insect Mol Biol 19(2): 253-62.
- Yankulov, K. and D. Bentley (1998). "Transcriptional control: Tat cofactors and transcriptional elongation." Curr Biol 8(13): R447-9.
- Yeung, M. L., L. Houzet, V. S. Yedavalli, *et al.* (2009). "A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication." J Biol Chem 284(29): 19463-73.
- Yi, R., Y. Qin, I. G. Macara, *et al.* (2003). "Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs." Genes Dev 17(24): 3011-6.
- Yoder, A., D. Yu, L. Dong, *et al.* (2008). "HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells." Cell 134(5): 782-92.

- Yokota, T., S. Iijima, T. Kubodera, *et al.* (2007). "Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C." Biochem Biophys Res Commun 361(2): 294-300.
- Yoshida, M., M. Kijima, M. Akita, *et al.* (1990). "Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A." J Biol Chem 265(28): 17174-9.
- Yung, E., M. Sorin, A. Pal, *et al.* (2001). "Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1." Nat Med 7(8): 920-6.
- Zaitseva, L., R. Myers and A. Fassati (2006). "tRNAs promote nuclear import of HIV-1 intracellular reverse transcription complexes." PLoS Biol 4(10): e332.
- Zalckvar, E., N. Yosef, S. Reef, *et al.* (2010). "A systems level strategy for analyzing the cell death network: implication in exploring the apoptosis/autophagy connection." Cell Death Differ.
- Zamborlini, A., Y. Usami, S. R. Radoshitzky, *et al.* (2006). "Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding." Proc Natl Acad Sci U S A 103(50): 19140-5.
- Zeng, Y. and B. R. Cullen (2006). "Recognition and cleavage of primary microRNA transcripts." Methods Mol Biol 342: 49-56.
- Zhai, Z., T. Sooksa-nguan and O. K. Vatamaniuk (2009). "Establishing RNA interference as a reverse-genetic approach for gene functional analysis in protoplasts." Plant Physiol 149(2): 642-52.
- Zhang, H., L. Wang, S. Kao, *et al.* (1999). "Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF." Curr Biol 9(21): 1271-4.
- Zhang, M., J. Fan, D. C. Taylor, *et al.* (2009). "DGAT1 and PDAT1 acyltransferases have overlapping functions in Arabidopsis triacylglycerol biosynthesis and are essential for normal pollen and seed development." Plant Cell 21(12): 3885-901.
- Zhong, H. and J. W. Simons (1999). "Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia." Biochem Biophys Res Commun 259(3): 523-6.

- Zhou, H., M. Xu, Q. Huang, *et al.* (2008). "Genome-scale RNAi screen for host factors required for HIV replication." Cell Host Microbe 4(5): 495-504.
- Zhou, Q. and P. A. Sharp (1996). "Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat." Science 274(5287): 605-10.
- Zhou, X., Y. Cui, X. Huang, *et al.* (2003). "Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells." Hum Gene Ther 14(11): 1089-105.
- Zimmerman, C., K. C. Klein, P. K. Kiser, *et al.* (2002). "Identification of a host protein essential for assembly of immature HIV-1 capsids." Nature 415(6867): 88-92.
- Zolotukhin, A. S. and B. K. Felber (1997). "Mutations in the nuclear export signal of human ran-binding protein RanBP1 block the Rev-mediated posttranscriptional regulation of human immunodeficiency virus type 1." J Biol Chem 272(17): 11356-60.
- Zuker, M. (1995-2010). "mfold server version 3.2." < <http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi>> [Retrieved 5 Mar 2008].
- Zuker, M. (2003). "Mfold web server for nucleic acid folding and hybridization prediction." Nucleic Acids Res 31(13): 3406-15.